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PROSTATE CANCER SCREENING AND DETECTION
“Medical research has made such progress, that there are practically no healthy people 
anymore.” – Aldous Huxley (1). This counterintuitive phenomenon as named by Huxley 
could easily be related to prostate cancer (PCa) care, being often summarized in terms 
such as ‘unnecessary testing’, ‘overdiagnosis’ and ‘overtreatment’. The occurrence of 
these terms and especially how to reduce them at time of detection and initial non-
invasive treatment of PCa are extensively discussed in this thesis.
The prostate is a walnut-size gland located in men between the bladder and penis, sur-
rounding the urethra. The prostate is part of the male reproductive system and secretes 
fluid that nourishes and protects sperm cells produced by the testicles. An enlarged 
prostate compresses the urethra and irritates the walls of the bladder, interfering with 
normal urination. More than half of men in their 60s suffer from this benign growth of 
the prostate called Benign Prostatic Hyperplasia (BPH) (2, 3). Another condition of the 
prostate, in general developed in men aged 50 years and older due to abnormal growth 
and division of epithelial cells, is PCa. PCa has the potential to spread to parts outside 
the prostate, usually the lymph nodes and bones, and can eventually lead to death. PCa 
is among the top three most lethal cancers in men from most western countries (4, 5). In 
the Netherlands a total of 12056 men were diagnosed with PCa in 2017, and 2862 men 
died because of PCa that year (6).
Traditionally, PCa is detected by systematic transrectal ultrasound (TRUS)-guided pros-
tate biopsies (SBx) that are performed in case of clinical suspicion of PCa based on an 
elevated prostate-specific antigen (PSA) level and/or abnormal digital rectal examina-
tion (DRE) (7). PSA is a protein almost exclusively produced by prostate epithelial cells 
and its serum level is usually elevated in case of PCa presence (8, 9). Therefore, PSA 
can be used as a marker for early PCa detection (10, 11). However, the serum PSA level 
can also be elevated due to benign prostate conditions like BPH, prostatitis, prostatic 
manipulation or instrumentation (12).
Despite the lack of specificity of PSA as a biomarker in PCa detection, opportunistic 
PSA-based PCa screening as introduced in the early 1990’s led to an increase of early 
PCa diagnoses and, in combination with improved treatment modalities to a reduction 
in PCa-specific mortality in Europe and the United States of America (USA) (13, 14). The 
rise of the PSA test and its apparently beneficial effect in PCa diagnostics motivated the 
initiation of studies exploring the effect of organized PCa screening on mortality and 
the possibilities of introducing a population-based screening program for PCa, like in 
the Netherlands nowadays is implemented for breast, cervical and colon cancer (15). 
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The two largest PSA-based PCa screening studies initiated in the early 1990s are the 
European Randomized Study of Screening for Prostate Cancer (ERSPC) performed in 
8 European countries, and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer 
screening trial performed in the USA (16, 17). These studies randomized over 250.000 
men in total to repeated PSA screening or control groups and show at a median follow-
up time of 16 years that with good compliance and no contamination, PSA-based PCa 
screening can reduce metastatic disease and PCa-specific mortality with approximately 
30% and 20%, respectively (18, 19).
The downsides of a purely PSA-based screening algorithm are, however, firstly the high 
number of men that need to be (repeatedly) tested to identify one men being at risk for 
potentially life threatening disease. This implies that most men tested will experience 
no benefit of screening. This is referred to as unnecessary testing. Furthermore, screen-
ing will result in a substantial (50%, range 23%-67%; number needed to diagnose 
[NND] 18, range 5-48) detection of indolent PCa that will never harm a patient, referred 
to as overdiagnosis (19-23). These cancer findings could primarily affect men’s mental 
health and subsequently actively treating these cancers with surgery or radiation 
therapy, which still often occurs, will basically not benefit a patients cancer-specific 
survival but could potentially come with the negative side effects from the active 
treatment such as incontinence and impotence with (further) reduction of the quality 
of life (20, 21, 24). This phenomenon is referred to as overtreatment. The estimated 
numbers of unnecessary testing, overdiagnosis and overtreatment of PSA-based PCa 
screening on population level are presented in table 1. In summary, on population level 
the benefits of PSA-based PCa screening do not to very limited outweigh the harms of 
screening. Therefore, PSA-based PCa screening remains one of the most controversial 
issues in urological practice.
Harms of PCa screening
Organized PSA-based 
PCa screening
Opportunistic PSA-based PCa screening 
(current clinical practice)
Unnecessary testing, % (NNI) 75% (570) 40% (493)
Overdiagnosis, % (NND) 50% (18) 40% (23)
Overtreatment, % 50% 50%
Table 1. An overview of the severity of the harms of organized and opportunistic PSA-based pros-
tate cancer screening on population level. The values are obtained/calculated using data from the 
main ERSPC and Göteborg screening trials (= average values; results could differ between popula-
tions) (19, 22, 23, 25, 26).




Selecting the right men that will benefit from screening and detection tests with the 
right tools is mandatory to be able to improve the harm-benefit ratio of PCa screening. 
In addition, the sampling technique in men identified as being at high risk for aggressive 
disease should be improved. Key components in identifying which men are suitable for 
(invasive) screening and detection tests are the estimation of life expectancy, risk of 
aggressive PCa and potential benefit of PCa treatment which is influenced by the life 
expectancy, as shown in figure 1. These components are depending on age, comorbid-
ity, the PSA level and other clinical parameters, and expected lead time of PSA screening 
(27). The selection of men that will benefit from screening and detection tests could 
potentially be done by upfront risk stratification strategies before embarking to inva-
sive procedures like a prostate biopsy (28).
ACTIVE SURVEILLANCE
A strategy to potentially counteract some of the harms of overdiagnosis and eventually 
subsequent overtreatment is Active Surveillance (AS) (29). The aim of AS is to delay 
or even completely avoid unnecessary invasive treatment of a prostate malignancy to 
prevent men from treatment related side effects (30). In AS men with a long life expec-
tancy likely to have an overdiagnosed cancer (i.e. low-risk PCa, often defined as Gleason 
 
Figure 1. A flowchart showing which men should be selected for prostate cancer screening and 
detection tests.
PSA: prostate-specific antigen; MRI: magnetic resonance imaging.
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score [GS] 3+3=6 or International Society of Urological Pathology [ISUP] grade 1 PCa) 
are closely monitored by repeated PSA measurements, DREs, prostate biopsies and 
recently also prostate magnetic resonance imaging (MRI), to switch only to active treat-
ment in case of tumor upgrading to higher risk disease (i.e. intermediate/high-risk PCa, 
often defined as GS ≥3+4 or ISUP grade ≥2 PCa), within the window of curability (31). 
AS has shown to be safe at long-term follow-up (32, 33). Recently, it was discovered 
that certain secondary Gleason 4 growth patterns (i.e. cribriform growth and intraductal 
carcinoma) reflect more aggressive disease than other growth patterns and could be 
prognostic drivers in cancer-specific survival (34). This implicates that inclusion criteria 
of AS-protocols could be considered to be extended, allowing the inclusion of limited 
ISUP grade 2 PCa without the presence of these secondary growth patterns to AS (35).
A downside of the currently applied AS-protocols is, however, the one size fits all ap-
proach. This results on one hand in strict monitoring of all low-risk PCa men, but on the 
other hand in potentially a lot of unnecessary follow-up testing and subsequent costs 
in men with a (very) low risk of disease upgrading (36). This could result in the opposite 
effect than intended with AS; to be less burdensome than active treatment and its po-
tential side effects. Therefore, the current protocols of AS should be improved by better 
selection of those men who are at high risk of disease upgrading and will benefit from 
follow-up testing and in case of confirmed disease upgrading will also benefit from a 
subsequent active treatment (37). Life expectancy, the risk of disease upgrading and 
ability to receive active curative treatment which is influenced by the life expectancy 
play a major role in identifying the men that will benefit from invasive follow-up testing 
in AS, as shown in figure 2. Again these aspects are depending on among others age, 
comorbidity, and PSA and other clinical parameters. Risk-based patient selection for 
follow-up testing made possible by risk stratification strategies could potentially be the 
way to go in AS (38, 39).
RISk STRATIFICATION
“Better prediction equals better prioritization.” – Asaf Bitton (40). This phrase describes 
proper risk stratification in effective population health management which is nowadays 
likely to be necessary to achieve the general aim of better health outcomes, better 
health care and lower health care costs. Risk stratification is defined as the constellation 
of activities to determine a person’s risk for suffering a particular condition and the 
need or lack for an intervention (41). Risk stratification has three goals in general: 1) 
predicting risks, 2) prioritizing interventions and 3) preventing negative outcomes (e.g. 
death – as well as unnecessary costs).
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The PSA test as standalone test already serves as a risk stratification tool. Half of the 
men at age 60 have a PSA below 1.0 ng/ml, whose 25 year risk of death from PCa turned 
out to be very low (42-45). However, as mentioned above an elevated PSA level lacks 
specificity. Therefore, international PCa guidelines also recommend the use of subse-
quent risk stratification tools for the prediction of a positive prostate biopsy as reflex 
tests after an elevated PSA level, which have led to the development of so-called risk-
adapted screening and detection algorithms (7, 28, 46-48). Risk stratification strategies 
in PCa care could support the process of shared informed decision-making and could 
potentially result in less unnecessary testing, less overdiagnosis and less overtreat-
ment. The currently most used risk stratification tools in PCa diagnosis and AS, and also 
mainly discussed in this thesis, are the combinations of clinical data (e.g. PSA-density 
[PSA-D]), novel blood- and urine-based (genetic) biomarkers, prediction models (i.e. 
risk calculators = combinations of [novel] biomarkers and clinical/radiological data) and 
imaging modalities which next to inform one about the risk at significant PCa also allow 
the performance of targeted biopsies (TBx) (e.g. prostate MRI with its derived predictive 
parameters) (28).
 
Figure 2. A flowchart showing which men on active surveillance for low-risk prostate cancer should 
be selected for follow-up (invasive) testing.
AS: active surveillance; PCa: prostate cancer; MRI: magnetic resonance imaging; PSA: prostate-spe-
cific antigen; DRE: digital rectal examination.
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GENERAL ObjECTIVE OF THIS THESIS
The general aim of this thesis is to investigate whether the use of risk stratification 
strategies at time of prostate cancer detection and at initiation and during an active 
surveillance strategy for low-risk prostate cancer could safely reduce the number of 
unnecessary referrals/tests, overdiagnosis and eventually subsequent overtreatment, 
without missing the diagnosis/treatment of clinically significant prostate cancer that 
potentially could harm a patient if left undetected/untreated.
OUTLINE OF RESEARCH qUESTIONS ADDRESSED IN THIS THESIS
The first part of the thesis will focus on prostate cancer screening and detection, and 
is divided into five chapters. These five chapters will focus on the following research 
questions:
o What is the long-term effect of PSA-based prostate cancer screening, and could it 
add to the ongoing discussion on the balance between harms and benefits of pros-
tate cancer screening? (Chapter 2 and 3)
o Can we select those men at high risk for aggressive disease who need further testing 
using currently available risk calculators, thereby avoiding unnecessary referrals, 
MRIs, prostate biopsies and overdiagnosis? (Chapter 2, 4, 5)
o Can magnetic resonance imaging-derived characteristics alone or combined with 
clinical parameters improve the selection of those men at high risk for aggressive 
disease who need a biopsy? (Chapter 5 and 6)
The second part of the thesis will focus on active surveillance and is divided into two 
chapters addressing the following research questions:
o Can we identify those men at high risk of disease upgrading who need a follow-up 
biopsy using magnetic resonance imaging and clinical parameters, avoiding unnec-
essary follow-up biopsies in men at low risk of disease upgrading? (Chapter 7 and 8)
o Can serial magnetic resonance imaging be used to monitor low-risk prostate cancer 
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AbSTRACT
This review discusses the most recent evidence for the currently available risk stratifica-
tion tools in the detection of clinically significant prostate cancer (csPCa), and evaluates 
diagnostic strategies that combine these tools. Novel blood biomarkers, such as the 
Prostate Health Index (PHI) and 4Kscore, show similar ability to predict csPCa. Prostate 
cancer antigen 3 (PCA3) is a urinary biomarker that has inferior prediction of csPCa com-
pared to PHI, but may be combined with other markers like TMPRSS2-ERG to improve its 
performance. Original risk calculators (RCs) have the advantage of incorporating easy to 
retrieve clinical variables and being free accessible as web tool/mobile application. RCs 
perform similarly well as most novel biomarkers. New promising risk models includ-
ing novel (genetic) markers are the SelectMDx and Stockholm-3 model (S3M). Prostate 
magnetic resonance imaging (MRI) has evolved as an appealing tool in the diagnostic 
arsenal with even stratifying abilities, also in the initial biopsy setting. Merging biomark-
ers, RCs and MRI results in higher performances than their use as standalone test. In the 
current era of prostate MRI, the way forward seems to be multivariable risk assessment 
based on blood and clinical parameters, potentially extended with information from 
urine samples, as triaging test for the selection of candidates for MRI and biopsy.
keywords
Prostate cancer detection; risk stratification; biomarker; risk calculator; magnetic reso-




Although the European Randomized study of Screening for Prostate Cancer (ERSPC) 
and the recent analyses from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer 
Screening Trial show evidence that prostate-specific antigen (PSA)-based screening 
significantly reduces prostate cancer (PCa)-specific mortality, screening for PCa remains 
a controversial issue (1-5). False positive PSA tests in patients with benign prostatic 
hyperplasia (BPH) and/or prostatitis result in unnecessary testing (performance of un-
necessary systematic transrectal ultrasound [TRUS]-guided prostate biopsy [SBx]). In 
addition, PSA-based screening can lead to the overdiagnosis, and potentially overtreat-
ment, of PCa which will never become clinically significant. These harms have a signifi-
cant effect on the quality of life and therefore diminish the number of quality-adjusted 
life years (QALYs) due to PSA-based PCa screening. Refinements to the PCa diagnostic 
pathway, focusing on detecting only those cancers that are potentially life-threatening, 
are needed to make the pathway less burdensome to patients and as such more cost-
effective and acceptable to the general population and health care providers (6).
International guidelines propose such refinements in men requesting their physician 
to “early detect” PCa by recommending an individualized opportunistic PCa screening 
policy (7, 8). This opportunistic screening goes along with shared informed decision-
making, taking into account the individual potential advantage and damage related 
to PSA testing (7, 8). Furthermore, guidelines recommend the use of risk stratification 
tools, such as novel biomarkers, risk calculators (RCs) and magnetic resonance imaging 
(MRI), for the prediction of a positive prostate biopsy as reflex tests after an elevated 
PSA level (9-17). This may support the process of shared informed decision-making, 
reduce the number of unnecessary biopsies by better identification of those men at risk 
of PCa, and better differentiate aggressive from non-aggressive cancers.
While these risk stratification tools have additional value within the diagnostic path-
way, physicians should ask themselves if these tools are necessary in every man with 
an elevated PSA level, taking into account the height of its additional diagnostic and 
predictive information, the burden for the patient, the availability and costs for society. 
Risk stratification could be based on one tool. Performing additional tests only in those 
men considered to be at high-risk of having clinically significant PCa (csPCa) (defined 
as Gleason score [GS] ≥ 3+4 or ≥ International Society of Urological Pathology [ISUP] 
grading group 2) could be an acceptable option (18, 19). The risk of promising “easy-to-
perform” tools is extensively (and unnecessary) testing of all men (not only the high-
risk men), which could result in the opposite effect than intended; to be specific and 
cost-effective (20). Clear and explicit directions for diagnostic pathways that combine 
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risk stratification tools after an elevated PSA level in order to potentially reduce the 
number of tests without missing csPCa are currently lacking.
The aim of this review is to discuss the most recent advancements of the state-of-the-
art risk stratification tools in the detection of csPCa, and their application in contem-
porary practice. Furthermore, we evaluated diagnostic pathways that combine several 
stratification tools to potentially realize a high csPCa detection rate together with a high 
cost-effectiveness.
2. NOVEL bIOMARkERS AND RISk CALCULATORS IN PROSTATE CANCER 
DIAGNOSIS
Several PSA derivatives have been proposed as PCa biomarkers to improve the specific-
ity of the PSA test. The percentage of free PSA (fPSA) to total PSA (tPSA) was introduced 
three decades ago but this test improved clinical judgment only when levels reached 
extreme values (21). More recently, fPSA has been found to include the isoforms benign 
PSA (bPSA), proPSA (with its most stable form [-2]proPSA) and intact PSA (iPSA) with 
usefulness in the detection of PCa (22). Combining these isoforms has resulted in the 
Prostate Health Index (PHI) and four-kallikrein (4K) panel. Furthermore, molecular 
biology has allowed the study of genes associated with PCa. Next to novel biomarkers 
many RCs have been developed to predict biopsy outcome. In addition, novel biomark-
ers have been incorporated into existing RCs and new PCa risk models including novel 
biomarkers have been developed (e.g. SelectMDx, Stockholm-3 [S3M]) (Table 1).
2.1. blood-based biomarkers: Prostate Health Index and Four-kallikrein 
panel
The PHI test result is based on the following mathematical formula: ([-2]proPSA/fPSA 
x √PSA) and is developed to predict the probability of any PCa and csPCa at prostate 
biopsy. PHI is the least expensive ($80 in the USA) of currently available commercial 
multiplex biomarkers and is suggested in the initial and repeat biopsy setting (8, 23, 
24). On average, using PHI with a cut-off of ≥25 to biopsy could avoid 40% of biopsies 
and reduce 25% of GS 6 diagnoses at the cost of missing 5% csPCa (25). Recently, 
Chiu et al. compared the performance of PHI in different ethnic groups from nine sites 
(1688 Asian and 800 European men), concluding that PHI was more effective in safely 




The 4Kscore is based on serum biomarkers (i.e. the 4K-panel = tPSA, fPSA, iPSA and 
human kallikrein 2 [hK2]) and includes clinical variables like age, digital rectal examina-
tion (DRE) and prior biopsy results to predict the risk of csPCa on biopsy. The 4Kscore 
is a commercially available assay, is not available in Europe and costs around $500 in 
the USA (27). Its use is recommended in patients undergoing initial and repeat biopsy 
(28). A systematic review to evaluate the performance of the 4Kscore in the pre-biopsy 
setting showed a pooled area under the curve (AUC) above 0.80 for the discrimination 
of csPCa, which was highly consistent across 11 studies involving over 10000 subjects 
(29). The AUC of the receiver operating characteristic (ROC)-curve summarizes the 
value of a test. The higher the AUC of the ROC-curve is, the more combinations of high 
sensitivity and specificity are available, thus the better the test performs. On average, 
using the 4Kscore with a cut-off risk of 9% csPCa to indicate systematic biopsy (SBx) 
could avoid 43% biopsies at the cost of missing 2.4% csPCa (12, 30, 31). In a compara-
tive study including 531 men undergoing first-time biopsy, Nordström et al. found that 
the PHI test and 4Kscore showed similar ability to predict the detection of csPCa (AUC 
0.71 versus 0.72) (32). In summary, the serum based biomarkers PHI and 4Kscore show 
comparable performance but are substantially different in price.
2.2. Urine-based biomarkers: PCA3, TMPRSS2-ERG, HOXC6, TDRD1 and DLX1 
genes
Prostate cancer antigen 3 (PCA3) is a gene that transcribes a long non-coding messenger 
RNA (mRNA) that is overexpressed in PCa tissue and is detectable in urine after DRE. The 
PCA3 score is calculated measuring the concentration of PCA3 mRNA in relation to PSA 
mRNA and costs around $300 in the USA (33). Guidelines recommend using a cut-off of 
35 in men with moderately elevated PSA for whom repeat biopsy is being considered 
(8, 28). Numerous studies indicate that the PCA3 score has greater accuracy for overall 
PCa detection in the repeat biopsy setting compared to tPSA and fPSA (34-36). Data 
about the association of the PCA3 score with csPCa are, however, conflicting (37-40). 
In recent years, comparative studies have demonstrated that PHI outperforms PCA3 for 
the prediction of csPCa on biopsy (41, 42). As the current paradigm emphasizes detec-
tion of csPCa, the potential of PCA3 as a reflex test is questionable.
Another gene associated with PCa and detectable in urine after DRE is TMPRSS2-ERG fu-
sion. Studies demonstrated that the TMPRSS2-ERG fusion gene has a greater diagnostic 
accuracy than tPSA, with a high specificity (93%) and positive predictive value (PPV) 
(94%) for the detection of PCa (43, 44). Unlike PCA3, TMPRSS2-ERG levels were as-
sociated with csPCa. However, its low sensitivity reduces its value as a standalone test. 
Combining PCA3 with TMPRSS2-ERG can improve the prediction of csPCa (15, 43, 44). A 
commercial test, the MiProstate Score (MiPS), incorporates PSA, PCA3 and TMPRSS2-ERG 
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to predict the risk of PCa and csPCa. MiPS costs around $700 in the USA and is a promis-
ing test following PSA screening, but has not yet been validated in prospective studies 
and directly compared with other biomarkers (45, 46).
Microarray analysis of mRNA from PCa tissue compared with normal prostate tissue 
revealed 39 potential biomarker candidates (40). Among them, eight mRNAs were 
upregulated in precipitates of urine obtained after DRE from men with PCa. From these 
eight genes a panel (HOXC6, TDRD1 and DLX1) was selected for the detection of PCa 
and in particular csPCa (47, 48). This urinary three-gene panel showed higher accuracy 
(AUC 0.77) to predict csPCa in biopsies compared with the PCA3 score or serum PSA.
2.3. Combinations of biomarkers and clinical data = risk calculators
2.3.1. Risk calculators including only standard clinical parameters
RCs have the advantage of incorporating easy to retrieve clinical variables. A systematic 
review identified 127 existing RCs in the field of PCa (9). Only six RCs to predict biopsy 
outcome have been externally validated in more than five study populations other than 
the development population: the ERSPC Rotterdam Prostate Cancer Risk Calculator 
(RPCRC), the Finne model, the Chun model, the Karakiewicz model, the Prostate Cancer 
Prevention Trial (PCPT) model and the ProstataClass model (10, 49-53). Besides PSA, the 
DRE was the most common predictor variable to be included in the risk models, followed 
by age, fPSA and transrectal ultrasound (TRUS) prostate volume (PV). In a recent head-
to-head comparison, RCs incorporating PV showed to be superior in identifying men 
at risk of csPCa (54). Therefore, incorporation of PV into RCs is recommended (54-56). 
The same study showed that the above-mentioned RCs and the so-called Sunnybrook 
RC have a moderate to well discriminatory ability when predicting any PCa (AUCs from 
0.64 to 0.72) (54, 57). The ERSPC RPCRC was shown to be slightly superior in predicting 
men at risk of csPCa. On average, using the ERSPC RPCRC with biopsy at a cut-off of 
4% csPCa risk could avoid 32% of biopsies and reduce 25% of GS 6 diagnoses while 
keeping a 95% sensitivity for detecting csPCa (54).
Another advantage of RCs using only readily available clinical data is that they are avail-
able as web tool and mobile applications (Apps), making (most of) them free accessible 
for everyone (58). A recent systematic review assessing the everyday functionality and 
utility of the currently available RC Apps showed that based on the Mobile Application 
Rating Scale, the ERSPC RPCRC App performed well (59).
2.3.2. Risk calculators including novel biomarkers next to clinical parameters
The original RCs were virtually all developed in the 1990s. That means that they do 
not include later-developed biomarkers. The addition of PHI to the ERSPC RPCRC three 
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(initial biopsy) and four (repeat biopsy) significantly improved the prediction of csPCa 
(60, 61). More recently, Loeb et al. confirmed the added value of PHI when incorporated 
into the PCPT RC and ERSPC RPCRC, and created a new PHI-based prediction model with 
an AUC of 0.75 (62).
The 4Kscore is in fact a risk prediction model combining novel biomarkers (i.e. the 4K-
panel) and standard clinical data. Verbeek et al. recently investigated in a cohort of 2872 
men (initial biopsy) the clinical impact of the 4Kscore, ERSPC RPCRC and the combina-
tion of both for predicting csPCa (63). In this study the 4Kscore and ERSPC RPCRC had 
similar AUCs (0.88 versus 0.87). The 4Kscore-ERSPC RPCRC combination significantly 
improved the AUC to 0.89 (64). Gain in net benefit must, however, be weighed against 
additional costs and the availability of tests.
The PCA3 score has also been investigated in conjunction with other variables. Hansen 
et al. designed a PCA3-based nomogram specifically to predict initial prostate biopsy 
results (65). This model could lead to the avoidance of 55% biopsies while missing 
2% of patients with csPCa. PCA3 has also been incorporated into existing prediction 
tools for men undergoing initial or repeat biopsy, such as the ERSPC RPCRC, PCPT RC 
(updated in 2018 with TMPRSS2-ERG added) and Chun model (66-70). Incorporation of 
PCA3 improved the diagnostic accuracy of all RCs, which is perhaps the most appropri-
ate application of PCA3 (71). Similarly, the addition of MiPS to the PCPT RC was superior 
to a base model (46). Using various cut-offs, the MiPS-PCPT RC model would avoid 35%-
47% of biopsies while missing 6%-10% low-risk PCa and 1.0%–2.3% csPCa.
Based on the high predictive accuracy for csPCa of the urinary three-gene panel - HOXC6, 
TDRD1 and DLX1 -, Van Neste et al. developed a new risk model combining HOXC6 and 
DLX1 with clinical parameters (age, PSA, DRE, PV and family history). This model is avail-
able as the SelectMDx test and costs around €300,- in Europe (40, 72). The European 
Association of Urology (EAU) guidelines suggest considering the use of SelectMDx in 
deciding whether to take an initial or repeat biopsy (8). The model demonstrated an 
AUC of 0.86 for csPCa and outperformed the base model without mRNA markers and 
the PCPT RC. Decision curve analysis suggested that SelectMDx could reduce 42% 
of biopsies while missing 2% csPCa. Recently, analyses showed that with SelectMDx 
quality-adjusted life years (QALYs) could be gained while saving healthcare costs in 
the initial diagnosis of PCa, making the use of SelectMDx before proceeding to biopsy 
potentially a cost-effective strategy (73-75). As stated by Van Neste et al. the SelectMDx 
model is mainly driven by the strong predictive value of PSA-density (72).
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Another new risk model is the S3M. This model is based on plasma protein biomarkers 
(PSA, fPSA, iPSA, hK2, MSMB, MIC1) combined with genetic polymorphisms (232 single 
nucleotide polymorphisms) and clinical variables (age, DRE, PV, family and biopsy his-
tory). The model was created using data from the Stockholm-3 study, with PSA-density 
being once more the strongest predictor (76). The S3M is not available outside of Swe-
den and it is difficult to judge its exact price (77). The S3M is proposed to be used in the 
initial biopsy setting. In a screening cohort, the S3M performed significantly better than 
PSA alone for the detection of csPCa (AUC 0.74 versus 0.56) (76). At the same level of 
sensitivity as the PSA test using a cut-off of ≥3.0 ng/mL to diagnose csPCa, use of the 
S3M could reduce the number of biopsies by 32% and avoid 17% GS 6 diagnoses (78). 
Recently, the S3M was updated and showed a slightly improved AUC (77). In a contem-
porary independent cohort, the S3M also performed well (38% biopsy avoidance at 
the cost of missing 6% csPCa) (79). The S3M’s performance characteristics should be 
compared with other biomarkers and RCs before wide incorporation in daily practice.
3. MAGNETIC RESONANCE IMAGING (MRI) AS CLINICAL “bIOMARkER” IN 
PROSTATE CANCER DIAGNOSIS
With the technological advancements in recent years and increasing experience among 
technicians, radiologists, urologists and pathologists, MRI has evolved as an appealing 
tool in the diagnostic arsenal (8). MRI has shown to be the preferred imaging modal-
ity for detecting areas suspicious for csPCa and allowing guidance for targeted biopsy 
(TBx), with a total cost of $700 - $3000 depending on regional differences in health-care 
systems outside of Europe (80, 81). In Europe, the costs of a prostate MRI is estimated 
to be €300 - €500 (81). TBx can be performed using in-bore MR-guided biopsy, cogni-
tive fusion biopsy and software fusion biopsy, without significant differences in the 
detection rate of csPCa among the three techniques (82). TBx is most often performed 
in combination with SBx. Guidelines for standardized prostate MR image acquisition 
and reporting are published (83). The Prostate Imaging – Reporting and Data System 
(PI-RADS) describes the assessment of MRI lesions, judged on a likelihood scale from 1 
to 5. A PI-RADS assessment score of 3 to 5 is mostly used as definition for a suspected 
lesion on MRI (83). Strategies incorporating MRI as a (subjective) “biomarker” in differ-
ent clinical settings have been undergoing investigation or are still being investigated. 
In addition, to better identify those men who would benefit from TBx and/or additional 
SBx after an MRI scan, MRI data have been combined with (objective) novel biomarkers 
and incorporated into existing and new developed risk models (Table 1).
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3.1. Initial biopsy setting
Although MRI with or without TBx (MRI strategy), in addition to or as a replacement 
of SBx, is increasingly investigated in the initial biopsy setting, guidelines do not yet 
recommend a pre-biopsy MRI or an upfront MRI-directed biopsy management in biopsy-
naïve men (8, 28). Over the last years studies have shown that MRI in combination with 
TBx significantly improved the detection rate of csPCa in the repeat biopsy setting but 
not (yet) in biopsy naïve men (80, 84). High-level evidence for csPCa detection by the 
MRI strategy as compared to SBx in biopsy-naïve men has been scarce until 2018.
Recently, two multicenter randomized controlled trials (RCTs) in biopsy-naïve men 
investigated the performance of the MRI strategy versus SBx (17, 85). The PRECISION 
trial showed that MRI in combination with TBx detected 12% more csPCa and 13% less 
low-risk PCa (= GS 6 PCa or ISUP grading group 1) than SBx, while a 28% reduction of bi-
opsies was realized. Porpiglia et al. also concluded that the MRI strategy outperformed 
SBx. Furthermore, two prospective multicenter studies investigating the agreement of 
PCa detection between the MRI strategy (i.e. without additional SBx) and SBx in biopsy-
naïve men have been published recently (86, 87). In the 4M-study and MRI-FIRST trial 
the proportion of detected csPCa by MRI with or without TBx (25%-32%) was similar to 
the proportion csPCa detected by SBx (23%-30%). However, the MRI strategy detected 
significantly less low-risk PCa compared to SBx and MRI could have avoided 18%-49% 
of biopsy procedures at the cost of missing 5% csPCa. Lastly, a Cochrane review deter-
mined in a mixed biopsy population (initial and repeat) that at a prevalence of 30% 
csPCa, the negative predictive value (NPV) for MRI, MRI-TBx, MRI strategy and SBx was 
90%, 93%, 90% and 87% (using template biopsy as reference standard), respectively 
(88). An additional agreement analysis showed an equivalent proportion of detected 
csPCa by MRI with or without TBx (22%) and SBx (20%) in biopsy-naïve men. However, 
the MRI strategy beneficially avoided the detection of a significant proportion (37%) of 
low-risk PCa and reduced 32% of biopsy procedures (negative MRI) at the cost of miss-
ing 4% csPCa, across 20 included studies involving over 5000 biopsy-naïve subjects.
3.2. Repeat biopsy setting
Guidelines recommend the use of MRI and TBx in the setting of persistent clinical sus-
picion of PCa after previous negative SBx (8, 28, 89). Studies have shown that the MRI 
strategy can significantly improve the detection of csPCa while reducing the detection 
of low-risk PCa and number of performed biopsy procedures in comparison to repeat 
SBx (80, 84, 90-93). The NPV of the MRI strategy in this setting is, however, also not 
100% (94-96).
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The Cochrane review from Drost et al. included 10 studies involving over 1500 sub-
jects to determine the agreement of PCa detection between the MRI strategy and SBx 
in the repeat biopsy setting (88). The analysis showed that the MRI strategy detected 
44% more csPCa than SBx. Furthermore, the MRI strategy avoided the detection of a 
significant proportion (38%) of low-risk PCa and reduced 32% of biopsies at the cost 
of missing 2% csPCa.
3.3. Novel biomarkers and MRI merged together
Gnanapragasam et al. showed in 279 men requiring a repeat biopsy that adding PHI to 
the MRI suspicion score improved csPCa prediction (AUC 0.75) compared to PSA + MRI 
alone (AUC 0.69). Using a PHI cut-off ≥35, 13% of low-risk PCa and 5% of csPCa was 
missed while 42% of men potentially spared a repeat biopsy (97). Recently, Druskin et 
al. showed in men with previous negative biopsy that PHI-density and PI-RADS score 
were complementary, with a PI-RADS score ≥3 or, if PI-RADS score ≤2, a PHI-density 
≥0.44, being 100% sensitive for csPCa. Using 0.44 as a threshold for PHI-density com-
bined with MRI, 35% of biopsies could have been avoided at the cost of missing 8% 
csPCa (98).
In a population of 300 men (initial and repeat biopsy) the combined use of 4K and 
prostate MRI showed to be superior in the prediction of csPCa (AUC 0.82) and patient’s 
selection for biopsy, compared to using the 4Kscore (AUC 0.70) or PI-RADS score (AUC 
0.74) individually (99). If one was to defer a biopsy in men with a negative MRI and a 
4Kscore <7.5%, one would avoid 15% of the biopsies and miss 2% csPCa.
3.4. Risk calculators including MRI data
Kim et al. determined the added value of MRI to the PCPT RC in the detection of csPCa 
on TBx and/or SBx in 339 men requiring initial or repeat biopsy (100). In patients with 
an estimated risk of csPCa ≤10%, the use of MRI in addition to the PCPT RC provided a 
significant improvement in clinical risk discrimination (AUC 0.60 versus 0.69). Radtke et 
al. added pre-biopsy MRI data (PI-RADS v1 score) to the ERSPC RPCRC parameters and 
developed newly fitted RCs that were superior to ERSPC RPCRC and PI-RADS score alone 
in their study cohort (101). However, net benefit of these RCs was observed only beyond 
the 10% risk threshold for csPCa. Recently, Alberts et al. improved the ERSPC RPCRCs. 
They used a multicenter cohort of 961 men who underwent SBx with or without TBx, 
and added next to PI-RADS v1 score age as parameter to the ERSPC RPCRCs (102). For 
the MRI-ERSPC RPCRC 3 net benefit was only observed above a 10% risk threshold for 
csPCa, which would result in 14% biopsies avoided while missing low-risk PCa in 13% 
and csPCa in 10% of biopsy-naïve men. The MRI-ERSPC RPCRC 4 would have avoided 
36% of repeat biopsies, missing low-risk PCa in 15% and csPCa in 4% of men.
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Other groups developed new MRI-based prediction models. Van Leeuwen et al. con-
structed a model based on the data of 393 biopsy-naïve men undergoing template bi-
opsy with or without TBx incorporating the same parameters as used in the MRI-ERSPC 
RPCRCs. Using a csPCa risk threshold of 10% would have avoided 28% of biopsies in 
their cohort, missing 13% low-risk PCa and 3% csPCa (103). Truong et al. developed a 
nomogram for predicting benign pathology on TBx in the setting of an abnormal MRI af-
ter previous negative biopsy (104, 105). The model (PSA, age, PV and PI-RADS v2 score) 
had an AUC ranging from 0.77 to 0.80. At a benign pathology risk threshold of 70% to 
biopsy, 29% of biopsies could be avoided with 14% low-risk PCa and 8% csPCa being 
missed. Recently, Mehralivand et al. constructed a RC to differentiate among patients 
with positive MRI findings who would benefit from TBx and SBx from those who would 
not (106). At a csPCa risk threshold of 20% to biopsy, 38% of biopsies could have been 
avoided while identifying 89% of csPCa.
Again, we are close to being confronted with dozens of RCs predicting biopsy outcome 
using amongst others MRI results. To avoid this, it is strongly advised that the publica-
tion of yet another model should only be pursued after performance is compared with 
already available models that have shown good discriminative capability. Calibration to 
a particular setting is relatively easy to do (provided that the predictive effects of other 
covariates are similar between the development and designated clinical setting), as now 
is stated in the new MRI-ERSPC RPCRC App. In that way we will create a situation where 
the best-performing model (both with respect to discrimination and calibration) will be 
used and that results can be compared that may potentially lead to further refinement.
4. DIAGNOSTIC PATHWAYS THAT COMBINE RISK STRATIFICATION TOOLS IN 
PROSTATE CANCER DIAGNOSIS
Prostate MRI seems to be the most useful risk stratification tool because of its ability to 
detect suspicious lesions and guide for TBx, next to inform one about the risk at csPCa 
(PI-RADS score). However, in a considerable proportion of patients the MRI will not show 
any abnormalities making it thereby potentially a redundant test. In addition, some 
patients will have false positive abnormalities on MRI (i.e. benign pathology or low-risk 
PCa) resulting in unnecessary TBx. The state-of-the-art challenge in the current MRI era 
is to identify those men who will benefit from an MRI with TBx, for maximum csPCa 
detection while reducing the number of unnecessary MRIs, biopsies and diagnoses of 
low-risk PCa. An option could be upfront risk stratification with a novel biomarker or RC 
(with or without novel biomarker(s) included), and if indicated subsequent MRI with if 
indicated subsequent biopsy (Table 1 and Figure 1).
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4.1. Upfront novel biomarker and if indicated subsequent MRI and biopsy
PHI has been tested as a predictor of a positive MRI in men requiring repeat biopsy 
(97). PHI scores were generally higher in men with an MRI lesion. However, using PHI 
only marginally increased predictive value compared to PSA in this study suggesting 
that PHI is unlikely to be useful as a triaging test in deciding if an MRI will be positive. 
Punnen et al. looked at diff erent sequencing strategies to combine the 4Kscore and 
MRI in a mixed biopsy population (initial and repeat) (99). A strategy of doing an initial 
4Kscore, followed by an MRI if the 4Kscore was greater than 7.5% and a subsequent 
TBx if the MRI was positive showed a 25%, 83% and 75% reduction in the number of 
Suspicion of PCa
(elevated PSA, abnormal DRE)
Upfront risk stratification
(e.g. novel biomarker, risk 





negative MRI positive MRI
TBx ± SBx






No PCa Yes PCa
Figure 1. Flowchart of men with elevated prostate-specifi c antigen (PSA) and/or abnormal digital 
rectal examination (DRE), with the combination of upfront risk stratifi cation and if indicated pros-
tate MRI and biopsy.
PSA: prostate-specifi c antigen; DRE: digital rectal examination; PCa: prostate cancer; MRI: magnetic 
resonance imaging; PI-RADS: MRI suspicion score; TBx: MRI-targeted biopsy; SBx: systematic bi-
opsy; AS: active surveillance.
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MRIs, biopsies and low-risk PCa diagnoses, respectively. However, this strategy resulted 
in 33% of csPCa being missed. A similar pathway using PCA3 score ≥35 as threshold 
would result in 52% MRI reduction, 76.4% reduction of biopsies and 86.6% less diag-
noses of low-risk PCa, at the cost of missing 47.5% csPCa (107). All studies conclude 
that optimized sequencing of novel biomarkers and MRI is the other way around, i.e. an 
initial MRI followed by a novel biomarker among only those men with a low to moderate 
suspicion score on MRI. However, that still would mean at least an MRI in every man with 
a suspicion of PCa.
4.2. Upfront risk calculator including only standard clinical parameters and 
if indicated subsequent MRI and biopsy
Alberts et al. studied whether upfront risk stratification with the ERSPC RPCRC could be 
used before the decision to perform an MRI in men confronted with a previous negative 
SBx while having a persistent suspicion of csPCa (19). The analysis was restricted to TBx 
outcomes. In their cohort, upfront ERSPC RPCRC-based patient selection for MRI would 
have avoided 51% of MRIs, 69% of biopsies and 25% of low-risk PCa diagnoses, while 
missing 10% csPCa. In a repeat biopsy setting, Drost et al. found that upfront use of the 
ERSPC RPCRC to select men for MRI with TBx could diagnose most of the csPCa (83%), 
while saving 37% of MRIs, 55% of biopsies and 66% of low-risk PCa diagnoses (108).
Recently, Mannaerts et al. showed in a retrospective biopsy-naïve cohort of 200 men 
that a pathway of initial ERSPC RPCRC, followed by an MRI if the ERSPC RPCRC advised 
to perform biopsy and subsequent SBx with additional TBx in case of a positive MRI, 
would reduce 37% of MRIs and biopsies, 23% of low-risk PCa diagnoses while missing 
6% csPCa (109). A TBx-only strategy after ERSPC RPCRC would have missed 27% of 
csPCa in this cohort. Currently, a Dutch prospective study (MR PROPER) evaluating the 
MRI strategy versus SBx in biopsy-naïve men (3000 inclusions aimed), both after initial 
risk stratification with the ERSPC RPCRC, is ongoing and will provide more clarity about 
the value of the ERSPC RPCRC-MRI pathway (110). In any case, results obtained till now 
argue for an ERSPC RPCRC-based selection for MRI with performance of only MRI with 
or without TBx in repeat biopsy men considered to be at high-risk of csPCa according to 
the ERSPC RPCRC, while biopsy-naïve men considered to be at high-risk should undergo 
both MRI with or without TBx and SBx.
4.3. Upfront risk calculator including novel biomarker(s) and if indicated 
subsequent MRI and biopsy
In a retrospective study the SelectMDx score was significantly higher in patients with a 
suspicious lesion on MRI compared to patients with a negative MRI. For the prediction 
of MRI outcome, the AUC of SelectMDx was 0.83 compared to 0.66 for PSA and 0.65 for 
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PCA3, suggesting a positive association between SelectMDx and the final PI-RADS v2 
score (111). Trooskens et al. presented data on the use of SelectMDx (including TRUS 
PV) to exclude low-risk patients from undergoing an MRI (112). A strategy of doing 
upfront SelectMDx, followed by an MRI if the risk for csPCa was greater than 10% and 
subsequent SBx with additional TBx if the MRI was positive (defined as PI-RADS score 
≥4), would reduce 35% of MRIs and biopsies, 52% of low-risk PCa diagnoses while 
missing 2% csPCa.
Grönberg et al. recently investigated the combination of S3M and MRI in a cohort of 532 
men who were referred for PCa workup (initial and repeat biopsy). Performing MRI with 
or without TBx and additional SBx only in men with a risk >10% for csPCa using the S3M 
would reduce the number of MRIs and biopsies with 38%, while diagnosing 42% less 
low-risk PCa at the cost of missing 8% csPCa cases (113). The strategy of performing 
only MRI with or without TBx for men with a positive S3M test would save even more 
biopsies (42%) and low-risk PCa diagnoses (46%), however, at the cost of missing 19% 
csPCa.
On average, the value of upfront risk stratification with one of the new risk models seems 
similar to the upfront use of the ERSPC RPCRC to select candidates for MRI. Taking into 
account the costs and availability of the tests, the ERSPC RPCRC might be preferable. 
However, to determine the most cost-effective diagnostic pathway in PCa diagnosis ide-
ally a large prospective cohort study of men biopsied irrespective of risk stratification 
tool outcome and retrospectively compared performance of all relevant stratification 
tools should become available for both the initial and repeat biopsy setting.
5. CONCLUSIONS
There are numerous risk stratification tools available that can help increase the speci-
ficity of PSA for the detection of csPCa in the initial and repeat biopsy setting. These 
tools may thereby refine the PCa diagnostic pathway, improving diagnostic outcome, 
reducing the burden for patients and making it more cost-effective and acceptable to 
the general population and health care providers. All risk stratification tools result in a 
considerable decrease in unnecessary testing and carry a generally small risk of missing 
csPCa.
Taking into account the costs, RCs using PSA and clinical parameters which perform 
similarly well as novel, most often more expensive, biomarkers seem to be the preferred 
choice. However, head-to-head-comparisons of all biomarkers and RCs are necessary. 
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Pre-biopsy prostate MRI has shown to have more added value in men requiring repeat 
biopsy than in biopsy-naïve men. Recent studies show evidence for an MRI-directed 
biopsy management in all men, including biopsy-naïve men.
Merging novel biomarkers, RCs and MRI results in higher diagnostic accuracies and net 
benefit than the use of these risk stratification tools as standalone test. However, in the 
state-of-the-art clinical decision-making, the patient should benefit from further test-
ing and treatment, even when the diagnostic test is “easy-to-perform”. Therefore, the 
way forward in the current era of prostate MRI is to have an accurate predictive low-cost 
risk stratification tool. This risk stratification tool as triaging test for the selection of 
candidates for further testing (e.g. MRI, biopsy) seems to be multivariable risk assess-
ment based on blood and clinical parameters, potentially extended with information 
from urine samples, which is free of use, available everywhere, extensively externally 
validated, and calibrated for different populations. Large prospective and comparative 
studies remain, however, necessary to fully assess the potentials and risks of these 
combined strategies.
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AbSTRACT
We assessed the effect of screening in the European Randomized study of Screening 
for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 
1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) 
and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0 ng/ml was 
excluded from randomization). Further PSA testing was offered to all men in the S-arm 
with 4-yr intervals starting at age 55 yr and screened up to the age of 74 yr. Overall, a 
PSA level of ≥3.0 ng/ml triggered biopsy. At time of analysis, 63% of men had died. 
Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 
0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36) respec-
tively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in 
a period without noteworthy contamination, shows that PSA-based screening could 
result in considerable reductions of M+ disease and mortality which if confirmed in 
larger datasets should trigger further discussion on pros/cons of PCa screening.
Patient summary
In a cohort with 19 yr of follow-up we found indications for a more substantial reduction 
in metastatic disease and cancer-specific mortality in favor of prostate cancer screening 
than previously reported. If confirmed in larger cohorts, these findings should be con-




The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown 
that prostate-specific antigen (PSA)-based screening results in a significant prostate 
cancer (PCa) mortality reduction at 13 yr of follow-up (FU) (1). In contrast to the ERSPC, 
the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial did not show 
a cancer-specific mortality reduction due to screening in their intention-to-screen 
analysis (2). However, recently published (modeling) analyses show that the ERSPC and 
PLCO trials in fact provide compatible evidence that screening reduces PCa mortality 
(3, 4). Despite these observed reductions, unnecessary testing and overdiagnosis still 
preclude PSA-based PCa screening from adoption as public health policy. However, the 
results of the ERSPC and PLCO trials may be affected by a relatively short FU and PSA 
contamination. Here, we assessed the effect of PSA-based PCa screening in an ERSPC 
Rotterdam study cohort (pilot 1 study) with men randomized in the period 1991-1992 
(an era in which PSA testing was uncommon) and enabling us to report on the basis of 
long-term FU.
ERSPC Rotterdam started with a series of five pilot studies in October 1991. Full ca-
pacity screening started in June 1994. In this work, we describe the results of the first 
pilot study of ERSPC Rotterdam. The participants of this ERSPC pilot 1 study are not 
included in the Rotterdam section of the main ERSPC trial. The other pilot studies were 
not included in the current analyses due to their period of randomization, length of FU 
and substantial differences in administrative procedures/screening processes. The pilot 
1 study protocol characteristics are described in earlier publications (5, 6). Briefly, 3331 
men aged 55-74 yr selected from the population registry of Rotterdam were invited 
for screening. The only exclusion criterion was a previous PCa diagnosis. Men who 
responded (n = 1186; recruitment rate of 35.6%) by returning the intake questionnaire 
and who provided signed informed consent were included and randomized after PSA 
testing (n = 1134) on a 1:1 basis to a screening (S) and control (C) arm. Men (n = 30) with 
a PSA level ≥10.0 ng/ml were excluded from randomization and directly referred to 
their general practitioner. The screening protocol consisted of PSA, digital rectal exami-
nation and transrectal ultrasound (TRUS) and was offered to all men in the S-arm with 
a 4-yr interval and applying the upper age limit of 74 yr (maximum of five consecutive 
screening rounds). In general, a PSA level ≥3.0 ng/ml triggered TRUS-guided biopsy. The 
primary endpoint was PCa-specific mortality. We also assessed the clinical/pathologi-
cal features of the cancers detected (at time of diagnosis) and calculated the relative 
risk (RR) of metastatic (M+) disease (defined as N1 and/or M1 and/or PSA >100 ng/ml), 
including M+ disease at diagnosis and during FU. Finally, we retrospectively randomized 
the initially excluded men (PSA ≥10.0 ng/ml) using the bootstrap procedure (n = 5000 
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iterations) to calculate risk reductions including all PSA values (hypothetical situation). 
Descriptive statistics were used to evaluate patient/tumor characteristics. Cumulative 
progression to M+ disease and PCa-specific mortality by arm were calculated using the 
Nelson-Aalen method (7). Numbers needed to screen (NNS) to avert one M+ disease 
and PCa death were calculated as the inverse of the absolute risk reduction and number 
needed to diagnose (NND) as the NNS multiplied by the excess PCa incidence in the 
S-arm. All analyses were performed using R, version 3.4.3.
Of the 1134 men with a PSA level <10.0 ng/ml, 553 (49%) were randomized to the 
S-arm and 581 (51%) to the C-arm. Median PSA level at baseline in S- and C-arm was 
1.2 ng/ml (interquartile range [IQR]: 0.5-2.2) and 1.1 ng/ml (IQR: 0.5-2.1), respectively. 
Further PSA measurements in the C-arm are not available. The median age at random-
ization and FU time was 64 (IQR: 60-69) and 19 yr (IQR: 12-24), respectively. Cumulative 
PSA contamination rate in the C-arm was estimated to be ± 4.5% (questionnaire data), 
with the first 4 yr a rate of 1.8%. In the S-arm 71 PCas were detected versus 57 PCas in 
the C-arm (Table 1). Excess incidence due to screening is 32 PCa cases per 1000 men 
randomized. The M+ disease was detected in three screened men versus eight men in 
the C-arm. During FU, seven men in the S-arm and 16 men in the C-arm progressed to 
M+ disease, resulting in an overall RR of M+ disease of 0.46 (95% confidence interval 
[CI]: 0.19-1.11) and a 19 yr-specific RR of M+ disease of 0.42 (95% CI: 0.16-1.08), in 
favor of screening (Figure 1A). At time of analysis, 63% (718/1134) of all men had died. 
Five men in the S-arm and 11 men in the C-arm died because of PCa. Overall RR of 
PCa death in men allocated to the S-arm relative to the C-arm was 0.48 (95% CI: 0.17-
1.36); 19 yr-specific RR of PCa death was 0.47 (95% CI: 0.14-1.50) in favor of screening 
(Figure 1B). The absolute risk reduction in M+ disease and PCa mortality was 14.9 (95% 
CI: -2-32) and 9.9 (95% CI: -5-25) per 1000 men, respectively. NNS to avert one M+ dis-
ease and PCa death is 67 (95% CI: 30-ND) and 101 (95% CI: 39-ND), respectively. NND 
was three (101/1000*32). In the S-arm, 75% of the PCa cases underwent treatment 
versus 25% underwent surveillance. In the C-arm, 53% of the PCa cases underwent 
treatment versus 30% surveillance (in 17% of the cases in C-arm, the choice of treat-
ment was unknown). Among the 30 men initially excluded from randomization, 19 were 
diagnosed with PCa including eight with M+ disease (Table 1). Of these men, 26 (87%) 
died including five PCa deaths. Retrospectively randomizing these 30 men resulted in 
an overall RR (in favor of screening and averaged over 5000 randomization procedures) 
of M+ disease and PCa death of 0.57 (95% CI: 0.27-1.20) and 0.59 (95% CI: 0.25-1.44), 
respectively.
This ERSPC Rotterdam pilot 1 study cohort, systematically screened in a period largely 
without PSA contamination and with more than 60% of the men deceased, confirms 
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that PSA-based PCa screening reduces M+ disease and PCa-specific mortality. The re-
ductions are, although statistically insignificant, considerable and if confirmed in larger 
datasets should again be weighed against the harms of unnecessary testing and overdi-





Total excluded cohort 
(n = 30)
No. % No. % No. %
T-stage
T1 29 41 20 35  5 26 
T2 27 38 24 42 8 42
T3 14 20 7 12 5 26
T4 1 1 6 11 1 5
N-stage
NX 37 52 34 60  8 42 
N0 34 48 19 33 9 47
N1 - - 4* 7 2** 11
M-stage
MX 25 35 25 44  4 21 
M0 43 61 25 44 12 63
M1 3 4 7* 12 3** 16
PSA >100 ng/ml - - - - 5*** 26
Gleason score
3+3 39 55 26 46  - - 
 ≥3+4 23 32 28 49 1 5
Unknown 9 13 3 5 18 95
Survival status – all men
Alive 189 34 227 39  4 13 
Death 364 66 354 61 26 87
Survival status – PCa men
Alive 50 70 40 70  3 16 
Death 21 30 17 30 16 84
Cause of death
PCa 5 1 11 3  5 19 
Other cause 359 99 343 97 21 81
Table 1. The clinical/pathological features (TNM-staging, Gleason grading) of the cancers detected 
(at time of diagnosis). Survival status and cause of death from both the screening and control arm 
of the men included and randomized with a prostate-specific antigen (PSA) level <10.0 ng/ml (n = 
1134) as well as of the men excluded because of a PSA level ≥10.0 ng/ml (n = 30).
*Three men had both N1 and M1 disease. **One man had both N1 and M1 disease. ***One man had 
both M1 disease and PSA >100 ng/ml at time of diagnosis.
PSA: prostate-specific antigen; PCa: prostate cancer.































































































































































































































developing despite screening, and reduction of M+ disease preceding PCa mortality 
reduction are also confirmed, proving the validity of our findings (8, 9). The reductions 
in M+ disease and PCa mortality are, however, substantially larger than the main ERSPC 
trial (54% vs 30% and 52% vs 21%, respectively) (1-4). This could be explained by the 
relatively long FU of this study implying that FU in the ERSPC trial could still be too short 
to see the full effect of screening, given the long natural history of screen-detected PCa 
(15-25 yr) and the fact that there was almost no PSA contamination in the C-arm of this 
study (10). We note that inclusion of men with high PSA values and therefore more likely 
to have disease beyond cure even if detected earlier resulted in the decrease in relative 
reduction of both M+ disease and PCa-specific mortality. The strengths of the present 
study include the relatively long FU, almost no PSA contamination, and more than 60% 
of men deceased at time of analysis. Therefore, this study is an appropriate comparison 
between screening and no screening and can be regarded as a good indicator of the full 
effect of PCa screening. Limitations to this work include the small sample size and low 
event rates necessitating confirmation of our findings in the ongoing randomized trials. 
It can, however, not be excluded that the magnitude of the RRs in this pilot study will be 
confirmed in the main ERSPC trial when having the availability of 19 yr of FU.
In conclusion, long term data predominantly coming from an era with hardly any con-
tamination  show that PSA-based PCa screening could result in a considerable reduction 
of both M+ disease and PCa-specific mortality which, if confirmed in larger datasets, 
should refuel the discussion on harms and benefits of PCa screening.
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According to their guidelines, Dutch general practitioners (GPs) refer men with prostate-
specific antigen (PSA) level ≥3.0 ng/ml to the urologist for risk-based patient selection 
for prostate biopsy using the Rotterdam Prostate Cancer Risk Calculator (RPCRC). Use 
of the RPCRC in primary care could optimize the diagnostic pathway even further by 
reducing unnecessary referrals. To investigate this, we calculated the risk and assessed 
the rate of men referred to the urologist with PSA level ≥3.0 ng/ml by implementing the 
RPCRC in a primary health care setting. 
Methods
In January 2014, an exploratory study was initiated in collaboration with the primary 
health care facility of the GP laboratory in Rotterdam. GPs were given the possibility to 
refer men with a suspicion of prostate cancer (PCa) or a screening wish to this primary 
care facility (STAR-SHL) where further assessment was performed by specially trained 
personnel. Risk-based advice on referral to the urologist was given to the GP on the 
basis of the RPCRC results. If requested, advice on the treatment of lower urinary tract 
symptoms (LUTS) was provided. All men signed informed consent.
Results
Between January 2014 and September 2017, a total of 243 men, median age 64 (in-
terquartile range [IQR], 57-70) years were referred for a consultation at the primary 
care facility. Of the 108 men with PSA level ≥3.0 ng/ml and a referral related to PCa, 
GPs were advised to refer 58 men to the urologist (54%). Of the men with available 
follow-up (FU) data (n=187, median FU, 16 [IQR, 9-25] months) 54 men were considered 
high-risk (i.e. had an elevated risk of PCa as calculated by the RPCRC). Of these men, 
51 (94%) were actually referred to secondary care by their GP, and so far 38 men un-
derwent biopsy. PCa was detected in 30 men (47% had Gleason score [GS] ≥3+4 PCa), 
translating to an overall positive predictive value (PPV) of 79%. Within the available FU 
time, 2 out of 38 (5%) men with PSA level ≥3.0 ng/ml which were considered low-risk 
have been diagnosed with GS 3+3 PCa.
Conclusions
Risk-stratification with the RPCRC in a primary health care setting could prevent almost 
half of referrals of men with PSA level ≥3.0 ng/ml to the urologist. In more than three-
quarters of men referred for prostate biopsy, the suspicion of PCa was confirmed and 
almost half of men had clinically significant PCa (GS ≥3+4 PCa). These data show a huge 




Primary care; prostate cancer; prostate volume; prostate-specific antigen (PSA); risk-
stratification.
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INTRODUCTION
Unnecessary testing, overdiagnosis and treatment with accompanying health care 
costs preclude that prostate-specific antigen (PSA)-based prostate cancer (PCa) screen-
ing can be adopted as a public health policy (1, 2). The delicate benefit-harm ratio of 
population-based screening is, however, difficult to translate to the individual patient 
(3). Therefore, guidelines recommend individualized opportunistic PCa screening along 
with shared informed decision-making, taking into account the individual potential 
advantage and damage related to PSA testing (4).
Risk calculators for the prediction of a positive prostate biopsy have been developed to 
support physicians in this informed decision-making, and to reduce the number of un-
necessary biopsies by better identification of those men at risk of PCa (5). The European 
Randomized Study of Screening for Prostate Cancer (ERSPC)-based Rotterdam Prostate 
Cancer Risk Calculator (RPCRC), for instance, reduces the percentage of unnecessary, 
potentially harmful, and costly transrectal ultrasound systematic biopsy (TRUS-Bx) by 
±33% when using PSA level ≥3.0 ng/ml and RPCRC risk ≥12.5% as cut-off values in the 
urology outpatient clinic (6-11). When adopting this strategy, only a small amount of 
potentially aggressive PCa would be missed. 
The guidelines for Dutch general practitioners (GPs) lowered the PSA cut-off value for 
referral to the urologist from 4.0 to 3.0 ng/ml, under the condition that the urologist 
uses the RPCRC for patient selection for biopsy (12). This policy results in an increased 
number of referrals to secondary care. This seems controversial, considering the cur-
rent demand of the Dutch government to reduce health care costs by keeping more 
care in the primary care. However, to adhere to government’s request, introduction of 
the RPCRC into the primary care setting could potentially result in further optimization 
of the diagnostic pathway by reducing unnecessary referrals to secondary care and, 
thereby reducing the number of biopsies, costs and workload. The implementation of 
PCa diagnostic risk models, like the RPCRC, based on PSA, digital rectal examination 
(DRE) and prostate volume on transrectal ultrasound (TRUS) and their impact on patient 
selection in primary care have never been investigated.
As such, the aim of this study was to assess the rate of men referred to the urologist with 
a PSA level ≥3.0 ng/ml by implementing multivariable risk-stratification with the RPCRC 
in a primary health care setting. In addition, we assessed adherence of GPs to the RPCRC 





Study design and population
In January 2014, this prospective observational study was initiated by the Erasmus MC 
in collaboration with the primary health care facility of the GP laboratory in Rotterdam 
(STAR-SHL). GPs were given the possibility of referring men with a suspicion of PCa or a 
screening wish to this primary care facility. Patients were then offered a so-called ‘pros-
tate consultation’. Inclusion criteria for study participation were prostate biopsy naïve 
or previously negative biopsied men of 18 years or older of all ethnic backgrounds who 
were referred by their GP for a prostate consultation and had sufficient understanding of 
the Dutch language. Men with previously diagnosed PCa were excluded. All men signed 
informed consent before enrolment. The study was approved by our institutional review 
board (METC Erasmus MC, number: MEC-2013-572) and conformed to the provisions of 
the Declaration of Helsinki.
Procedures and data collection
Patients were offered an assessment including DRE and TRUS, regardless of their PSA 
level , at the primary care facility. DRE was carried out to estimate the prostate volume 
and search for abnormalities of the prostate. TRUS of the prostate was performed to 
measure the prostate volume and presence of hypo-echogenic lesions. Study partici-
pation included prospective registration of these data in an anonymized database; no 
additional investigations were done. In case a man did not give his informed consent 
for data collection, he could still undergo all the examinations and the risk calculation, 
however, without any data registration for research purposes. 
All described examinations are considered routine clinical practice in a urology outpa-
tient clinic to evaluate lower urinary tract symptoms (LUTS) or PCa. The examinations 
were performed by specially trained Erasmus MC personnel from the department of 
Urology. With the collected data, the risk of finding any PCa and potentially aggressive 
PCa in case of performing a prostate biopsy was calculated using the RPCRC calculators 
3 or 4 (http://www.prostatecancer-riskcalculator.com/). Based on the outcome of the 
RPCRC, recommendations on referral to the urologist were formulated as follows:
- Risk of positive prostate biopsy < 12.5%: no biopsy;
- Risk of positive prostate biopsy 12.5%-20%: consider a biopsy, depending on the 
comorbidity of the patient and on the risk of a high grade or extended PCa (>4%);
- Risk of positive prostate biopsy > 20%: prostate biopsy.
The findings, the calculated risk of finding PCa and the risk-based advice on referral 
to the urologist were reported to the GP using the electronic patient chart. He or she 
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subsequently decided whether or not to refer the patient to a urologist for prostate 
biopsy. If requested, advice on the treatment of LUTS was provided. 
The calculated risks and the associated advice were matched with information on actual 
referral and biopsy rates. Biopsy outcome if applicable was also assessed. In case of 
a PCa diagnosis initial treatment was recorded together with available follow-up (FU) 
data. All information was retrieved through direct contact with the different GP prac-
tices. GPs were initially not aware of the fact that they would be contacted to provide 
FU information. 
Outcomes
The primary outcome of this study was to assess the rate of men with a PSA level ≥3.0 
ng/ml considered at high-risk (i.e. having an elevated calculated PCa risk) on the basis 
of the RPCRC. The secondary outcomes were the compliance rate of GPs and patients 
to the RPCRC based advice, the rate of detected (clinically significant) PCa in the urol-
ogy outpatient clinic and the rate of missed PCa within the available FU time. Clinically 
significant PCa (csPCa) was defined as any Gleason score (GS) ≥3+4 PCa found in biopsy 
specimens.
Statistical analysis
Demographic characteristics are presented for the overall group of men. Categorical 
data are reported as count (percentage). Continuous data are reported as median (in-
terquartile range [IQR]). Descriptive statistics were used to evaluate the primary and 
secondary outcomes. All analyses were performed using the Statistical Package for the 
Social Sciences (SPSS) for Windows (version 21.0. IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics
Between January 2014 and September 2017, a total of 243 men were referred by their 
GP for a prostate consultation at the primary care facility. Median age and PSA level was 
64 (IQR, 57-70) years and 2.5 (IQR, 0.9-5.8) ng/ml, respectively. The largest group of 
men (44%) were referred by their GP because of a PCa screening wish and/or advice for 
LUTS. Of the 243 men, 46% (n=112) had a PSA level ≥3.0 ng/ml. Other relevant baseline 




A substantial part of men (71%) with PSA level <3.0 ng/ml were referred for LUTS. The 
majority of men (n=108, 96%) with PSA level ≥3.0 ng/ml had a referral related to PCa 
(Table 2). Of these 108 men, 54% (n=58) were considered high-risk and advised to be 
referred to the urologist by their GP. Eight men with PSA level <3.0 ng/ml, who according 
to the guidelines should not be referred, were advised to be referred for prostate biopsy 
on the basis of the RPCRC results. The rest of the men were considered low-risk and 
based on the RPCRC would not benefit from a PCa-related visit to the urologist (Figure 
1). The median calculated risk of finding any PCa and potentially aggressive PCa in the 66 
men considered high-risk was 37% (IQR, 21-59%) and 14% (IQR, 5-39%), respectively.
Characteristic Median Interquartile range
Age (years) 64 57-70
PSA (ng/ml) 2.5 0.9-5.8
Prostate volume on TRUS (ml) 38 26-59.5
No. %
PSA:
<3.0 ng/ml 131 54
≥3.0 ng/ml 112 46
Abnormal DRE 42 17
Abnormal TRUS 32 13
Previous biopsy 6 3
Indication:
PCa screening 104 43
LUTS 31 13
Screening & LUTS 108 44
Previously screened 72 30
PCa in family 32 13
Already LUTS medication 24 10
Total cohort 243 100
Table 1. Patient characteristics of the total group (n=243).
PSA: prostate-specific antigen; TRUS: transrectal ultrasound; DRE: digital rectal examination; PCa: 
prostate cancer; LUTS: lower urinary tract symptoms.
PSA PCa screening Screening & LUTS Only LUTS Total cohort
<3.0 ng/ml 38 66 27 131
≥3.0 ng/ml 66 42 4 112
Total cohort 104 108 31 243
Table 2. Referral reasons for consultation stratified for PSA level subgroup in total cohort (n=243).
PCa: prostate cancer; LUTS: lower urinary tract symptoms; PSA: prostate-specific antigen.






























































































































































Referral rate, biopsy outcomes and treatment types
Of the total of 243 men, FU data were available of 187 men (FU cohort). Median FU time 
was 16 (IQR, 9-25) months. Of these 187 men, 45% (n=84) had a PSA level ≥3.0 ng/ml; 
this was similar to the rate of men with PSA level ≥3.0 ng/ml in the total cohort. In the 
FU cohort, 54 men (8 men with PSA level <3.0 ng/ml and 46 men with PSA level ≥3.0 ng/
ml) were considered high-risk (Figure 1). The median calculated risk of finding any PCa 
and potentially aggressive PCa in prostate biopsy in these 54 men was also 37% (IQR, 
21-59%) and 14% (IQR, 5-39%), respectively. The rates of men considered low- and 
high-risk in this FU cohort were similar to the rates in the total cohort for both PSA level 
subgroups. 94% (n=51) of men considered high-risk were actually referred to second-
ary care and so far 38 (75%) men underwent prostate biopsy. The median calculated 
risk of finding any PCa and potentially aggressive PCa in these 38 men was 47% (IQR, 
32-67%) and 19% (IQR, 9-44%), respectively. Any PCa was detected in 30 men, includ-
ing 14 (47%) men with GS ≥3+4 PCa. This constitutes an overall positive predictive 
value (PPV) of 79%. Only 6 of 38 men with PSA level ≥3.0 ng/ml considered low-risk 
and therefore not advised to be referred were, however, referred to the urologist by 
their GP. Within the available FU time, in two of these men GS 3+3 PCa was detected, 
resulting in an overall negative predictive value (NPV) of 96% for any PCa and 100% 
NPV for csPCa. An overview of treatments applied to the 30 PCa patients is presented 
in table 3. The majority of men (80%, n=24) underwent active curative treatment (i.e. 
radiation therapy or radical prostatectomy [RARP]).
DISCUSSION
In 2016, the incidence of PCa was 11.064 and the 10-year prevalence of PCa was 79.223 
in the Netherlands (13). The number of new PCa cases is expected to increase by 49% 
in 2030 and consequently the PCa health care costs will rise as well. The importance 
of an effective diagnostic algorithm in PCa is therefore high. The primary health care 
Treatment type Number %




ADT ± chemotherapy 1 3
Total 30 100
Table 3. Overview of treatment types undergone by the men with PCa (n=30).
EBRT: external beam radiation therapy; RARP: robot assisted radical prostatectomy; ADT: androgen 
deprivation therapy.
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could help to further refine PCa detection strategies to become more acceptable to the 
general population and health care providers (e.g. costs of the prostate consultation 
at the primary care facility are 85 versus 592 Euros for a same consultation at a Dutch 
urologist). However, GPs are still uncertain about managing PCa screening, and for that 
reason men with PCa suspicion or a screening wish receive different care depending on 
their GP’s reasoning and practice preferences (14, 15). The implementation of validated 
PCa diagnostic risk models in primary care could be a solution for this problem and may 
help the GP to facilitate informed decision-making and improve patient selection for 
referral to secondary care.
The present study is the first study evaluating a risk calculator for patient selection 
for prostate biopsy in primary care. We show that by implementing multivariable risk-
stratification with the RPCRC in a primary health care setting the rate of men referred 
to the urologist for prostate biopsy with PSA level ≥3.0 ng/ml could be reduced with 
almost 50%. In more than 75% of men referred for biopsy according to the advice of 
the RPCRC, the suspicion of PCa has been confirmed and almost half of these men had 
GS ≥3+4=7 PCa. The vast majority of those men diagnosed with PCa received active 
treatment with curative intent (only 17% of men were followed-up on active surveil-
lance [AS]). This seems to indicate a favourable ratio between clinically significant 
and insignificant PCa after multivariable risk-stratification with the RPCRC in primary 
care. Within the available FU time, in only 5% of men with PSA level ≥3.0 ng/ml who 
were considered low-risk based on the RPCRC non-csPCa (GS 3+3=6) has been missed. 
The RPCRC uses readily available information like PSA and DRE. DRE is already often 
performed in the GP setting for volume estimation. In addition, abdominal ultrasound 
instead of TRUS could be used in GP practices for more accurate volume estimation. This 
is thought to easily be performed by GPs or trained nurses. Our study thereby suggests 
an important and relevant role for multivariable risk-stratification in primary care to 
improve patient selection for referral to secondary care.
Health care systems with a strong primary care component are more cost-effective than 
those that are predominantly led by hospital specialists (16). No previous studies have, 
however, described the use of PCa diagnostic risk models in the GP setting. Some papers 
recommend that PSA levels should no longer be referred to as “normal” or “elevated” 
but should be incorporated into appropriate multivariable risk-based strategies to 
provide individualized risk information for decision making in primary care practices 
(17-19). Only a few studies from primary care have examined signs next to an elevated 
PSA level that could predict PCa and improve patient selection for referral to secondary 
care this way. In the present study, the RPCRC showed an overall PPV of 79% for PCa. 
This is significantly higher than the PPV for any PCa (ranging from 12% to 42%) of 
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DRE alone or DRE in combination with weight loss and nycturia in primary care patients 
found by Walsh et al. and the CAPER studies (20, 21). 
Several studies have investigated the use of PCa risk calculators, including the RPCRC, 
in secondary care. Our rates of referrals/biopsies avoided, missed PCa and doctors’ 
compliance are in line with these previously well-established results of PCa risk cal-
culators in secondary care (5, 7, 9, 22-24). In contrast to these secondary care results, 
the rate of detected PCa in men considered high-risk was significantly higher in our 
cohort (79% vs. 15-49% in the other publications). The rate of detected csPCa was, 
however, similar. The benefits for the PCa diagnostic pathway obtained by using risk 
calculators for patient selection for biopsy seem similar in both primary and secondary 
care; probably being even more cost-effective when performing this risk-stratification 
in the primary care setting.
Unexpectedly, the compliance rate of GPs to the RPCRC-based advice on referral to 
secondary care was very high (94%). Within the short FU time already 75% of the men 
considered high-risk have actually been biopsied. It must be noted, that despite the 
very high PPV in those men considered at high-risk and actually biopsied it seems that 
there is room for improvement. More than half of men had a GS 3+3 PCa and based on 
only their Gleason grading could be considered as being overdiagnosed. In principle, 
based on their grading these men are eligible for AS. However, most men (69%) in 
whom GS 3+3 PCa (without taking into account e.g. tumour volume, MRI characteristics) 
was detected underwent active treatment, which could be considered as overtreatment. 
This implies that if we really aim to counterbalance the harms of PSA testing we should 
not only focus on reducing unnecessary referrals but also aim to uncouple diagnosis 
from treatment (25).
The strength of the present study is that all the examinations and risk calculation were 
performed in a true primary care population with prostate-related questions without 
any pre-selection. Therefore, we were able to test the RPCRC also in men with a PSA 
level <3.0 ng/ml who were referred mainly for LUTS advice and not specifically for PCa. 
On the basis of the RPCRC results, eight of these men (PSA levels ranging from 0.7 to 
2.8 ng/ml) were advised to be referred for further analysis; in two of these men PCa was 
detected. This reinforces the argument to implement PCa risk models in primary care 
since men considered high-risk according to the RPCRC and subsequently diagnosed 
with PCa are found in both PSA ranges. The fact remains that men with a PSA level <3.0 
ng/ml are mainly seen by GPs because the majority of them are not referred to the 
urologist.
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The present study is limited by the fact that the examinations were performed at the 
primary care facility by specially trained Erasmus MC personnel from the Department of 
Urology. Given that measuring the prostate volume with TRUS is not common practice 
for GPs and requires additional training and a TRUS-device, it still remains difficult to 
translate our study results to the real GP’s office. However, risk-stratification with the 
RPCRC could also be performed with only PSA and a DRE-based prostate volume. Both 
information is available in the GP setting. Besides, volume measurement with simple 
abdominal ultrasound instead of TRUS could be performed by trained GPs or nurses 
and could help to more accurately estimate the prostate volume. These measures might 
result in comparable RPCRC results as shown in the present study. The second limitation 
of this study is the fact that the diagnostic accuracy of the RPCRC in our primary care 
cohort could not be investigated within the full cohort since not all men considered 
high-risk underwent prostate biopsy. When additional FU data become available this 
will give new insight in PCa detection not only in these men but possibly also in those 
men initially considered as low-risk according to the calculations of the RPCRC.
In conclusion, our study shows that individualized multivariable risk-stratification for 
prostate biopsy based on PSA, DRE and prostate volume on TRUS in primary care may 
reduce unnecessary referrals to secondary care and, thereby reduce the number of 
biopsies, costs and workload in the urology outpatient clinic. Further studies in larger 
cohorts need to be performed, including the inclusion of GPs or trained nurses to ac-
tually perform the DRE and/or (abdominal) ultrasound, to confirm these findings and 
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AbSTRACT
We aimed to investigate the relation between largest lesion diameter, prostate-specific 
antigen density (PSA-D), age, and the detection of clinically significant prostate cancer 
(csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging – Report-
ing and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013-2019) from 
two referral centers were included. A multivariable logistic regression analysis was 
performed. The discrimination and clinical utility of the built model was assessed by the 
area under the receiver operation curve (AUC) and decision curve analysis, respectively. 
A higher PSA-D and higher age were significantly related to a higher risk of detecting 
csPCa, while largest index lesion diameter was not. The discrimination of the model 
was 0.80 (95% CI 0.73-0.87). When compared to a biopsy-all strategy, decision curve 
analysis showed a higher net benefit at threshold probabilities of ≥2%. Accepting a 
missing ≤5% of csPCa diagnoses, a risk-based approach would result in 34% of TBx ses-
sions and 23% of low-risk PCa diagnoses being avoided. In men with PI-RADS 3 index 
lesions scheduled for first-time TBx, the balance between the number of TBx sessions, 
the detection of low-risk PCa, and the detection of csPCa does not warrant a biopsy-all 
strategy. To minimize the risk of missing the diagnosis of csPCa but acknowledging the 
need of avoiding unnecessary TBx sessions and overdiagnosis, a risk-based approach is 
advisable.
keywords





The Prostate Imaging – Reporting and Data System (PI-RADS) score is important for 
standardized prostate magnetic resonance imaging (MRI) acquisition and reporting 
(1-4). Depending on the nature of the cohort and by following the PI-RADS guidelines, 
a not negligible number of lesions will be scored as PI-RADS 3, which is termed equivo-
cal (5). The prevalence of clinically significant prostate cancer (csPCa, often defined as 
International Society of Urological Pathology [ISUP] grade ≥2 PCa) in biopsied PI-RADS 
3 cases varies from 3% to 50% in the literature (6, 7).
PI-RADS 3 lesions are challenging because their characteristics in MRI have a great 
overlap with benign conditions (8, 9). On the other hand, tumors that are less visible by 
using T2-weighted (T2W) and apparent diffusion coefficient (ADC)-based tissue contrast 
might be classified as PI-RADS 3, despite the presence of Gleason ≥4 patterns (10). The 
PI-RADS guidelines propose recommendations for MRI-directed biopsy strategies, but 
do not clearly state how to deal with these category 3 imaging findings. In men with an 
overall PI-RADS score 3 on prostate MRI, an MRI-directed biopsy should be considered; 
however, biopsy can be avoided or deferred in carefully chosen patients if they are not 
at high risk of csPCa (2). Thus, while a targeted biopsy (TBx) may appear to be the logical 
next step in PI-RADS 3 cases, monitoring lesion characteristics with follow-up MRI and 
thereby postponing biopsies also seems to be an acceptable option (11).
The risk stratification of suspicious MRI lesions could help to avoid unnecessary biop-
sies. Studies on sub-classifying PI-RADS 3 lesions are limited and include most often 
small cohorts. The available data indicate that prostate-specific antigen density (PSA-D) 
might be useful in predicting the presence of csPCa (7, 11-17). From the perspective 
that size matters, subcategorizations of PI-RADS 3 lesions based on size have been 
proposed (18-21). However, sufficient evidence to develop clear directions on lesion 
characteristic-specific management of PI-RADS 3 lesions in csPCa diagnosis is still lack-
ing, especially in men scheduled for MRI and TBx for the first time.
Using one of the largest series of men with an overall PI-RADS score of 3 on prostate 
MRI undergoing a first TBx session currently available, we aimed to investigate whether 
stratifying PI-RADS 3 lesions based on the largest (index) lesion diameter could aid 
in avoiding TBx sessions and low-risk PCa diagnoses without missing the diagnosis of 
csPCa. In addition, acknowledging earlier publications of its potential usefulness we 
also studied PSA-D as stratification tool and combined this information with the largest 
index lesion diameter and age in a multivariable prediction model.




This retrospective study was approved by the institutional review boards of the Univer-
sity Düsseldorf Medical Faculty and Erasmus University Medical Center with a waiver of 
written informed consent (NL45884.078.13/A301321).
Between October 2013 and July 2019, a total of 2557 consecutive men with clinical 
suspicion of PCa (initial/repeat biopsy) or on active surveillance (AS) for low-risk PCa 
underwent a multiparametric MRI (mpMRI) and, if indicated, TBx of suspicious MRI le-
sions with additional systematic prostate biopsy (SBx) if applicable to guidelines at one 
of the two tertiary referral centers. A total of 1809 men had a positive MRI, defined as an 
overall PI-RADS score ≥3. In the current study, we included the 292 men with an overall 
PI-RADS score 3 undergoing a first TBx session (Figure 1). 
 
Figure 1. Flowchart of patients included in this study.
MRI: magnetic resonance imaging; PI-RADS: Prostate Imaging Reporting and Data System; NPV: 





MRIs were performed on a 3.0-Tesla MR scanner (Magnetom Trio Siemens [Düsseldorf, 
Germany] or Discovery MR750 GE Healthcare [Rotterdam, The Netherlands]) with a 
32-channel pelvic phased-array coil. MRI protocols included T2W, diffusion-weighted 
imaging (DWI) with ADC reconstructions and dynamic contrast enhanced (DCE) imaging. 
MRIs were reviewed by radiologists with 5 to 9 years of prostate MRI experience accord-
ing to the PI-RADS version 1 or version 2 guidelines (1, 4). MRI lesions with a PI-RADS 
score from 3 to 5 were defined as suspicious. Prostate volume on MRI was calculated 
using the prolate ellipsoid formula (length × width × height × π/6). Reported largest 
lesion diameter measurements were indicative for TBx decision management in daily 
practice, not for scientific volume estimations. Largest lesion diameter was preferably 
measured on an axial image, or otherwise on the image which best depicted the find-
ing. Peripheral and transition zone lesions were preferably measured on ADC and T2W 
imaging, respectively, or otherwise on the sequence that allowed the best visualization 
of the lesion.
Prostate biopsy
MRI-TBx was performed using an MRI-transrectal ultrasound (TRUS) fusion system 
(UroNav® Invivo [Düsseldorf, Germany] or UroStationTM Koelis [Düsseldorf, Germany, 
Rotterdam, The Netherlands]). The suspicious MRI lesions were targeted with 2-5 cores 
per lesion, depending on the lesion size. If indicated, an additional SBx (8-12 cores, 
depending on the prostate volume) was performed by the same operator. All the biopsy 
procedures were performed by a transrectal approach and by experienced operators.
Pathological review of biopsy specimens
Biopsy specimens were reviewed by experienced pathologists according to the ISUP 
2014 modified Gleason score (GS)/Grade Group (G) system (22). The presence of an in-
vasive cribriform growth pattern (CR) and/or intraductal carcinoma (IDC) was recorded. 
In general, csPCa and thereby the recommendation for treatment was defined as any GS 
≥3+4 PCa or ISUP grade ≥2 PCa found by TBx and/or SBx. Since our aim is to avoid TBx 
sessions, analyses are based on the TBx histopathology outcomes. The results of SBx 
were not used.
Study endpoints
Analyses of the largest (index) lesion diameter were performed at the patient and lesion 
level (= Supplementary Material). Analyses including PSA-D and age were performed at 
the patient level only.
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Three definitions for csPCa were analysed:
I:  ISUP grade ≥2 PCa (currently the most used, = primary outcome);
II: ISUP grade ≥2 with CR and/or IDC PCa;
III: ISUP grade ≥3 PCa.
Two definitions of “TBx avoided” were used:
- patient level = a complete TBx session avoided per patient;
- lesion level = a TBx procedure avoided per lesion (= Supplementary Material).
Primary outcomes:
- PCa detection in TBx specimen of men with equivocal MRI result (PI-RADS score 3);
- results in terms of avoiding TBx sessions and the detection of low-risk PCa of a risk 
stratification strategy based on the largest index lesion diameter accepting missing 
≤5% of csPCa diagnoses (definition I).
Secondary outcomes:
- results in terms of avoiding TBx sessions and the detection of low-risk PCa of a risk 
stratification strategy based on PSA-D accepting missing ≤5% of csPCa diagnoses 
(definition I);
- performance and clinical utility of a multivariable prediction model including age, 
largest index lesion diameter, and PSA-D for TBx decision management in men with 
equivocal MRI result (PI-RADS score 3).
Statistical analysis
Descriptive statistics were used to report the patient characteristics. Categorical data 
are reported as count (percentage). Continuous data are reported as median (interquar-
tile range [IQR]). Statistically significant differences in continuous non-parametric data 
were assessed with the Mann-Whitney U test. The Chi-square test for trend was used 
to test for differences in categorical data; in case of small numbers the Fischer’s exact 
test was used. PSA-D was calculated by dividing the PSA level by the MRI‐measured 
prostate volume. The relation of largest index lesion diameter, PSA-D and age at time 
of biopsy, and csPCa (I) detection was assessed using (multivariable) logistic regression. 
Age was included as a potential predictor in order to comply with the large age range 
of men in daily clinical practice, and because recent prostate MRI-risk calculators have 
shown that age could significantly add to original PCa risk calculators (23). For a better 
interpretation of the coefficients, we used the age per 10 years and multiplied the PSA-
D value by 10. The discrimination of the resulting multivariable prediction model was 
assessed by the area under the receiver operation curve (AUC). The confidence interval 
of the AUC was calculated with 2000 bootstrap samples. The clinical utility of the model 
105
6
was assessed with decision curve analysis. Analyses were performed using Statistical 
Package for the Social Sciences (version 24.0; IBM, Armonk, NY, USA) and R version 3.5.1.
RESULTS
Cohort characteristics and prostate cancer detection
The Düsseldorf and Rotterdam cohorts significantly differed in all reported patient char-
acteristics, except the time of follow-up (Table 1). The majority of men had a previous 
negative SBx procedure, and more than one PI-RADS 3 lesion on MRI. Any PCa, csPCa (I), 
csPCa (II) and csPCa (III) was detected in 32% (92/292), 13% (39/292), 7% (20/292) 
and 3% (10/292) of all men, respectively. In men with an initial suspicion of PCa, the 
csPCa (I) detection was significantly lower compared to men with previous negative SBx 
and men on AS. In the Düsseldorf cohort consisting of mostly biopsy-naïve men (42%) 
and men with a previous negative biopsy (53%), csPCa (I) was detected in 3% (4/154) 
of men. In the Rotterdam cohort consisting of mostly men on AS (51%) and men having 
a previous negative biopsy (45%), csPCa (I) was detected in 25% (35/138) of men.
The 292 men included had a total of 525 PI-RADS 3 lesions (Table 2). The median (IQR) 
largest lesion diameter was 11 (9-13) mm. The majority of PI-RADS 3 lesions was lo-
cated in the transition zone of the prostate. In these lesions, any PCa, csPCa (I), csPCa 
(II) and csPCa (III) was detected in 21% (108/525), 8% (43/525), 4% (20/525) and 
2% (10/525), respectively. There was no significant difference in csPCa (I) detection 
between peripheral- and transition-zone PI-RADS 3 lesions.
Risk stratification for TBx decision based on largest index lesion diameter
In this PI-RADS 3 cohort, in univariate analysis the largest index lesion diameter is not 
a statistically significant predictor (p=0.70) of csPCa (I) (Table 3). It must be noted that 
csPCa (I) is more often detected in men with larger PI-RADS 3 index lesions compared to 
men with smaller index lesions. When accepting missing ≤5% of csPCa (I) diagnoses, a 
threshold for largest index lesion diameter of ≥7mm would result in 10% fewer TBx ses-
sions and 26% of low-risk PCa diagnoses being avoided (Table 4, Supplementary Table 1). 
Risk stratification for TBx decision based on PSA-density
In this PI-RADS 3 cohort, in univariate analysis PSA-D is a statistically significant predic-
tor (p<0.001) of csPCa (I) (Table 3). Men with csPCa (I) had significantly higher PSA-D 
than men without csPCa (I). When accepting missing no more than 5% of csPCa (I) diag-
noses, a PSA-D threshold of ≥0.11ng/ml² would result in avoiding 25% of TBx sessions 
and 11% of low-risk PCa diagnoses (Table 4).
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Multivariable risk prediction for Tbx decision
Multivariable logistic regression showed that a higher PSA-D and a higher age at time 
of biopsy were significantly (p≤0.001) related to a higher risk of csPCa (I) diagnosis in 
PI-RADS 3 cases, while the largest index lesion diameter was not (p=0.51) (Table 3). 
To avoid data-dependent variable selection for the regression model, the largest index 
lesion diameter is included in the model despite not being a significant predictor. The 
discrimination of this model is 0.80 (95% CI 0.73-0.87). The model has a higher net 
benefit compared to a biopsy-all PI-RADS 3 patients strategy at threshold probabilities 








Age (yr), median (IqR) 64 (58-69) 61 (53-67) 67 (61-72) <0.001
Follow-up time (yr), median (IqR) 2 (1-3) 3 (2-4) 2 (1-3) 0.083
PSA level (ng/ml), median (IqR) 8.1 (6-12.2) 7.3 (5.5-11) 9.5 (6.6-13.1) 0.001
Prostate volume on MRI (ml), median (IqR) 52.3 (36-78.8) 58 (44.8-83.3) 46 (31-68.5) <0.001
PSA-density (ng/ml/ml), median (IqR) 0.16 (0.11-0.25) 0.13 (0.1-0.18) 0.23 (0.13-0.31) <0.001
Indication of prostate MRI, no. (%)  
Initial PCa diagnosis 69 (24) 64 (42) 5 (4) <0.001
Previous negative biopsy 144 (49) 82 (53) 62 (45)
Active Surveillance 79 (27) 8 (5) 71 (51)
DRE findings, no. (%)  
benign 191 (65) 75 (49) 116 (84) <0.001
Suspected 60 (21) 38 (25) 22 (16)
Unknown 41 (14) 41 (27) 0 (0)
PI-RADS 3 lesions on MRI, no. (%)  
1 132 (45) 16 (10) 116 (84) <0.001
2 89 (31) 69 (45) 20 (15)
3 69 (24) 67 (44) 2 (1)
4 2 (1) 2 (1) 0 (0)
Highest grade at Tbx, no. (%)  
no PCa 200 (69) 141 (92) 59 (43) <0.001
G 1 53 (18) 9 (6) 44 (32)
G 2 19 (7) 2 (1) 17 (12)
G 2 with CR and/or IDC 10 (3) 0 (0) 10 (7)
G 3 9 (3) 2 (1) 7 (5)
G 4-5 1 (1) 0 (0) 1 (1)
Table 1. Patient characteristics.
IQR: interquartile range; PSA: prostate-specific antigen; MRI: magnetic resonance imaging; PCa: 
prostate cancer; DRE: digital rectal examination; PI-RADS: Prostate Imaging Reporting and Data 
System; TBx: targeted biopsy; G: grade; CR: cribriform growth pattern; IDC: intraductal carcinoma.
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TBx sessions and 13% fewer low-risk PCa diagnoses at the cost of missing 3% csPCa (I). 
Table 5 shows the numbers of avoided TBx sessions, low-risk PCa diagnoses and missed 
csPCa (I) for the model using a risk threshold range of 2% to 10%. When accepting 
missing no more than 5% of csPCa (I) diagnoses, a risk threshold of 7% would result in 
34% fewer TBx sessions and 23% low-risk PCa diagnoses avoided. When not accepting 
missing the diagnosis of csPCa (I), a risk threshold of 3% should be applied resulting in 














Lesion size (largest diameter, mm), median (IqR) 11 (9-13) 12 (10-13) 10 (7-12) <0.001
Lesion zone, no. (%)
Peripheral zone 186 (35) 107 (30) 79 (49) <0.001
Transition zone 324 (62) 246 (68) 78 (48)
Central zone 2 (1) 0 (0) 2 (1)
>1 zone 13 (3) 10 (3) 3 (2)
Lesion location, no. (%)
Anterior 340 (65) 258 (71) 82 (51) <0.001
Posterior 178 (34) 103 (28) 75 (46)
both 7 (1) 2 (1) 5 (3)
Grade at Tbx, no. (%)
no PCa 417 (79) 346 (95) 71 (44) <0.001
G 1 65 (12) 10 (3) 55 (34)
G 2 23 (4) 5 (1) 18 (11)
G 2 with CR and/or IDC 10 (2) 0 (0) 10 (6)
G 3 9 (2) 2 (1) 7 (4)
G 4-5 1 (1) 0 (0) 1 (1)
Table 2. PI-RADS 3 lesion characteristics.
IQR: interquartile range; TBx: targeted biopsy; PCa: prostate cancer; G: grade; CR: cribriform growth 
pattern; IDC: intraductal carcinoma; PI-RADS: Prostate Imaging Reporting and Data System.
Variable
Univariable analysis Multivariable analysis (model)
Odds ratio 95% CI p value Odds ratio 95% CI p value
Age (per 10 years) 2.62 1.62 – 4.25 <0.001 2.31 1.43 – 3.92 0.001
Largest index lesion diameter 1.01 0.96 – 1.01 0.70 1.02 0.96 – 1.08 0.51
PSA-density (multiplied by 10) 1.65 1.31 – 2.10 <0.001 1.53 1.21 – 1.97 <0.001
Table 3. Output of the logistic regression analyses.
PSA: prostate-specific antigen.
































Monitor all patients   292 (100%) 53 (100%) 39 (100%) 20 (100%) 10 (100%)
biopsy all patients 0 (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
≥4mm - 3 (1%) 3 (6%) 0 (0%) 0 (0%) 0 (0%)
≥5mm - 11 (4%) 5 (9%) 1 (3%) 1 (5%) 0 (0%)
≥6mm - 19 (7%) 10 (19%) 1 (3%) 1 (5%) 0 (0%)
≥7mm - 29 (10%) 14 (26%) 2 (5%) 2 (10%) 1 (10%)
≥8mm - 41 (14%) 16 (30%) 5 (13%) 3 (15%) 2 (20%)
- ≥0.05ng/ml² 5 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
- ≥0.10ng/ml² 55 (20%) 4 (1%) 2 (5%) 1 (5%) 1 (10%)
- ≥0.11ng/ml² 73 (25%) 6 (11%) 2 (5%) 1 (5%) 1 (10%)
- ≥0.12ng/ml² 91 (31%) 9 (17%) 3 (8%) 1 (5%) 1 (10%)
- ≥0.15ng/ml² 141 (48%) 14 (26%) 5 (13%) 1 (5%) 1 (10%)
- ≥0.20ng/ml² 183 (63%) 19 (36%) 10 (26%) 2 (10%) 2 (20%)
Table 4. Summary table of the avoided targeted biopsy sessions and prostate cancer diagnoses 
missed, when using the largest index lesion diameter or PSA-density as a stratification tool.
PSA: prostate-specific antigen; TBx: targeted biopsy; ISUP: International Society of Urological Pa-
thology; PCa: prostate cancer; CR: cribriform growth pattern; IDC: intraductal carcinoma.
 
 





Patients with PI-RADS 3 index lesions scheduled for first-time TBx represent a diagnos-
tic problem, as there is controversy regarding whether these men should be biopsied or 
could safely be monitored with follow-up MRI. In this study, using a large international 
dataset, we found that csPCa with a detection percentage of 3%-13% (based on differ-
ent definitions) on first-time TBx was uncommon in PI-RADS 3 cases. This could imply 
that PI-RADS score 3 cases represent a category of men in whom initially monitoring 
with follow-up MRI could be a realistic option. The csPCa (I) detection at the patient 
level was 13% in our total population, with almost half of the cancers being not higher 
than ISUP grade 2 PCa without CR and/or IDC. Our csPCa (I) detection percentage is in 
line with the recent meta-analysis of Maggi et al. which included 25 studies, showing 
a csPCa detection percentage in PI-RADS 3 cases of 18.5% (95% CI 16.6-20.3; range 
3.4-47) (7). The reasons for the wide range of csPCa detection in PI-RADS 3 index 
lesions in the literature include, among others, the considerable interobserver vari-
ability in the characterization of equivocal lesions caused by reader experience and 
differences in technical performance, the prevalence of csPCa in different populations 
and TBx-related factors. These factors could potentially also explain the difference in 
csPCa (I) found between the Düsseldorf and Rotterdam cohorts. The low event rate in 
the Düsseldorf cohort limited us to perform logistic regression analyses separately per 
cohort. For these analyses the two cohorts were regarded as one, in line with analyses 
on heterogeneous cohorts (24).
Threshold Tbx sessions ISUP grade 1 PCa ISUP grade ≥2 PCa
Risk of csPCa Avoided (n, %) Not detected (n, %) Missed diagnosis (n, %)
Monitor all patients 292 (100%) 53 (100%) 39 (100%)
biopsy all patients 0 (0%) 0 (0%) 0 (0%)
≥2% 10 (3%) 1 (2%) 0 (0%)
≥3% 30 (10%) 2 (4%) 0 (0%)
≥4% 47 (16%) 4 (8%) 1 (3%)
≥5% 65 (23%) 7 (13%) 1 (3%)
≥6% 84 (30%) 9 (17%) 2 (5%)
≥7% 97 (34%) 12 (23%) 2 (5%)
≥8% 119 (42%) 16 (30%) 3 (8%)
≥9% 137 (48%) 20 (38%) 3 (8%)
≥10% 150 (53%) 22 (42%) 4 (10%)
Table 5. Performance and clinical utility of the prediction model: numbers of avoided TBx sessions, 
low-risk PCa diagnoses and missed csPCa using a risk threshold range of 2% to 10%.
CsPCa: clinically significant prostate cancer; TBx: targeted biopsy; ISUP: International Society of 
Urological Pathology; PCa: prostate cancer.
CHAPTER 6 | Equivocal PI-RADS three lesions on prostate magnetic resonance imaging
110
Instead of a monitoring all or a biopsy-all PI-RADS 3 patients strategy, a more realistic 
approach to avoid TBx sessions and low-risk PCa diagnoses would be to apply a risk 
stratification strategy. Risk stratification for TBx decision solely based on the largest 
index lesion diameter did not aid in avoiding TBx sessions while assuring csPCa (I) 
detection. On the contrary, risk stratification based on PSA-D only or a multivariable ap-
proach including next to the largest index lesion diameter, PSA-D, and age could result 
in avoiding a substantial number of TBx sessions and low-risk PCa diagnoses at the cost 
of missing only limited numbers of csPCa (I) diagnoses. These results suggest that when 
TBx is considered in men with PI-RADS 3 index lesions scheduled for first-time TBx, risk 
stratification based on PSA-D or preferably a multivariable model-based risk stratifica-
tion approach is advisable.
To the best of our knowledge, this is the first study to investigate largest (index) lesion 
diameter as a stratification tool in a large daily clinical cohort of men with PI-RADS 3 
index lesions. According to our results, largest index lesion diameter is not a signifi-
cant predictor of csPCa in PI-RADS 3 cases. To lower the risk of statistical overfitting, 
largest index lesion diameter is included in the multivariable prediction model (25). 
In our cohort, slightly more csPCa (I) was detected in PI-RADS 3 index lesions with a 
diameter ≥10mm (14%, 31/217), compared to index lesions with a diameter <10mm 
(11%, 8/75). This finding could suggest that csPCa is relatively rare in smaller PI-RADS 
3 index lesions. Rais-Bahrami et al. suggest that small MRI index lesions (≤7mm) may 
correspond to benign lesions or indolent cancers (18). Furthermore, Rosenkrantz et al. 
proposed to upgrade a PI-RADS 3 to a PI-RADS 4 lesion on the basis of larger size (20, 
26). These assumptions do, however, not take into account the scenario that in the stud-
ied series small PI-RADS 3 index lesions harboring csPCa could have been mis-sampled 
by TBx. The absence of csPCa in the TBx specimens would then mean that csPCa was 
missed and not that there was no csPCa present (6, 27). However, if this would really 
be the case follow-up of the lesions with MRI could overcome the problem of missing a 
timely csPCa diagnosis.
PSA-D showed to be a significant clinical predictor of csPCa in our cohort. Applying 
solely PSA-D as risk stratification tool could result in 25% less TBx sessions and 11% 
less low-risk PCa diagnoses missing only 5% csPCa (I). This high predictive value of 
PSA-D in PI-RADS 3 cases is in line with previous studies, and also with studies reporting 
on TBx and SBx histopathology outcomes (17). Venderink et al. showed that offering a 
biopsy to only PI-RADS 3 men with a PSA-D of ≥0.15ng/ml2 resulted in 42% of biopsy 
sessions avoided at the cost of missing 6% csPCa. Lowering the threshold to ≥0.12ng/
ml2 would result in 26% of biopsy sessions avoided, missing no csPCa (28). Therefore, 
PSA-D may represent a good index to decide which PI-RADS 3 men should undergo a 
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biopsy (29). The risk stratification of PI-RADS 3 cases could further be improved by a 
model-based approach in which PSA-D, largest index lesion diameter, and age are com-
bined in a multivariable prediction model that predicts the risk of csPCa of a PI-RADS 
3 man, as shown by our findings. To the best of our knowledge, our study is one of the 
first studies, next to the work of Di Trapani et al., to show the high added value of such 
a model-based approach in safely avoiding TBx sessions and low-risk PCa diagnoses in 
specifically PI-RADS 3 cases (29).
Next to the most often used definitions for csPCa, we studied the prevalence of PI-
RADS 3 lesions related to the presence of CR and IDC in TBx specimens. CR and IDC are 
prognostic drivers in cancer-specific survival, even more than other Gleason 4 patterns 
(30, 31). Although ISUP grade ≥2 PCa was our primary outcome measure for csPCa, the 
incorporation of this secondary growth patterns information into the risk stratification 
could further improve the selection of men who will benefit from treatment, especially 
because almost half of the detected ISUP grade ≥2 PCa in our cohort was ISUP grade 2 
without CR and/or IDC PCa. Therefore, we may argue that the threshold for csPCa should 
be ISUP grade ≥2 with CR and/or IDC PCa to save even more TBx sessions in men with 
PI-RADS 3 index lesions and thereby avoid the (over)detection of ISUP grade 2 PCa, 
which potentially could never harm a patient if left undetected (32).
The strength of our study is the inclusion of data from two centers, resulting in one of 
the largest series of men with an overall PI-RADS score 3 undergoing first-time TBx. This 
makes our study results more generally representative by giving more an overall view 
of the real-world setting of PI-RADS 3 lesions in daily practice, compared to reporting 
single center results. It must, however, be noted that every institution should know 
their own test performance statistics when making clinical decisions based on prostate 
MRI findings, because of existing differences in radiology, fusion biopsy and pathology 
learning curves per institution (33). Furthermore, our analysis of different csPCa defini-
tions including the presence of secondary growth patterns is of high added value for 
further clinical decision-making.
Some limitations of our study should be highlighted. First, our study has a retrospective 
design and could thereby introduce a selection bias. However, our study represents a 
cohort of consecutive men. Second, men included were treated over a long time frame in 
which changes in the PI-RADS classification also occurred. However, the newer PI-RADS 
versions may not necessarily be better regarding diagnostic accuracy than the original 
PI-RADS version (34-36). Third, we did not include SBx or prostatectomy outcomes as 
reference standard in our analyses. Some literature suggests to perform a combined 
biopsy strategy in PI-RADS 3 cases (7). However, since our primary objective was to 
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establish directions for lesion characteristic-specific management of PI-RADS 3 lesions 
in csPCa diagnosis, SBx outcomes would not have been of added value to answer our 
research questions. Furthermore, our results are similar to studies investigating PSA-D 
as stratification tool but reporting on TBx and SBx outcomes (17). This suggests that the 
TBx-only strategy could be similar in csPCa detection to the combined biopsy strategy in 
PI-RADS 3 cases. Nevertheless, when considering a biopsy in PI-RADS 3 men, we advise 
that adding SBx to TBx should be discussed at an individual level taking into account 
the benefits and harms. Fourth, although we have found potential predictors of csPCa in 
men with a PI-RADS 3 index lesion, the constructed prediction model is not (yet) usable 
in clinical practice for TBx decision management. To construct a more robust prediction 
model for TBx decision in PI-RADS 3 cases, more data are necessary and an external 
validation of the model is advised before its application in clinical practice. Lastly, the 
lesion measurements, although measured according to the PI-RADS recommendations, 
were not standardized. We acknowledge that standardized MRI lesion measurement 
should be the gold standard (37, 38). However, as long as this is not implemented in 
routine clinical practice, lesion measurement according to the PI-RADS guidelines is the 
daily workflow in most hospitals.
CONCLUSIONS
Overall, in men with PI-RADS 3 index lesions scheduled for first-time TBx, the balance 
between the number of TBx sessions, detection of low-risk PCa and detection of csPCa 
does not warrant a biopsy-all strategy. If the (low) risk of not diagnosing csPCa in these 
men is accepted, monitoring these men with follow-up prostate MRI could be consid-
ered as the optimal strategy avoiding TBx and the detection of low-risk PCa. To minimize 
the risk of missing the diagnosis of csPCa while acknowledging the need to avoid un-
necessary TBx sessions and overdiagnosis, a model-based risk stratification approach 
including at least PSA-D could be considered. More data are necessary to construct a 
robust clinically useful prediction model for TBx decision management in PI-RADS 3 
cases. Future large-scale studies should also focus on the need, optimal intervals, and 
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The fear of undergrading prostate cancer (PCa) in men on active surveillance (AS) 
have led to strict criteria for monitoring, which have resulted in good long-term 
cancer-specific survival, proving the safety of this approach. Reducing undergrading, 
MRI-targeted biopsies are increasingly used in men with low-risk disease despite their 
undefined role yet. The objective of this study is to investigate the rate of upgrading 
using MRI-targeted biopsies in men with low-risk disease on AS, stratified on the basis 
of PI-RADS and PSA-density, with the aim to reduce potential unnecessary repeat biopsy 
procedures.
Methods
A total of 331 men were prospectively enrolled following the MRI-PRIAS protocol. MR 
imaging was according to Prostate Imaging Reporting and Data System (PI-RADSv2) 
guidelines. Suspicious MRI lesions (PI-RADS 3-5) were additionally targeted by MRI-
TRUS fusion biopsies. Outcome measure was upgrading to Gleason score (GS) ≥3+4 
with MRI-targeted biopsies, stratified for PI-RADS and PSA-density.
Results
In total, 25% (82/331) of men on AS showed upgrading from GS 3+3. Only 3% (11/331) 
was upgraded to GS ≥8. In 60% (198/331) a suspicious MRI lesion was identified, but 
in only 41% (82/198) of men upgrading was confirmed. PI-RADS 3, 4 and 5 categorised 
index lesions, showed upgrading in 30%, 34% and 66% of men, respectively. Stratifica-
tion to PI-RADS 4-5, instead of PI-RADS 3-5, would have missed a small number of high 
volume Gleason 4 prostate cancer in PI-RADS 3 category. However, further stratification 
into PI-RADS 3 lesions and PSA-density <0.15 ng/mL2 could result in a safe targeted 
biopsy reduction of 36% in this category, without missing any upgrades.
Conclusions
Stratification with the combination of PI-RADS and PSA-density may reduce unnecessary 
additional MRI biopsy testing. Overall, the high rate of detected upgrading in men on 
AS may result in an unintended tightening of continuing in AS. Since patients, included 
under current AS criteria showed extremely favorable outcome, there might be no need 
to further restrict continuing on AS with MRI and targeted biopsies.
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In the Western world, about one half of all patients diagnosed with prostate cancer 
(PCa) has low-risk disease (1). In low-risk disease, active treatment hardly yields sur-
vival benefit (2). Therefore, active surveillance (AS) is the recommended option for the 
initial management of low-risk disease (3, 4).
Monitoring in AS is based on repeated PSA measurements, clinical T-staging based on 
digital rectal exams, and repeated random systematic transrectal ultrasound (TRUS)-
guided biopsies (3). Repeated biopsies are cumbersome for patients and have severe 
complication risks. Moreover, sampling errors lead to underestimation of the Gleason 
grading (5).
The fear of undergrading PCa in men on AS has however led to strict criteria for monitor-
ing, which has resulted in good long-term cancer-specific survival, proving the safety of 
this approach (6). To reduce the fear of undergrading, MRI and MRI-targeted biopsies are 
increasingly used in the management of patients with clinically low-risk PCa, despite 
their role has not yet been established definitively (7). The use of MR imaging in AS has 
improved the inclusion of true low-grade PCa; targeted biopsies of suspected lesions 
on MRI may result in excluding those men found with intermediate/high-grade PCa (8).
However, this additional testing by MRI and MRI targeted biopsy may result in an 
unintended reclassification to perceived higher risk. This is termed as ‘risk inflation’; 
a cancer that is stable may be more accurately sampled at MRI-targeted biopsy and 
found to include higher risk features than when it was sampled in a routine systematic 
manner (9). This lesion targeting results in an increase in risk attribution if traditional 
criteria (i.e. Gleason score [GS], cancer core length and the proportion of positive cores 
on routine sampling) are still applied. It would therefore be wrong to falsely encourage 
men to cease AS because of an apparent increase in risk (reclassification) rather than a 
true change in their cancer.
Appropriate risk thresholds are not yet understood when MRI and MRI-targeted biopsies 
are used. In this study we investigate the upgrading with MRI and MRI-targeted biopsies 
in men with low-risk disease on AS, and examine the potential reduction of targeted bi-
opsies by stratifying to PI-RADS and PSA-density. We explore the possible risk inflation 
by MRI and targeted biopsies, and look into the potential extension of GS thresholds for 
continuing in AS when using MRI in strict monitoring.
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METHODS
The study was HIPAA compliant and was approved by the institutional ethical review 
board (NL45884.078.13/A301321). Written informed consent with guarantee of confi-
dentiality was obtained from the participants. Men with low-risk PCa are prospectively 
enrolled in our in-house database as part of our AS protocol. From November 2013 until 
October 2017 a total of 347 consecutive men on AS for low-grade (GS 3+3) PCa detected 
by TRUS guided biopsy received a first multi-parametric MRI and targeted biopsies of 
visible suspicious MRI lesions at our tertiary referral center.
A total of 331 men were included in the current study. Men were excluded (16/347), as 
they did not undergo additional targeted biopsy, despite of having a positive MRI (n=8 
PI-RADS 3 lesions, n=8 PI-RADS 4 lesions). Results of part of this prospective cohort 
have been previously published (10).
In 50% (166/331) men were participants of the PRIAS study (www.prias-project.org), an 
international web-based AS study with strict criteria for inclusion at diagnosis (GS 3+3, 
T-stage ≤cT2, PSA ≤10 ng/ml, ≤2 positive cores, PSA density <0.2) and follow-up (11). 
Within the MRI-PRIAS side study protocol an MRI and targeted biopsies (if indicated) 
are performed at baseline (3 months after diagnosis) and during every repeat standard 
TRUS-guided biopsies, scheduled at 1, 4, 7 and 10 years after diagnosis. Inclusion in 
the MRI-PRIAS side study is also possible after ≥1 repeat TRUS-guided biopsies. The 
only reclassification criterion in the MRI-PRIAS side study is the presence of high-grade 
PCa (GS ≥3+4) at MRI-targeted biopsy. A head-to-head comparison of MRI-targeted 
with standard TRUS-guided biopsies was only available in repeat biopsies, and was not 
further investigated in this study.
The remaining 165/331 (50%) men in the present study had low-grade PCa based 
on standard TRUS-guided biopsy findings, but were followed-up outside of the PRIAS 
protocol as they did not meet the strict PRIAS inclusion criteria or were referred from a 
center not participating in PRIAS. All men were included in our prospective, institutional 
review board approved database, which is HIPPA compliant.
Multi-parametric MRI
The institutional MRI protocol included T2-weighted imaging (T2w), diffusion-weighted 
imaging (DWI) with apparent diffusion coefficient (ADC) reconstructions, and dynamic 
contrast enhanced (DCE) imaging, as previously described (12), according to the Pros-
tate Imaging Reporting and Data System (PI-RADS) version 2 guidelines (13). MRI was 
performed on a 3-T system (Discovery MR750, General Electric Healthcare, USA) using a 
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32-channel pelvic phased-array coil. All MRIs were reviewed by one urogenital radiolo-
gist (IGS) with over 5 years of prostate MRI experience. Individual lesions were scored 
according to the PI-RADSv2 5-point likelihood scale for high-grade PCa, and the index 
lesions were annotated and delineated (13). Visible MRI lesions with a PI-RADS score 
from 3 to 5 were defined as suspicious. 
MRI-targeted biopsy 
The MRI-TRUS fusion technique was used (UroStation™, Koelis, France) to perform the 
targeted biopsies of all suspicious lesions, identified on MRI. The suspicious MRI le-
sions, delineated on DICOM images, were targeted with 2 – 4 cores under ultrasound 
guidance. Experienced operators (FHD, DFO, JFV) performed the biopsy procedures. 
Pathological review of biopsy specimens
One expert uropathologist (GJvL) reviewed all biopsy specimens according to the Inter-
national Society of Urological Pathology (ISUP) 2014 modified Gleason Score (14). GS 
upgrading was defined as any GS ≥3+4 PCa found by MRI-targeted biopsies.
Study objectives
The primary objective of this study was to identify upgrading with MRI and MRI-targeted 
biopsies (benefit) in men on AS with GS 3+3. In line with this objective, the absence of 
upgrading (harm) despite of additional testing with MRI and targeted biopsies, was also 
assessed. The outcome measure is the presence/absence of upgrading to GS ≥3+4.
The secondary objective was to assess the value of risk-stratification based on MRI (PI-
RADS) and PSA-density for the presence/absence of additional upgrading. Additional 
analysis was performed with the outcome measure of GS ≥4+3, focussing on risk infla-
tion with MRI.
Statistical analysis
In accordance with the START recommendations, the outcome measure of clinically 
significant PCa for MRI and targeted biopsies is the biopsy result of GS 3+4 and higher 
(15). The PSA density was calculated using the MRI-measured prostate volume. The 
MRI-measured volume was calculated by the prolate ellipsoid formula (length x width 
x height x π/6). The PSA density cut-off point of 0.15 and 0.20 ng/mL2 was used for 
stratification (16-19). Histograms of the stratified PI-RADS and GS biopsy outcomes 
were constructed to visualize in which men GS upgrading did or did not occur.
Statistical tests were two-sided with the criterion of significance set at P<0.05. Statisti-
cally significant differences in continuous non-parametric patient characteristics were 
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assessed with the Mann-Whitney U test, while the χ2 test for trend was used to test for 
differences in categorical patient characteristics; in case of small numbers the Fischer’s 
exact test was used. Statistical analyses were performed with SPSS for Windows (Ver-
sion 21.0. Armonk, NY: IBM Corp.). In addition, R version 3.4.2 and R-package ggplot2 
(20) were used for visualization. Gleason scores were dichotomized using cut-off score 
Gleason ≥3+4, and Gleason ≥4+3, in which a zero indicated a GS below the cut-off and 
a one indicated a GS above the cut-off score.
RESULTS
In 331 men on AS for GS 3+3 PCa, the median (interquartile range) age and PSA level 
at diagnosis were respectively 67 (range, 62–72) years and 8.0 (range 5.6–12.0) ng/mL 
(Table 1). A total of 66/331 (20%) men had more than two positive systematic biopsy 
cores at diagnosis. A total of 155/331 (47%) men received their first MRI at baseline, 
while 176/331 (53%) men received their first MRI at confirmatory biopsy or at surveil-
lance biopsy. In these men no previous MRI was performed. Men included in PRIAS did 
not significantly differ from men not included in PRIAS, accept for a small PSA and PSA-
density difference (Table 1), reflecting PRIAS inclusion criteria.
Benefit of additional testing with MRI and targeted biopsies
Upgrading in all men on AS
In total, 25% (82/331) of men on AS showed upgrading from GS 3+3, due to additional 
testing by MRI and if indicated targeted biopsies. The majority (71%) was upgraded to 
GS 3+4, only 16% (13/82) and 13% (11/82) to GS 4+3 and GS ≥4+4, respectively. Most 
of the upgraded index lesions (82%) were categorized into PI-RADS 4 and 5. Highest 
GS’s were associated with PI-RADS 4 and 5.
Upgrading in men with a suspicious MRI index lesion
In 60% (198/331) a suspicious lesion was identified on MRI, and was additionally 
biopsied (Figure 1). 41% (82/198) of these suspicious lesions showed upgrading from 
GS 3+3 to GS 3+4 or higher. In PI-RADS 3, 4 and 5 index lesions, the upgrading was 30% 
(15/50), 36% (36/101) and 66% (31/47), respectively.
Upgrading in men with a PI-RADS 3 lesion
Of all suspicious index lesions on MRI, 25% (50/198) was categorised into PI-RADS 
3 (Figure 1), meaning that the MRI abnormalities are equivocal to high- or low-grade 
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respectively, showing the additional value of targeting these PI-RADS 3 lesions. None of 
these lesions however showed GS ≥4+4.
Figure 3. Unnecessary MRIs (blue in left graphs) (left) and unnecessary targeted biopsies (blue in 
right graphs) for Gleason cut-off score GS ≥3+4 (upper half) and GS ≥4+3 (lower half), for detecting 
clinically significant prostate cancer (red) in men with initially low-risk disease, based in traditional 
criteria. 
























































































































































































































































































































































































































































































































































































Harms of additional testing with MRI and targeted biopsies
Abundantly or unnecessary MRI and targeted biopsies
In 40% (133/331) of men, no suspicious lesions on MRI were identified. In these men 
MRI testing did not result in MRI-targeted biopsies, and no further harm was attributed.
In 59% (116/198) of men with a suspicious MRI, additional MRI-targeted biopsies did 
not result in upgrading: GS 3+3 PCa was confirmed in 44% (87/198), and no PCa was 
detected in 15% (29/198). These biopsies can be considered as harm and this was most 
prominent in the PI-RADS 3 category (70% GS 3+3 or no PCa) (Figure 2). Similar analysis 
for PI-RADS 4 and PI-RADS 5 category resulted in 64% and 34% unnecessary targeted 
biopsies.
Abundantly or unnecessary MRI and targeted biopsies adjusted to risk inflation
When looking at the detection of GS ≥4+3 PCa additional testing did not result in 
upgrading in respectively 93% (307/331) of all MRIs, and in 88% (174/198) of all MRI-
targeted biopsies (Figure 3).
Potential strategies to reduce further harm
Excluding PI-RADS 3 lesions from targeted biopsies
Excluding PI-RADS 3 index lesions from targeted biopsies would result in a reduction of 
25% (50/198) targeted biopsies, however, still missing 18% (15/82) of all upgrades to 
GS ≥3+4. Missed upgrading to GS ≥4+3 would be 5% (4/82).
Stratifying to PSA-density before targeting suspicious MRI lesions
Figures 4 and 5 show the number of men with targeted biopsies, stratifying to PIRADS 
and to PSA-density.
PSA-density cut-off ≥0.15 ng/mL2
Upgrades to GS ≥3+4 in PI-RADS 3 lesions were all identified in men with a PSA-density 
of ≥0.15 ng/mL2. Hence, when first stratifying according to a PSA-density cut-off ≥0.15 
ng/mL2 in men with a PI-RADS 3 lesion, would result in a MRI-targeted biopsy reduc-
tion of 36% (18/50) in this category, without missing any upgrade to GS 3+4 or higher. 
These results are plotted in figure 5 to visualize the amount of additional MRI testing 
with targeted biopsies, in men with initially low-risk disease on AS. The PSA-density 
thresholds of 0.15 and 0.20 ng/mL2 are depicted as dotted lines.
Even for PI-RADS 4 lesions, risk stratification by PSA-density could be beneficial if ad-
justment to potential risk inflation is performed: only 1% (1/82) of all upgrades would 
have been missed, reducing 43% (43/101) of targeted biopsies in this category.
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PSA-density cut-off ≥0.20 ng/mL2
Stratifying according to the PSA-density cut-off ≥0.20 ng/mL2 would result in a targeted 
biopsy reduction of 44% (22/50) of all PI-RADS 3 index lesions, at the cost of missing 
2% (2/82) upgrades; these 2 index lesions were classified as GS 3+4. When changing 
outcome to GS ≥4+3, the reduction of 44%  in targeted biopsies of PI-RADS 3 lesions, 
coincides with not missing any upgrades to GS 4+3 or higher (Figures 4 and 5).
Figure 6. Active surveillance and initial MRI. Men included in active surveillance (circle 1), based on 
traditional criteria (PSA, clinical T-stage and Gleason score by systematic ultrasound-guided biop-
sies) have excellent prognosis as shown by long-term follow-up of several clinical trial (6,30,35). 
Nowadays, men undergo additional MRI, as suggested by recent reviews (8,36). These MRIs show in 
more than half at least one suspicious lesion. Subsequently, these lesions are biopsied by MRI-tar-
geted approach (circle 2). A significant proportion shows upgrading (circle 3), of which the majority 
is Gleason score (GS) 3+4 (circle 4). In current clinical practice all upgraded men are advocated to 
cease active surveillance and change into active treatment, despite good prognosis (circle 5). This 
suggests ‘risk inflation’. In the hypothesized clinical practice, only men with upgrading to primary 
Gleason 4 pattern and higher are excluded from active surveillance (circle 6), correcting the pres-
ent initiated ‘risk inflation’ by MRI. 




In our data on men on AS, additional testing with MRI and targeted biopsies could be 
regarded as beneficial in 25% of men: additional testing resulted in an upgrade to GS 
≥3+4 as compared to the GS 3+3 PCa based on systematic TRUS-guided biopsy findings. 
Our results matches well with upgrading data of other studies on AS, varying from 16% 
to 29% (21-27). This rate of upgrading was even higher (41%) as we consider only 
those men who had a positive MRI, defined as PI-RADS 3 to 5. However, the relevance 
of identifying and acting on this upgrading cannot be adequately interpreted without 
the presence of long-term data on cancer-specific survival. In fact, a similar cohort of 
men with low-risk disease, without additional testing by MRI and targeted biopsies, has 
a 15-year cancer-specific survival of 94,3% (6).
Autopsy data show that many men with intermediate-risk disease (Gleason 7) are never 
diagnosed and therefore have clinically ‘insignificant’ cancer (28, 29). The Prostate Test-
ing for Cancer and Treatment (ProtecT) trial, which compared in a randomized controlled 
manner three modalities of management (active monitoring, radical prostatectomy, 
and external beam radiotherapy) on patients with localized PCa (30), demonstrated no 
significant difference in the 10-year cancer-specific survival or overall survival.
In the ProtecT trial there was a difference in metastasis rate, however, favouring radical 
treatment at 10 years follow-up. This difference in metastasis rate is considered to re-




Threshold csPCa: GS ≥3+4 
 
 









Stratification into PSAD <0.15 and ≥0.15
PI-RADS 3 P3 and PSAD <0.15 P3 and PSAD ≥0.15   P3 and PSAD <0.15 P3 and PSAD ≥0.15
PI-RADS 4   P4 and any PSAD   P4 and PSAD <0.15 P4 and PSAD ≥0.15
PI-RADS 5   P5 and any PSAD     P5 and any PSAD
Stratification into PSAD <0.20 and ≥0.20
PI-RADS 3 P3 and PSAD <0.20 P3 and PSAD ≥0.20   P3 and PSAD <0.20 P3 and PSAD ≥0.20
PI-RADS 4   P4 and any PSAD     P4 and any PSAD
PI-RADS 5   P5 and any PSAD     P5 and any PSAD
Table 2. Summarised strategies to reduce targeting biopsies in low-risk men in active surveillance 
based on current data.
CsPCa: clinically significant prostate cancer; GS: Gleason score; PSAD: prostate specific antigen-
density; PI-RADS: MRI suspicion score.
























































































































































































































































































































































































































































































































































































































CHAPTER 7 | Reduction of MRI-targeted biopsies in men with low-risk prostate cancer
144
monitoring is clearly associated with an increased risk of progression. Nonetheless, the 
lack of a mortality difference emphasizes that the majority of Gleason 7 patients are not 
at risk in the 10-year time frame.
In the Sunnybrook surveillance cohort the 15-year metastasis rate was at least 20% 
in Gleason 7 cancer at initial diagnosis (31). In a recent study, however, no increase 
in metastasis rate or progression of intermediate risk patients on surveillance was re-
ported compared to low risk, with up to 10 year follow-up (32). This suggests that many 
intermediate risk patients may still be candidates for AS (33).
The experiences described were from the pre-MRI era: men with Gleason 7 PCa at 
standard systematic biopsy sampling might have consisted partially of men with higher 
Gleason grades. Today, such patients will have the benefit of an MRI and targeted biop-
sies, with a high likelihood of a more accurate biopsy and hence better representative 
histopathology results (34). This may result in an unintended tightening of inclusion for 
AS, as schematically depicted (Figure 6) (35, 36).
We detected 25% upgrading to Gleason 7 and higher, however, only 3% was Gleason 
8 and higher, identical to other published reports (26, 37). It is likely that only these 
men with Gleason 8 and higher disease significantly influenced cancer-specific survival 
in men classified as having low-risk disease, in which the overall prognosis showed to 
be excellent in the pre-MRI era (6). We may argue that low-risk patients upgraded with 
targeted biopsies to intermediate-risk disease should not be excluded from AS based 
on the Gleason criterion alone. The higher precision of MRI and targeted biopsies may 
create the opportunity to specify new risk thresholds that potentially could open AS to 
a larger group of patients. Treatment decisions should be based on multiple parameters 
next to patient age and co-morbidity, including percentage of Gleason 4, growth pat-
terns (e.g. cribriform), PSA-density, and MRI findings.
Therefore, the major challenge is accurate patient selection for AS, without the burden 
of intensively additional testing.  The additional testing by MRI and targeted biopsies, 
recommended in recent reviews on MRI in AS (8, 36), comes with an extra invasive 
procedure, increasing the burden for patients staying in AS.
In this study, MRIs were abundantly or unnecessary performed in 75% of men in AS. Fur-
thermore, unnecessary targeted biopsies were performed in 59% in men with a suspi-
cious MRI (Figure 3), most prominent in PI-RADS 3 and 4 assessment category (Figure 2). 
Unnecessary testing would even be 93% for MRI and 88% for targeted biopsies, if we 
accept GS 3+4 as less significant disease. This critical evaluation of additional invasive 
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testing is not to devaluate MRI, instead, this evaluation supports exploring refinements 
in the role of MRI at primary diagnosis and in AS, as proposed in figure 6.
The PI-RADS steering committee recommended to biopsy lesions with PI-RADS category 
4 and 5, and not lesions with PI-RADS category 1 and 2 (13). For findings with PI-RADS 
category 3, biopsy may or may not be appropriate, depending on factors other than 
MRI alone. In our study we biopsied all PI-RADS category 3 lesions, and detected high 
volume Gleason 4 pattern in 8% PI-RADS 3 lesions (all GS 4+3, no GS ≥4+4). We may 
argue that in some circumstances this might be acceptable, reducing the additional 
harms of additional biopsies. However, further stratification by PI-RADS to biopsy only 
PI-RADS category 4 and 5 would result in missing high volume Gleason 4 pattern, as also 
confirmed by other studies (23, 38).
We therefore additionally investigated the combination of PSA-density and MRI to fur-
ther tailor the patient risk stratification in reducing unnecessary biopsies and improving 
the balance between the benefit and harms of additional testing. Using the PSA-density 
cut-off ≥0.15 ng/mL2 in men with a PI-RADS 3 lesion would result in a targeted biopsy 
reduction of 36% in this category, without missing any upgrade to GS 3+4 or higher 
(Figures 4 and 5). Even for PI-RADS 4 lesions, tailored risk stratification by PSA-density 
could be beneficial if adjustment to risk inflation is performed (Figures 4 and 5, Table 2).
Others have confirmed this correlation, however, data in men on AS is limited (37, 
39-41). In a multivariate cox-regression analysis, the PSA-density was shown to be a 
positive predictor to detect upgrading in men on AS, with a hazard ratio of 1.72 (40). In 
a receiver operating characteristic (ROC) analysis by Lai et al. the optimal PSA-density 
cut-off point was 0.18 ng/mL2 with an AUC of 0.77 (39). The optimal cut-off in men 
on AS should be further determined in larger cohorts. In a cohort of men with initially 
diagnosed low-risk disease by MRI/US fusion biopsy and monitoring with serial fusion 
biopsies, still PSA-density was an important predictor of subsequent upgrading (41). 
Our study clearly suggests that men on AS with a PI-RADS 3 index lesion and a PSA-
density of <0.15 ng/mL2 may not benefit from a follow-up biopsy.
Incorporating prostate MRI at primary PCa diagnosis will result in better discrimination 
between true low-risk disease and intermediate-/high-risk disease. If TRUS-guided bi-
opsies combined with MRI and targeted biopsies are able to minimize misclassification 
of PCa, we may abandon the currently used confirmation biopsy testing at 1 year in AS 
management, as depicted in figure 7. MRI and targeted biopsies are increasingly used 
in the surveillance management of patients with clinically low-risk PCa; however, their 
role has not yet been established definitively (7). We may hypothesize that surveillance 
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management of men with low-risk PCa will incorporate results from MRI and targeted 
biopsies into multivariate risk models in nearby future (Figure 7B) (42).
Our study comes with some limitations. First, our study is a retrospective design. 
Retrospective studies are known for their risk of selection bias. However, our study 
represents a prospectively monitored cohort of consecutive men on AS, with strict 
monitoring (within or without the PRIAS protocol). Second, we did not perform co-
reading of MRIs, which likely would have increased detection sensitivity. However, 
even without co-reading the MRI detection rate in our cohort is comparable to those 
reported in recent publications on MRI in AS (21-27). Third, clinicians involved were 
not blinded to clinical data and MRI results. Hence, this process is daily clinical practice 
and therefore can be extrapolated to other hospitals. Fourth, the presence of standard 
systematic biopsy results in this study next to MRI-targeted biopsies would have shown 
the imperfection of MRI in detection all clinically significant PCa. Studies evaluating this 
added value are reporting up to 11% additionally found clinically significant PCa (8). As 
part of the monitoring protocol, the majority of men received their initial MRI without 
additional systematic biopsies. However, this group of men will decrease as a result 
of the increased introduction of MRI and targeted biopsies at the primary diagnostic 
work-up.
We acknowledge that the outcome measurement of our analysis was upgrading, based 
on MRI-revealed Gleason grading as recommended by the START consortium (15). 
Instead, the cancer-specific survival rate in long-term follow-up would have been more 
appropriate, especially in disputing the relevance of this high upgrading rate due to 
MRI targeted biopsies. However, this outcome may be debatable in a cohort of men with 
mostly low-risk disease that exhibits excellent long-term cancer-specific survival (6), 
and furthermore experiences most shifts from AS to active treatment during the first 2 
years of follow-up (43).
CONCLUSIONS
In this study on AS, we detected by MRI-targeted biopsies an upgrading to Gleason 7 
and higher in 25%, however, only 3% was Gleason 8 and higher. This rate of upgrading 
was even higher (41%) as we consider only those men who had a suspicious finding on 
prostate MRI, defined as PI-RADS 3 to 5. Further stratification to PI-RADS 4-5 would have 
missed a small number of primary Gleason 4 PCa in the PI-RADS 3 category. Stratification 
with the combination of PI-RADS and PSA-density may reduce unnecessary additional 
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MRI biopsy testing. We showed that men on AS with a PI-RADS 3 index lesion and a 
PSA-density of <0.15 ng/mL2 will not benefit from a follow-up targeted biopsy.
The high rate of detected upgrading may result in an unintended tightening of continu-
ing in AS. Since patients, included under current surveillance criteria showed extremely 
favorable outcome, there might be no need to further restrict continuing on AS with MRI 
and targeted biopsies. The higher precision of MRI and targeted biopsies may create the 
opportunity to specify new risk thresholds that potentially could open AS to a larger 
group of patients.
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To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the 
utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with 
low-risk prostate cancer (PCa) at 1-year of active surveillance (AS).
Patients and Methods
We retrospectively included 111 consecutive men with low-risk (International Society 
of Urological Pathology [ISUP] Grade 1) PCa, who received protocolled repeat MRI with 
or without TBx and repeat SBx at 1-year of AS. TBx was performed in Prostate Imaging-
Reporting and Data System (PI-RADS) score ≥3 lesions (MRI-positive men). Upgrading 
defined as ISUP Grade ≥2 PCa (I), Grade ≥2 with cribriform growth/intraductal carcinoma 
PCa (II), and Grade ≥3 PCa (III) was investigated. Upgrading detected by TBx only (not by 
SBx) and SBx only (not by TBx) was investigated in MRI-positive and -negative men, and 
related to radiological progression on MRI (Prostate Cancer Radiological Estimation of 
Change in Sequential Evaluation [PRECISE] score).
Results
Overall upgrading (I) was 32% (35/111). Upgrading in MRI-positive and -negative men 
was 48% (30/63) and 10% (5/48) (P <0.001), respectively. In MRI-positive men, there 
was upgrading in 23% (seven of 30) by TBx only and in 33% (10/30) by SBx only. Radio-
logical progression (PRECISE score 4-5) in MRI-positive men was seen in 27% (17/63). 
Upgrading (I) occurred in 41% (seven of 17) of these MRI-positive men, while this was 
50% (23/46) in MRI-positive men without radiological progression (PRECISE score 1-3) 
(P =0.534). Overall upgrading (II) was 15% (17/111). Upgrading in MRI-positive and 
-negative men was 22% (14/63) and 6% (three of 48) (P =0.021), respectively. In MRI-
positive men, there was upgrading in three of 14 by TBx only and in seven of 14 by SBx 
only. Overall upgrading (III) occurred in 5% (five of 111). Upgrading in MRI-positive 
and -negative men was 6% (four of 63) and 2% (one of 48) (P =0.283), respectively. In 
MRI-positive men, there was upgrading in one of four by TBx only and in two of four by 
SBx only.
Conclusion
Upgrading is significantly lower in MRI-negative compared to MRI-positive men with 
low-risk PCa at 1-year of AS. In serial MRI-negative men, the added value of repeat SBx 
at 1-year surveillance is limited and should be balanced individually against the harms. 
In serial MRI-positive men, the added value of repeat SBx is substantial. Based on this 
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cohort, SBx is recommended to be performed in combination with TBx in all MRI-positive 
men at 1-year of AS, also when there is no radiological progression.
keywords
Low-risk prostate cancer; active surveillance; prostate MRI; PI-RADS; PRECISE; upgrad-
ing.
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INTRODUCTION
Active surveillance (AS) is a widely used strategy for managing men with low-risk 
prostate cancer (PCa) to reduce overtreatment and treatment-related side-effects, with 
confirmed oncological safety at long-term follow-up (1). The fear of under grading at 
time of diagnostic biopsy has led to the development of AS protocols with strict criteria 
for inclusion and monitoring, like the Prostate cancer Research International Active 
Surveillance (PRIAS) study (www.prias-project.org) (2).
Today, magnetic resonance imaging (MRI) and targeted biopsy (TBx) are increasingly 
used in the evaluation of patients with low-risk PCa who initially opt for AS, based on 
systematic transrectal ultrasound-guided prostate biopsy (SBx) findings (3). The ad-
ditional use of a first pre-biopsy MRI and subsequent TBx in these men can aid in the 
exclusion of higher risk men with International Society of Urological Pathology (ISUP) 
Grade (G) 2 and higher PCa, irrespective of the timing of the MRI during follow-up (i.e. at 
baseline, confirmatory or surveillance biopsy) (4-9). A first pre-biopsy MRI in the evalua-
tion of men on AS for low-risk PCa has therefore recently been adopted in the European 
Association of Urology (EAU) PCa guidelines (10).
An MRI-based monitoring strategy in men with low-risk PCa on AS is attractive to health 
systems and patients, potentially avoiding a prostate biopsy procedure with its at-
tendant morbidities as much as reasonably possible. The Prostate Cancer Radiological 
Estimation of Change in Sequential Evaluation (PRECISE) criteria could help to qualify 
radiological risk of progression on serial prostate MRI (11, 12). However, the role of 
MRI in monitoring and its potential to guide the indication for repeat biopsies (i.e. 
confirmatory and surveillance biopsies) during AS is still unclear. Unanswered issues 
in clinical practice are whether SBx could be omitted in cases of a negative follow-up 
MRI, whether only TBx should be performed in cases of a positive follow-up MRI, and 
whether biopsies should only be performed in cases of radiological disease progres-
sion on follow-up MRI. Recent studies provide contradictory findings in men on AS for 
low-risk PCa as to whether or not serial MRI could obviate the need for repeat biopsies 
(13-24). Hamoen et al. showed an overall added value for repeat (confirmatory) SBx at 
1-year of AS of 42% as compared to 7% added value for serial MRI with or without TBx 
(MRI ± TBx) (18). However, Thurtle et al. and Elkjaer et al. found much more added value 
for serial MRI ± TBx (30%-50%), and less added value for repeat SBx (9%-12%) in their 
cohorts (19, 20). Substantial evidence on implementing prostate MRI as a monitoring 
tool in men on AS for low-risk PCa is still lacking.
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As virtually all AS protocols advise a repeat biopsy procedure after 1 year on AS, we 
aimed to determine the potential guidance of serial prostate MRI (i.e. positive or nega-
tive MRI, with or without radiological progression) in the utility of repeat TBx and SBx in 
men with low-risk PCa at 1-year of AS, using different definitions for clinically significant 
PCa (csPCa) as outcome measures.
PATIENTS AND METHODS
Study population
This retrospective study was approved by our Institutional Review Board (IRB; 
NL45884.078.13/A301321), and written informed consent with guarantee of confiden-
tiality was obtained from all study participants. No additional data other than already 
collected as part of this IRB-approved study was sought for the analyses done in this 
study. Men with low-risk PCa (ISUP Grade 1) were prospectively enrolled in our in-house 
clinical database as part of our AS protocol. All men were followed according to the 
MRI-PRIAS study protocol (www.prias-project.org). In summary, they underwent an MRI 
± TBx at baseline (3 months after the detection of low-risk PCa on diagnostic SBx), and 
during every repeat SBx scheduled at 1 year (confirmatory biopsy), and 4, 7 and 10 years 
(surveillance biopsy) after diagnosis (Figure 1). The only upgrading or re-classification 
criterion was the presence of ISUP Grade 2 (Gleason score [GS] 3+4) and higher PCa at 
biopsy.
From November 2013 to May 2019, 517 consecutive men on AS for ISUP Grade 1 PCa 
underwent at least one prostate MRI during follow-up. At time of analysis, 252 men 
had undergone an MRI ± TBx at baseline. Results of part of this cohort have been previ-
ously published (8, 9). In all, 70/252 (28%) men had upgrading after first MRI-TBx and 
therefore ceased AS, and 71/252 (28%) men had not yet undergone a second MRI ± 
TBx at time of analysis. In the present study, we included 111 men on AS for low-risk 
PCa who had undergone both an MRI ± TBx at baseline and at the time of the scheduled 
confirmatory SBx 1 year after initiation of AS (Figure 1).
Multiparametric MRI
Multiparametric MRI (mpMRI) at both time points was performed on a 3.0-Tesla MR scan-
ner (Discovery MR750; General Electric Healthcare, Chicago, IL, USA) with a 32-channel 
pelvic phased-array coil. The institutional MRI protocol included T2-weighted imaging 
(T2w), diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) re-
constructions, and dynamic contrast enhanced (DCE) imaging, according to the Prostate 
Imaging-Reporting and Data System (PI-RADS) version 1 and 2 guidelines (25). All MRIs 
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were reviewed by one urogenital radiologist with >7 years’ experience of prostate MRI. 
Individual lesions were scored according to the PI-RADS 5-point likelihood scale for 
csPCa, and the index lesions were annotated and delineated (25). Visible MRI lesions 
with a PI-RADS score of 3-5 were defined as suspicious.
Serial MRI scans were all compared to the initial imaging by the reporting radiologist 
according to the PRECISE criteria (11, 12). The PRECISE recommendations use a 5-point 
likelihood scale to qualify radiological progression on MRI in men on AS with se-
rial prostate MRIs. PRECISE score 1-2 corresponds to resolution/regression of previous 
features suspicious on MRI (based on a decreased radiological size/stage/conspicuity/
PI-RADS score), PRECISE score 3 corresponds to radiological stable disease, and PRECISE 
score 4-5 to disease progression on MRI (based on an increased radiological size/stage/
conspicuity/PI-RADS score). In clinical practice, a positive serial MRI without radiologi-
cal progression is defined as PRECISE score 1-3.
MRI-targeted biopsy and systematic biopsy
Biopsies were performed in a separate session. All men with a positive (serial) MRI 
underwent TBx. An MRI-ultrasound fusion system (UroStationTM, Koelis, France) was 
Figure 1. Flowchart of patients included in this study.




used to take TBx of all suspicious lesions identified on MRI. The suspicious MRI lesions, 
delineated on Digital Imaging and Communications in Medicine (DICOM) images, 
were targeted with 2-5 cores/lesion. An additional SBx (8-12 cores, depending on the 
prostate volume) was taken in all men at the time of confirmatory biopsy and was not 
blinded from MRI results. The biopsy procedures were performed by four experienced 
operators.
Pathological review of biopsy specimens
One expert uropathologist reviewed all biopsy specimens according to the ISUP 2014 
modified Gleason score/Grade Group system (26). The presence of an invasive cribri-
form growth pattern (CR) and/or intraductal carcinoma (IDC) was routinely recorded. 
Upgrading, and thereby the recommendation to switch to active treatment, was defined 
in clinical practice as any ISUP Grade ≥2 PCa found by MRI ± TBx and/or SBx.
Study endpoints
We compared the percentage of upgrading of ISUP Grade 1 PCa to csPCa between the 
results of MRI ± TBx and SBx in MRI-positive and -negative men on AS at the time of 
confirmatory biopsy (1-year surveillance). In addition, we assessed the percentage of 
upgrading related to the PRECISE score (i.e. regressive, stable and progressive features 
on prostate MRI). The percentage of upgrading was calculated using three different 
definitions of csPCa: (definition I) ISUP Grade 2 and higher PCa, (definition II) ISUP Grade 
2 with CR and/or IDC and higher PCa, and (definition III) ISUP Grade 3 and higher PCa.
Primary outcomes are:
1) upgrading (definition I) in MRI-positive and -negative men.
2) upgrading (definition I) related to the radiological changes between first and second 
MRI (PRECISE score), in MRI-positive and -negative men.
Secondary outcome is:
1) upgrading based on higher thresholds (definition II and III) for csPCa.
Statistical analysis
Descriptive statistics were used to report the clinical patient characteristics and per-
centages of upgrading. Statistically significant differences in continuous non-parametric 
data were assessed with the Mann-Whitney U test and Wilcoxon signed rank test. The 
Chi-square test for trend, McNemar test and Wilcoxon signed rank test were used to 
test for differences in categorical data. In accordance with the Standards of reporting 
for MRI-targeted biopsy studies (START) recommendations, cross-tabulation of the 
confirmatory biopsy outcomes was performed to compare the percentage of upgrading 
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detected by MRI ± TBx vs SBx (27). Analyses were performed using Statistical Package 
for the Social Sciences (version 24.0; IBM, Armonk, NY, USA), with a two-tailed level of 
significance set at P <0.05.
RESULTS
Patients’ characteristics
The clinical patients’ characteristics with subsequent low-risk PCa profiles did not show 
significant differences (except for age) at baseline and at confirmatory biopsy at 1-year 
of AS (Table 1).
Upgrading (definition I) at 1-year surveillance, in MRI-positive and -negative 
men
At 1-year surveillance, 57% (63/111) of men had a positive follow-up MRI and 43% 
(48/111) had a negative follow-up MRI. Overall upgrading (definition I) occurred in 
32% (35/111, 95% CI 23-41), as a result of TBx and/or SBx (Table 2). Upgrading in 
MRI-positive and -negative men was 48% (30/63, 95% CI 35-61) and 10% (five of 48, 
95% CI 4-23) (P <0.001, 95% CI for the difference 21-51), respectively. In MRI-positive 
men, upgrading was 23% (seven of 30) by TBx only, 33% (10/30) by SBx only, and 43% 
(13/30) by both TBx and SBx (Suppl. Table 1 for cross-tabulation of biopsy data).
In a total of 23 MRI-positive men, SBx detected upgrading. 43% (10/23, 95% CI 23-66) 
of the detected upgrading by SBx in these men was (also) located on the contralateral 
side of the suspicious MRI lesion(s). The overall upgrading in MRI-positive men increased 
with the PI-RADS score from 38% (five of 13, 95% CI 14-68) in PI-RADS score 3, 48% 
(19/40, 95% CI 32-64) in PI-RADS score 4, 60% (six of 10, 95% CI 26-88) in PI-RADS 
score 5 MRIs. Based on TBx results no correlation was found of upgrading related to 
higher PI-RADS score.
Upgrading (definition I) at 1-year surveillance, related to changes on MRI in 
MRI-positive and -negative men
Radiological progression (PRECISE score 4-5, i.e. from non-suspicious to suspicious 
and suspicious to more suspicious) in MRI-positive men was observed in 27% (17/63). 
Upgrading (definition I) in these men was 41% (seven of 17, 95% CI 18-67), as a result 
of TBx and/or SBx. Upgrading occurred in three of seven by TBx only and in three of 
seven by SBx only (Table 3). No radiological progression (PRECISE score 1-3) in MRI-












Age (yr), median (IqR) 66 (60-70) 67 (61-71) <0.001
PSA level (ng/ml), median (IqR) 6.8 (5.1-9.1) 6.9 (5.2-9.4) 0.352
Prostate volume (ml), median (IqR) 42 (30-56) 41 (31-55) 0.695
PSA density (ng/ml/ml), median (IqR) 0.17 (0.11-0.25) 0.15 (0.12-0.27) 0.864
Clinical stage, n (%)    
T1c 85 (77) 80 (72) 0.665
T2a 22 (20) 25 (23)  
T2b 2 (2) 4 (4)  
T2c 1 (1) 2 (2)  
T3a 1 (1) 0 (0)  
TRUS findings, n (%)    
benign 93 (84) 91 (82) 0.774
Suspected 18 (16) 20 (18)  
Number of positive diagnostic cores, n (%)    
1 46 (41) N/A N/A
2 36 (32) N/A  
3 19 (17) N/A  
4 7 (6) N/A  
5 2 (2) N/A  
6 1 (1) N/A  
PI-RADS score of MRI, n (%)    
1-2 52 (47) 48 (43) 0.303
3 15 (14) 13 (12)  
4 35 (32) 40 (36)  
5 9 (8) 10 (9)  
PRECISE score of MRI, n (%)    
1-2 N/A 14 (13) N/A
3 N/A 80 (72)  
4-5 N/A 17 (15)  
Time between MRIs (months), median (IqR) N/A 10 (9-13) N/A
Overall ISUP Grade at biopsy, n (%)    
no PCa N/A 31 (28) N/A
G 1 111 (100) 45 (41)  
G 2 N/A 18 (16)  
G 2 with CR and/or IDC N/A 12 (11)  
G 3 N/A 5 (5)  
G 4-5 N/A 0 (0)  
Table 1. Patients’ characteristics at baseline and at 1-year confirmatory biopsy.
*p values calculated based on the comparison between the baseline and confirmatory character-
istics for the total cohort.
IQR: interquartile range; PSA: prostate-specific antigen; TRUS: transrectal ultrasound; PI-RADS: 
Prostate Imaging Reporting and Data System; MRI: magnetic resonance imaging; PRECISE: Prostate 
Cancer Radiological Estimation of Change in Sequential Evaluation; ISUP: International Society of 
Urological Pathology; PCa: prostate cancer; G: Grade; CR: cribriform growth pattern; IDC: intraduct-
al carcinoma; N/A: not applicable.
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CI 35-65), found by TBx and/or SBx. Upgrading was 17% (four of 23) by TBx only and 
30% (seven of 23) by SBx only.
PRECISE score 3 (i.e. stable radiological features) in MRI-negative men was observed in 
88% (42/48), in whom upgrading occurred in 10% (four of 42, 95% CI 3-23) (Table 3). 
Radiological regression from suspicious to non-suspicious findings (PRECISE score 1-2) 
in follow-up MRI-negative men was observed in 13% (six of 48), in whom upgrading 
occurred in 17% (one of six, 95% CI 1-64).
Upgrading at 1-year surveillance, based on higher thresholds (definition II 
and III) for clinically significant prostate cancer
Overall upgrading (definition II) was 15% (17/111, 95% CI 9-23). Upgrading in MRI-
positive and -negative men was 22% (14/63, 95% CI 13-35) and 6% (three of 48, 95% 
CI 1-17) (P =0.021, 95% CI for the difference 2-28), respectively. In MRI-positive men, 
there was upgrading in three of 14 by TBx only, and in seven of 14 by SBx only (Table 2). 
Related to PRECISE, upgrading was 18% (three of 17, 95% CI 4-43) for PRECISE score 
4-5 and 15% (14/94, 95% CI 8-24) for PRECISE score 1-3 (Table 3).
Overall upgrading (definition III) was 5% (five of 111, 95% CI 2-10). Upgrading in MRI-
positive and -negative men was 6% (four of 63, 95% CI 2-16) and 2% (one of 48, 95% 
CI 1-11) (P =0.283, 95% CI for the difference -5-13), respectively. In MRI-positive men 
there was upgrading in one of four by TBx only, and in two of four by SBx only (Table 2). 
Related to PRECISE, upgrading was 6% (one of 17, 95% CI 1-29) for PRECISE score 4-5 
and 4% (four of 94, 95% CI 1-11) for PRECISE score 1-3 (Table 3).
DISCUSSION
The guidance of serial prostate MRI in the utility of repeat biopsies, when monitoring 
low-risk PCa men on AS, has not been clearly established. In our clinical practice of men 
with low-risk PCa on AS with subsequent MRI at baseline and at 1-year follow-up, overall 
upgrading from low- to intermediate/high-risk PCa (definition I) at 1-year surveillance 
was 32%. Upgrading was significantly lower in MRI-negative men (10%) compared to 
MRI-positive men (48%). In MRI-positive men, SBx detected a substantial additional 
proportion of upgrading not detected by TBx; almost half detected on the contralateral 
side of the suspicious MRI lesion(s). Upgrading was similar in MRI-positive men with 
radiological progression and without radiological progression. In these two groups the 
additional value of SBx in upgrading to ISUP Grade 2 and higher PCa was 43% and 30%, 
respectively. This argues for additional repeat SBx in men with and in men without 
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radiological progression on positive MRI. The other studied thresholds for upgrading 
([definition II] ISUP Grade ≥2 with CR and/or IDC PCa, and [definition III] ISUP Grade 
≥3 PCa) resulted in a lower overall upgrading (15% and 5%, respectively). At these 
thresholds, similar results were found with only limited upgrading in MRI-negative men 
and substantial added value of SBx in MRI-positive men. These results suggest that in 
serial MRI-negative men with low-risk PCa, repeat SBx at 1-year surveillance should be 
balanced against the harms on an individual basis. The risk of missing a timely diagnosis 
of high-risk PCa is low. In serial MRI-positive men, however, repeat SBx combined with 
TBx should be performed in all MRI-positive low-risk PCa men at 1-year surveillance to 
gain maximal diagnostic precision. This strategy could save a repeat biopsy procedure 
at 1-year follow-up in 43% of men at the cost of missing 2%-10% of csPCa (depending 
on the threshold used) in our population.
Two important clinical implications from our present results are: to consider omitting 
SBx in serial MRI-negative men at 1-year AS, and to perform both SBx and TBx in serial 
MRI-positive men. Previous studies have also investigated the value of serial MRI and 
TBx in monitoring men on AS for low-risk PCa. With respect to the applied AS protocol 
(i.e. the time interval between follow-up testing), the studies of Thurtle et al., Elkjaer 
et al. and Hamoen et al. are similar to our present study (18-20). Our present results 
of overall upgrading (32%) and added value of repeat SBx in MRI-positive (33%) and 
MRI-negative men (10%) at 1-year surveillance of low-risk PCa are mostly in line with 
the results of Hamoen et al. (25% overall upgrading and an added value of repeat SBx 
in serial MRI-positive men of 36%, while in MRI-negative men of 50%). The difference 
in added value of SBx in MRI-negative men is probably caused by the fact that in our 
present study 48 (43%) men had a negative MRI and repeat SBx, while only 8 (11%) 
men of Hamoen et al.’s cohort had a negative MRI and SBx. Our overall percentage of 
upgrading is also consistent with the stable 25% re-classification found at each repeat 
SBx in the entire PRIAS study (without the use of MRI) (2). This finding confirms the high 
value of re-sampling the prostate with SBx in men at 1-year AS, which after upfront risk 
stratification with MRI appears to have the most added value in MRI-positive men.
Thurtle et al. and Elkjaer et al. showed, however, a lower overall upgrading (14%-16%) 
at confirmatory biopsy in their cohorts and less added value of repeat SBx (12%-18% 
added value of repeat SBx in serial MRI-positive men and 5%-7% in MRI-negative 
men). These differences to our present study could be explained by our daily clinical 
practice AS cohort of men with low-risk PCa as opposed to the men with very low-risk 
PCa included in their studies. Furthermore, in the Hamoen et al. study and in our present 
study, the repeat SBx was not taken blinded from the MRI results which, could benefi-
cially influence the SBx outcomes.
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Consistent with the upgrading results in other studies, most men, if upgraded, were 
upgraded from ISUP Grade 1 to Grade 2 PCa in our present cohort. This is probably 
(partially) caused by previous sampling error, as low-risk PCa profiles remained equal. 
This confirms the finding that most men following an AS programme rarely have high-
risk disease (ISUP Grade 3 and higher PCa) during follow-up and therefore have a good 
cancer-specific survival (1, 28).
Our present results indicate performing SBx in combination with TBx in all MRI-positive 
men at 1-year AS, and also when there is no radiological progression, which is in line 
with the recommendations from Hsiang et al. and Chesnut et al. (23, 24). In the total 
cohort, we detected more upgrading in men with a PRECISE score 4-5 (41%) compared 
to men with a PRECISE score 1-3 (30%) on follow-up MRI. This finding is in line with 
Dieffenbacher et al., who studied the impact of serial MRIs in AS using the PRECISE 
score at 4-years follow-up (21). However, they showed a much better discrimination of 
the PRECISE scoring system for AS disqualification, with only 10% upgrading detected 
in men with a PRECISE score 1-3. Differences might be explained by the fact that we 
analyzed a cohort at 1-year of AS with substantial added value of repeat prostate 
sampling with SBx, while they analyzed a cohort at time of third follow-up saturation 
biopsy (4-years after initial diagnosis). This has probably resulted in an improved pa-
tient selection for AS with only limited added value of repeat sampling of the whole 
prostate at time of their analysis. In addition, the fact remains that the assessment of 
serial MRIs in men on AS is challenging, as upgrading still occurs with some regularity 
in men with an apparent stable low-risk disease on positive MRI due to the high value 
of repeat prostate sampling. Therefore, serial MRIs and the PRECISE criteria need to be 
investigated more often in clinical AS cohorts of men with low-risk PCa to help with 
the creation of a robust dataset to define proper radiological thresholds of clinically 
significant disease in men on AS.
The present study is the first to investigate the role of serial prostate MRIs in a daily 
clinical practice of AS (following a strict protocol) related to the presence of CR and 
IDC in biopsy specimens. CR and IDC are prognostic drivers in survival, even more than 
other Gleason 4 subpatterns (29). Kweldam et al. showed that men with ISUP Grade 2 
PCa with the presence of CR/IDC were associated with a worse disease-specific survival 
(67%) at 15-years follow-up, compared to men with ISUP Grade 2 PCa without the pres-
ence of CR/IDC (94%) and men with Grade 1 PCa (99%) (30). Identifying these Gleason 
4 patterns in men on AS may therefore be of high clinical relevance, with subsequently 
a large population staying on AS without CR/IDC. In our present population, overall up-
grading defined by ISUP Grade ≥2 with CR and/or IDC PCa (definition II) decreased from 
32% to 15%, potentially saving even more biopsy procedures (e.g. in PI-RADS score 3 
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men) and keeping more men on AS. Incorporation of this tumour-specific information 
into risk stratification could further improve selection of men who will benefit from 
active treatment. We may argue that the threshold for upgrading in men on AS should 
be changed to ISUP Grade ≥2 with CR and/or IDC PCa, to (falsely) exclude less men from 
AS and thereby to reduce the rate of overtreatment and treatment-related side-effects.
Some limitations of our study should be highlighted. First, our study has a retrospective 
design and could thereby introduce a selection bias. However, our study represents a 
prospective cohort of consecutive men on AS with strict monitoring. Second, clinicians 
involved were not blinded to clinical data and MRI results. Hence, this process is daily 
clinical practice and therefore can be extrapolated to other hospitals. Third, the sample 
size of our study is relatively small, which could reduce generalizability. However, in 
comparison to similar studies in recent literature it is the second largest sample size 
available in a study on the use of serial MRI in men on AS at 1-year surveillance for low-
risk PCa. Lastly, the median follow-up time is limited to 33 months. We acknowledge 
that the outcome measurement of our analysis was upgrading at 1-year surveillance. 
The cancer-specific survival rate in a long-term follow-up would have been more ap-
propriate to make hard inferences about the need for and frequencies of surveillance 
testing. This outcome may, however, be debatable in a cohort of men with low-risk 
disease who exhibit excellent long-term cancer-specific survival and who furthermore 
experience most shifts from AS to active treatment during the first 2 years of follow-up 
(31).
In conclusion, at 1-year surveillance the performance of repeat SBx in serial MRI-negative 
men should be discussed per individual based on one’s balance between benefits (e.g. 
not missing any intermediate/high-risk disease) and harms (e.g. unnecessary biopsy, 
biopsy complications). In serial MRI-positive men, repeat SBx should be performed 
together with MRI-TBx in all MRI-positive men, and also when there is no radiological 
progression. These findings are irrespective of upgrading threshold. Future large-scale 
studies should confirm this and focus on other surveillance issues in the current MRI era, 
such as the need for, the intervals and frequencies of surveillance testing from 2 years 
after the diagnosis of low-risk PCa.
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SUPPLEMENTARY MATERIALS
























Repeat Sbx outcome (ISUP grade), n
 
no PCa G 1 G 2
G 2 with 
CR and/
or IDC
G 3 G 4-5 Total
Negative MRI
(PI-RADS 1-2)
no targets 23 20 2 2 1 0 48
Positive MRI
(PI-RADS 3-5) + TBx
no PCa 8 1 1 1 0 0 11
G 1 2 22 4 3 1 0 32
  G 2 2 4 5 1 1 0 13
  G 2 with CR and/or IDC 0 0 2 3 0 0 5
  G 3 0 1 0 0 1 0 2
  G 4-5 0 0 0 0 0 0 0
  Total 35 48 14 10 4 0 111
Supplementary Table 1. Cross-tabulation of serial MRI with or without targeted biopsy results vs 
repeat systematic biopsy results, at 1-year surveillance.
MRI: magnetic resonance imaging; TBx: targeted biopsy; ISUP: International Society of Urologi-
cal Pathology; PI-RADS: Prostate Imaging Reporting and Data System; TBx: targeted biopsy; SBx: 












As described in the introduction section (Chapter 1) of this thesis, the main objective 
was to study whether the use of risk stratification strategies could reduce a) the harms 
of PSA-based prostate cancer screening (i.e. unnecessary testing and overdiagnosis; 
Part I) and b) overtreatment (i.e. active treatment in those cases that have an indolent 
course; Part II) without affecting the benefit of screening (i.e. reducing suffering and 
dying from the disease). Several research questions regarding this objective will be 
answered in this general discussion. In addition, future perspectives will be discussed.
PART I: CAN RISk STRATIFICATION AT TIME OF PROSTATE CANCER DETECTION 
REDUCE UNNECESSARY REFERRALS/TESTS, OVERDIAGNOSIS AND 
OVERTREATMENT WITHOUT MISSING CLINICALLY SIGNFICANT PROSTATE 
CANCER THAT COULD HARM A PATIENT IF LEFT UNDETECTED?
What is the long-term effect of PSA-based prostate cancer screening, and 
could it add to the ongoing discussion on the balance between harms and 
benefits of prostate cancer screening?
The aim of PCa screening is to find a potentially harmful csPCa within the window of 
curability, which in the case of PCa implies that screening involves men that do not have 
any symptoms related to PCa. Whether a man can truly benefit from an early detection 
and treatment of his PCa depends on the interaction of how aggressive (and sensitive 
for treatment) the potentially present disease is and how long the patient will live (1). 
Therefore, the European Association of Urology (EAU), the United States Preventive 
Services Task Force (USPSTF) and the American Urological Association (AUA) guidelines 
state that in men with a life expectancy of more than 10-15 years PCa screening could 
be considered after the process of shared-informed decision making (2-4) (Chapter 2).
To understand the impact of untreated localized PCa on life expectancy and quality of 
life, knowledge on the natural history of screen-detected PCa is important. Swedish 
long-term data on initial untreated early-stage PCa show that after 30 years of follow-
up and 99% of men in the study cohort deceased, 17% of men died because of PCa; the 
majority died 15-25 years after the initial diagnosis (5, 6). This finding was confirmed 
by the Prostate Cancer Intervention Versus Observation Trial (PIVOT) which showed an 
excellent 15- and 20-years disease-specific survival for low- to intermediate-risk PCa 
without initial curative treatment (7, 8). The two largest randomized controlled trials 
(RCTs) on PCa screening, reporting results with approximately 9 years follow-up after 
diagnosis can therefore not yet be representative for the full effect of screening in 
reducing metastatic disease and PCa mortality. Many screen-detected cancers are, at 
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time of detection, low or intermediate risk and as such will have a long natural history 
(15-25 years) (9-12).
Next to a limited follow-up time, PSA contamination in the control arms of the ERSPC and 
PLCO trials is another phenomenon that affects the relative result of mortality reduction 
when comparing the two arms of the trials. The reported rate of PSA contamination in 
the control arms of the ERSPC and PLCO trials ranges from 19% to 70% (13, 14). Studies 
have shown that after adjustment for nonattendance and PSA contamination the effect 
of organized PCa screening as conducted in the Rotterdam section of the ERSPC could 
increase, with a reduction of the risk of dying from PCa up to 51% for an individual 
man choosing to be screened repeatedly as compared to a man that was not screened 
(15, 16). Reporting on the effect of screening with long-term follow-up data without (or 
individually identified) PSA contamination is therefore valuable in gaining more insight 
into the full effect of PSA-based PCa screening. Having those data will contribute to the 
ongoing discussion on the balance between harms and benefits of PCa screening.
In Chapter 3 it was shown that data from the first pilot study of the ERSPC Rotterdam 
section (median follow-up time of 19 years, almost no PSA contamination and more 
than 60% of men deceased at time of analysis) suggest that there could be a more 
substantial relative reduction in metastatic disease (54%) and PCa-specific mortality 
(52%) in favor of PSA-based PCa screening than previously reported (17). Obviously, 
the relatively small sample size and low event rates resulted in wide confidence in-
tervals and statistically insignificant reductions, and for now, limit drawing definitive 
conclusions.
It can however not be excluded that the magnitude of the relative risks in the first ERSPC 
Rotterdam pilot study will be confirmed in the main ERSPC trial when having the avail-
ability of 19 years or more of follow-up, as rates of metastatic disease and PCa death in 
the screening arms of both studies do not differ much. The most recent update of the 
main ERSPC trial at 16 years of follow-up already shows that the absolute reduction in 
PCa mortality still increases, compared to earlier publications (12). More importantly, 
longer follow-up in the main ERSPC trial seems to go along with a reduction of the 
harms of PCa screening on a population level. The number needed to invite (NNI) to 
prevent one PCa death was 570 at 16 years follow-up compared with 1947 at 9 years 
and 742 at 13 years. The number of cases needed to diagnose (NND) to avert one PCa 
death declined from 48 at 9 years of follow-up to 18 in the recent update at 16 years 
(9, 12, 18). With extended follow-up the NND will likely continue to decrease (but this 
should be interpreted with some caution since the PCa incidence in the control group is 
gradually catching up with the screening arm). Similar findings have been reported from 
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the Swedish section of the ERSPC trial, having the availability of 18 years of follow-up 
and suggesting that the results of PSA-based PCa screening could be more beneficial 
than previously thought (19). It remains to be seen whether the ERSPC trial as a whole 
will confirm these observations. Differences in study populations, a-priori risks of PCa, 
screening protocols and screening duration between centers influence the main out-
come of the trial (20).
So, although there are indications that in the long run the harm-benefit ratio of PSA-
based PCa screening could be more beneficial than reported so far and an introduction 
of a population-based screening program for PCa could become a possibility in the near 
future, the finding that to detect 5000 prostate cancers more than 20000 biopsy pro-
cedures were needed, i.e. a positive predictive value (PPV) of only 24%, should trigger 
all stakeholders to work on improvement (12, 21). By following the current protocols 
many men will experience short-term screening related harms, while only a selected 
number of men would benefit from the potentially considerable beneficial long-term 
effect of PSA-based PCa screening on metastatic disease and PCa-specific mortality, as 
suggested by the findings in Chapter 3. These short-term harms should be minimized 
and experienced by as few men as possible. If this could be achieved it would open the 
door to PCa screening on a large scale, like recently proposed for the European set-
ting by proponents within the EAU (22-24). Recent developments in risk stratification 
and targeted tissue sampling will hopefully convince those stakeholders that consider 
overdiagnosis and overtreatment unavoidable, insurmountable and unethical impacts 
on men’s quality of life (25). Therefore, to identify and treat the prostate cancers that 
have impact while leaving aside the rest of the detectable cancers we should not focus 
too much on the question ‘To screen or not to screen?’, but much more on the question 
‘If we screen, what is the optimal way to do that?’. Examples of adjustments to optimize 
screening and detection pathways of PCa to get the best for our patients will be dis-
cussed in detail in the next sections of the general discussion, and a new screening and 
detection strategy will be proposed.
Can we select those men at high risk for aggressive disease who need 
further testing using currently available risk calculators, thereby avoiding 
unnecessary referrals, MRIs, prostate biopsies and overdiagnosis?
Multivariable risk-based patient selection for referral to the urologist
To predict whether a man harbors a potentially harmful csPCa and whether the events 
(i.e. metastases and death) of this harmful csPCa will occur before the competing risk 
of death from another cause, is difficult. However, our understanding of which men may 
benefit from PSA-based PCa screening has improved over the past few years (e.g. men 
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with a positive family history, men from African descent, men with a life expectancy 
of >10-15 years) (26-28). Unfortunately, detailed analyses of the population of men 
screened within the trials has up to now not succeeded in a clear-cut strategy that 
substantially improves the harm-benefit ratio (29). For example, when using a purely 
PSA-based screening algorithm screening within a wider age range, narrowing the 
screening intervals or lowering the PSA threshold for referral to biopsy would indeed 
increase the detection of csPCa but at the same time increase the number of unneces-
sary screening tests and overdiagnosis (30, 31). One of the biggest challenges in PCa 
screening remains to decrease its harms without affecting its benefits.
In the Netherlands a screening and detection algorithm based on PSA only (threshold 
of 3.0 ng/ml) to select for a referral to the urologist and potentially (invasive) further 
testing would result in a benign outcome in 60%-75% of biopsied men, and up to half 
of the detected PCa being clinically insignificant (12, 32, 33). Better prediction of a 
patient’s risk of harboring csPCa and thereby better selection for referral for further 
testing (i.e. MRI, biopsy) could reduce the percentage of unnecessary testing and cause 
a more favorable clinically significant to insignificant ratio of PCa detected (34, 35). 
Multivariable risk calculators (RCs) for the prediction of a positive prostate biopsy have 
been developed to support physicians to better identify those men at risk of csPCa. 
Among six extensively externally validated RCs, the ERSPC Rotterdam Prostate Cancer 
Risk Calculator (RPCRC) showed to be slightly superior in predicting men at risk of csPCa 
(36, 37). On average, using the ERSPC RPCRC in a urology outpatient clinic with biopsy 
at a cut-off point of 4% csPCa risk could avoid 32% of biopsies and 25% of low-risk 
PCa diagnoses while keeping a 95% sensitivity for detecting csPCa (34, 38) (Chapter 2).
In the Dutch health care system general practitioners (GPs) play an important role since 
they are the first link in the chain of many diagnostic pathways. Men with a suspicion 
of PCa or a PCa screening wish first visit their GP, where after balancing the individual 
potential advantages and damages related to screening, a PSA test and if indicated, a 
referral to the urologist will be conducted. Therefore, this is the first point within the 
PCa diagnostic pathway where optimization of the pathway by better risk stratification 
should take place (39). GPs are, however, still uncertain about managing PCa screening 
and detection, and for that reason men receive different care depending on their GP’s 
reasoning and practice preferences (40, 41). The implementation of validated PCa diag-
nostic risk models in primary care could be a solution for this problem and may help the 
GPs to facilitate informed decision-making and improve patient selection for referral.
In Chapter 4 it was shown that use of the ERSPC RPCRC in a primary care setting (cen-
tralized GP laboratory and test center) could reduce the rate of men with a PSA level 
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≥3.0 ng/ml referred to the urologist with almost 50%, without missing any csPCa in 
men considered low risk (42). Although in more than 75% of the high-risk men referred 
for biopsy the suspicion of PCa was confirmed, almost half of the detected PCa among 
these men was low-risk disease according to the Gleason grading. This indicates that 
there is room for improvement of this strategy. Nevertheless, the considerable reduc-
tion in unnecessary referrals to the urologist suggests an important and relevant role for 
multivariable risk stratification in primary care. To further validate and translate these 
findings to the individual GP’s offices, studies with GPs or trained nurses performing 
the tests necessary to calculate individual risk are indicated. DRE is not unknown in 
the GP setting, and could also be used for prostate volume estimation after training. In 
addition, simple abdominal ultrasound instead of transrectal ultrasound (TRUS) could 
be used in GP practices for more accurate volume estimation (43).
Based on the findings in Chapter 4 it can be concluded that (at least) for the Dutch 
primary health care setting multivariable risk stratification for patient selection for 
referral to the urologists, is the first step in optimizing the pathway of PCa screening 
and detection. Large-scale implementation should be top priority when considering the 
introduction of a population-based PCa screening program. Therefore, risk stratification 
starting at the GP’s office is the first step of the proposed PCa screening and detection 
strategy (Figure 1) in this thesis.
Multivariable risk-based patient selection for prostate MRI and biopsy
The recently updated Dutch, European and North-American PCa guidelines recommend 
to perform a pre-biopsy prostate MRI in all men with a (initial or persistent) suspicion 
of csPCa (i.e. biopsy-naïve and repeat biopsy setting), before embarking to a prostate 
biopsy procedure (44-49). MRI is a useful tool because of its ability to detect suspicious 
lesions in the prostate and as a guidance for targeted prostate biopsies (TBx). In addition, 
the MRI based PI-RADS score provides information on the likelihood of having a csPCa. 
The MRI PCa diagnostic pathway is considered to be superior to the traditional TRUS 
diagnostic pathway, as it improves diagnostic accuracy and it limits both the amount 
of invasive procedures, overdiagnosis and overtreatment (44). However, performing 
a prostate MRI in all men with an elevated PSA level is a challenge due to limits in 
resources, capacity and availability of expertise. In addition, in a considerable propor-
tion of patients the MRI will not show any abnormalities making it thereby potentially 
a redundant test. Furthermore, some patients will have false positive abnormalities on 
MRI (i.e. benign pathology or low-risk PCa) resulting in unnecessary TBx (Chapter 2). 
Multivariable risk stratification could potentially help to better select upfront which 
men will benefit from a prostate MRI and subsequent biopsies (50-53). In that way, 
upfront pre-MRI risk stratification could optimize the PCa diagnostic pathway by avoid-































































































































































































































































































































































ing the performance of unnecessary pre-biopsy prostate MRIs and thereby potentially 
avoiding (even more) unnecessary biopsies and diagnoses of low-risk PCa.
Recently, Van Poppel et al. presented a new risk-adapted algorithm as a guidance in 
whom, and how to apply early detection of csPCa in 2020 and beyond. It should how-
ever be mentioned that the proposed algorithm was not based on prospective research 
data but on state-of-the-art knowledge and expert opinion (24). Chapter 5 of this thesis 
shows the preliminary results of a prospective multicenter clinical effectiveness study 
conducted in the Netherlands among 21 centers, investigating the performances of 
such a new risk-based PCa diagnostic strategy. This so-called MR PROPER study aims 
to compare the diagnostic performance, cost-effectiveness and quality of life of an 
MRI-driven PCa diagnostic pathway versus a systematic biopsy (SBx) driven pathway in 
biopsy-naïve men with a suspicion of PCa, based on an upfront individual multivariable 
risk stratification using the ERSPC RPCRC. The first clinical outcomes of the MR PROPER 
study provide evidence that the ERSPC RPCRC can be used as upfront risk stratification 
tool for the selection of biopsy-naïve candidates for a prostate MRI and subsequent 
biopsy procedure (54). The ERSPC RPCRC-MRI pathway resulted in men considered 
to be at high-risk of PCa according to the ERSPC RPCRC in a csPCa and low-risk PCa 
detection rate of 27% and 9%, respectively. Restricting prostate MRIs and biopsies to 
only high-risk men selected by the ERSPC RPCRC could reduce 20% of MRIs and 59% 
of biopsies, at the cost of missing only 4% csPCa. The MR PROPER study is herewith 
the first large prospective study to demonstrate that a risk-based MRI PCa diagnostic 
pathway is the approach for the future. Careful evaluation of patients with a need for 
a diagnostic work-up with prostate MRI would not only avoid costs and resources but 
could also improve the performance of the MRI pathway itself.
In line with previous studies, the MR PROPER study shows that the MRI pathway is non-
inferior to the TRUS pathway in biopsy-naïve men with regard to csPCa detection, but 
is superior for detecting fewer low-risk PCa and reducing biopsy procedures. In other 
words, the MRI pathway can reduce the harms of PCa diagnostics without affecting the 
benefit. The reduction of harms can further be increased by better upfront selection of 
whom will benefit from the MRI pathway. This selection can be done with multivariable 
risk stratification tools like the ERSPC-RPCRC but also tests like e.g. the SelectMDx-test 
or 4Kscore could play a role here (50-54). The value of upfront risk stratification with 
one of these risk models in avoiding prostate MRIs, biopsies and low-risk PCa diagnoses 
is comparable (Table 1). The common denominator in all these tools is inclusion of 
the strong predictive value of the PSA-density (PSA-D). Therefore, at time of pre-MRI 
risk stratification accurate prostate volume estimation with e.g. a TRUS examination is 
advisable.
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Summarizing the above, it can be concluded that multivariable risk stratification should 
be performed before selecting men for prostate MRI and subsequent biopsies to 
improve the harm-benefit ratio of the PCa diagnostic pathway. The MRI pathway with 
upfront risk stratification could be considered as a way forward in the current era of 
prostate MRI in PCa diagnosis. Therefore, pre-MRI multivariable risk stratification is a 
crucial part of the optimal PCa screening and detection pathway as proposed in this 
thesis (Figure 2).
Multivariable risk calculator including MRI data for prostate biopsy selection
To better identify those men who will benefit from TBx and/or additional SBx after a 
prostate MRI, MRI parameters have been incorporated into existing and new developed 
risk models. In Chapter 2 promising results of multivariable prediction models including 
MRI parameters (mostly the PI-RADS score) for both the initial and repeat biopsy setting 
are shown. The MRI risk prediction models have a high accuracy with area’s under (AUC) 
the receiver-operating characteristic curves (ROC) ranging from 0.69 to 0.93 (55-61). 
On average, usage of the risk models could result in 30% biopsy (i.e. TBx and/or SBx) 
procedures and 15% low-risk PCa diagnoses avoided, at the cost of missing 5% csPCa 
diagnoses (21). The added value of multivariable risk stratification after the perfor-
mance of an MRI depends on the a-priori risk of csPCa and the degree of pre-MRI risk 
stratification in a population. Furthermore, it is important to realize that the creation of 
dozens of MRI risk models on limited sample size, often single center study populations 
should be avoided. Preferably, a situation is created where high quality, good perform-
ing, already available models (both with respect to discrimination and calibration) are 
extensively externally validated and calibrated for different populations. This could 
lead to further refinement and improvement of the models (62, 63). Recently, Püllen 
et al. performed an external validation and head-to-head comparison of three exist-
ing MRI risk prediction models (64). The accuracy and potential of all three models are 
confirmed in this study, with the best results in avoiding unnecessary biopsies shown by 
the MRI-ERSPC risk calculator (Table 1).
MRI risk calculators should preferably be applied as third stratification tool after the 
performance of a PSA test (i.e. first stratification step) and upfront multivariable risk-
based patient selection for prostate MRI (i.e. second stratification step) with the aim to 
not only reduce prostate biopsies and overdiagnosis but also the number of unneces-
sary MRIs (65). MRI risk calculators could support physicians and patients in several 
aspects of biopsy decision-making. Their added value in avoiding unnecessary biopsies 
holds especially for those men considered being at high(er) risk of csPCa before MRI, 
but that subsequently after MRI have a PI-RADS score 1-3. This new knowledge when 
used in another risk stratification step, including MRI result, could lead to a change from 
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being at high(er) risk for csPCa to being at low(er) risk of harboring csPCa. Furthermore, 
MRI risk calculators can aid in the choice on method of biopsy in case the MRI is positive. 
For instance, patients considered being at high risk of csPCa according to multivariable 
risk stratification with an obvious PI-RADS 5 lesion on MRI could be biopsied by only 
TBx, i.e. omitting the SBx procedure of an additional 12 cores. On the other hand, in 
men considered being at high risk of csPCa with a PI-RADS 3 or small PI-RADS 4 lesion, 
the combined result of an elevated risk estimation and MRI location indicates the need 
for TBx and SBx to gain maximal diagnostic yields (66, 67). Therefore, there is without 
doubt added value for multivariable risk stratification including MRI data to decide for a 
subsequent prostate biopsy (and potentially biopsy strategy) within the PCa detection 
pathway. Hence, multivariable risk stratification after MRI is part of the optimal screen-























































Risk calculators including MRI data:
MRI-ERSPC RPCRC 3 (cut-off ≥10% csPCa) --> TBx + SBx Initial 0 26 13 4
Model Distler (cut-off ≥10% csPCa) --> TBx + SBx Initial 0 0 ND 0
Model Radtke (cut-off ≥10% csPCa) --> TBx + SBx Initial 0 3 ND 1
Diagnostic strategies combining tools:
Initial 4Kscore (cut-off ≥7.5% csPCa) --> MRI + TBx + SBx Initial 21 34 33 3
Initial ERSPC RPCRC 3 (cut-off ≥5% csPCa) --> MRI + TBx + SBx Initial 20-37 59 59 4
Initial SelectMDx (cut-off ≥13% csPCa) --> MRI + TBx + SBx Initial 38 60 58 13
Table 1. An updated overview of the performances of MRI risk calculators and risk-based PCa di-
agnostic strategies (all on average; results can differ between populations). (adapted from table 
1, Chapter 2)
MRI: magnetic resonance imaging; PCa: prostate cancer; csPCa: clinically significant prostate can-
cer; ERSPC: European Randomized Study of Screening for Prostate Cancer; RPCRC: Rotterdam Pros-
tate Cancer Risk Calculator; TBx: targeted biopsy; SBx: systematic biopsy; ND: not determined; 4K: 
four-kallikrein.
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Can magnetic resonance imaging-derived characteristics alone or combined 
with clinical parameters improve the selection of those men at high risk for 
aggressive disease who need a biopsy?
Magnetic Resonance Imaging-derived parameters
Important for standardized prostate MRI acquisition and reporting is the PI-RADS score 
(45, 68, 69). The MRI-derived parameters that are included in the PI-RADS score are, 
among other things, the degree of hypo-intensity, the greatest lesion dimension, the 
ADC value and the degree of contrast enhancement. Combining these MRI-derived 
parameters into the PI-RADS score is known as a strong predictor of csPCa, with up to 
80% csPCa found in PI-RADS score 5 lesions (70). Some urologists and radiologists in 
the field of PCa diagnosis therefore suggest that the PI-RADS score on prostate MRI 
should serve as standalone test to select those men at high risk for csPCa who need a 
prostate biopsy (45, 71-73). This suggestion could be confirmed with data from the MR 
PROPER study (Chapter 5) showing a csPCa detection rate of 5% in men with a negative 
MRI and 79% in men with a PI-RADS score 5. Whether the MRI-derived parameters that 
are combined into the PI-RADS score are useful as standalone risk stratification tests to 
predict csPCa is debatable.
Studies on ADC values in predicting the diagnosis of PCa show promising results that 
the ADC value can help differentiate clinically insignificant from csPCa. Especially quan-
titative measurement of the mean ADC improved differentiation of benign versus ma-
lignant prostate lesions, compared with clinical assessment (74, 75). Radiomic machine 
learning had comparable but not better performance than mean ADC assessment (76, 
77). From the perspective that lesion size could matter, Rais-Bahrami et al. suggested 
that small MRI index lesions (≤7mm) may correspond to benign lesions or indolent 
cancers (78). Furthermore, Rosenkrantz et al. proposed additional criteria to adjust the 
current PI-RADS version 2 guidelines, and to upgrade a PI-RADS 3 to a PI-RADS 4 lesion 
on the basis of lesion size (using thresholds of ≥10mm or ≥15mm), since substantial 
more csPCa would be detected in the larger lesions (79). In Chapter 6 of this thesis, it 
was investigated whether stratifying PI-RADS 3 lesions based on largest (index) lesion 
diameter could aid in avoiding TBx sessions and low-risk PCa diagnoses without missing 
the diagnosis of csPCa. Largest lesion diameter appeared not be a significant predictor 
of csPCa in the studied PI-RADS 3 cases (80). Perhaps that the lack of standardized MRI 
lesion measurement influenced the predictive value of lesion diameter in this study 
(81).
Hence, the PI-RADS score on prostate MRI could be used to select those men at high 
risk for csPCa who need a prostate biopsy. In men with a PI-RADS score 1-2 primarily 
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clinical and if indicated further radiological follow-up rather than performing directly 
SBx could be considered. In the rest of men (i.e. PI-RADS score ≥3) a biopsy procedure 
(i.e. TBx with or without SBx) could be considered, preferably after further risk stratifica-
tion with specific MRI-derived parameters like the ADC value. The value of lesion size 
(i.e. lesion diameter or lesion volume) as standalone test in predicting the presence of 
csPCa needs further investigation, preferably after performing standardized MRI lesion 
measurements.
MRI-derived parameters combined with clinical data
An important clinical predictor of csPCa is PSA-density (i.e. PSA divided by prostate 
volume [PSA-D]). In 1992 Benson et al. already reported that PSA-D had better ability to 
predict PCa than PSA alone (82). Especially in the PSA range of 4-20ng/ml, PSA-D could 
improve cancer risk stratification compared with PSA alone. In a more recent head-to-
head comparison, PCa risk calculators incorporating PSA and prostate volume (i.e. PSA-
D) were shown to be superior in identifying men at risk of csPCa (36). The incorporation 
of prostate volume into risk calculators is therefore recommended (Chapter 2) (83, 84).
In Chapter 6 the added value of PSA-D in predicting csPCa in PI-RADS 3 cases is shown. 
Applying solely PSA-D as risk stratification tool in PI-RADS 3 men could result in 25% 
less TBx sessions and 11% less low-risk PCa diagnoses missing only 5% csPCa (80). 
Therefore, PSA-D may represent a good index to decide which PI-RADS 3 men should 
undergo a subsequent prostate biopsy. Risk stratification of PI-RADS 3 cases could 
further be improved by a model-based approach in which MRI-derived parameters (i.e. 
largest index lesion diameter) and clinical parameters (i.e. PSA-D and age) are combined 
in a multivariable prediction model that predicts the risk of csPCa of a PI-RADS 3 man. 
The discrimination of this model was 0.80 (95% CI 0.73-0.87). When compared to a 
biopsy all PI-RADS 3 men strategy, decision curve analysis showed a higher net benefit 
at threshold probabilities ≥2%. Such a model-based approach in PI-RADS 3 men, would 
result in 34% less TBx sessions and 23% of low-risk PCa diagnoses avoided missing no 
more than 5% of csPCa diagnoses.
It is evident that combining MRI-derived characteristics with clinical parameters can 
improve the selection of those men at high risk for aggressive disease who need a 
biopsy. Other studies that constructed a prediction model for csPCa detection show 
comparable findings, with models mainly driven by the strong predictive value of PSA-D 
(58, 85). Therefore, it is advisable to perform a multivariable risk stratification strategy 
for biopsy-decision making also after the performance of a prostate MRI, and to not let 
depend the biopsy decision-making on only the MRI PI-RADS score (Figure 2).








































































































































































































































































































































































































































































In PCa screening and detection a positive benefit-to-harm ratio is mandatory to make 
the disease and its diagnostic pathway acceptable to the general population and 
health care providers. There are indications that in the long run the harm-benefit ratio 
of PSA-based PCa screening could be more beneficial than reported so far. However, 
by following the current diagnostic protocols many men will experience short-term 
screening related harms, while only a selected number of men would benefit from 
the potentially considerable beneficial long-term effect of PSA-based PCa screening 
on metastatic disease and PCa-specific mortality. These short-term harms should be 
minimized and experienced by as few men as possible. Multivariable risk stratification 
and thereby a risk-based PCa diagnostic strategy in men with an elevated PSA level are 
the keys to a reduction of the harms of PCa diagnostics without affecting the benefit. 
The optimal screening and detection strategy as proposed in this general discussion 
(Figure 1 [= primary care part] and Figure 2 [= secondary/tertiary care part]) therefore 
starts with multivariable risk stratification in the primary care for patient selection 
for referral to the urologist. This reduces the rate of men with PSA levels ≥3.0 ng/ml 
unnecessarily referred to secondary care and may help the GPs to facilitate informed 
decision-making. The next optimization step is the performance of a second multivari-
able risk assessment including an accurate prostate volume estimation (e.g. by TRUS) by 
the urologist to select men for prostate MRI, as it significantly reduces the numbers of 
unnecessary prostate MRIs. The final optimization step in the proposed new screening 
and detection pathway is the performance of multivariable risk stratification combining 
clinical and radiological parameters after the performance of a prostate MRI to decide 
for a subsequent prostate biopsy and biopsy strategy. Such an approach can result in a 
reduction of unnecessary prostate biopsies, a reduction of overdiagnosis, also in men 
with abnormal findings on MRI.
Future perspectives
PCa has a high impact on the healthcare budget. As a result of increased life expectancy 
and the subsequent rise of the PCa incidence, the total estimated economic costs of PCa 
in Europe exceed €8,43 billion (86). In this light, the cost-effectiveness and Quality of 
Life (QoL) of PCa diagnostic strategies, next to their clinical performances, should be ad-
dressed. Therefore, it is even more unlikely that a purely PSA-based PCa screening and 
detection algorithm will be introduced for an organized population-based PCa screen-
ing program. The risk-based MRI PCa screening and detection pathway, as proposed in 
this thesis, has compared to a PSA-based strategy great potential to identify and treat 
the cancers that have impact while leaving aside the rest of the detectable cancers (24). 
Data and ongoing in-depth analyses from the MR PROPER study (i.e. Dutch nationwide 
setting) will soon provide more detailed insight in the cost-effectiveness and QoL of 
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such a detailed risk-based detection strategy. These results will aid in the discussion 
on whether, how and when a nationwide organized risk-adjusted population-based 
PCa screening program could be indicated in the (near) future. Furthermore, results of 
new, still ongoing, European risk-adjusted screening studies (e.g. PROBASE, ProScreen, 
The Göteborg prostate cancer screening 2 and STHLM3-MR Phase 2 trial) will lead to 
new insights in the field of population-based screening for PCa in the European setting 
in 2021 and beyond (87-90). At short notice, the study endpoints like the numbers of 
detected PCa, performed prostate MRIs and biopsy procedures will become available, 
informing us about the potential reduction in short-term PCa screening related harms 
by these risk-adjusted screening strategies. In the longer term, study endpoints like 
the number of metastatic disease and PCa-specific mortality, reflecting the potential 
long-term benefits of risk-adjusted PCa screening, will become clear.
Within the risk-based PCa screening and detection pathway, as proposed in figures 1 and 
2 of this thesis, there is still room for improvement. The exact role and feasibility of mul-
tivariable risk stratification in the primary care needs further investigation before wide 
incorporation in daily clinical practice. Large-scale studies with substantial follow-up 
including the inclusion of GPs to actually perform the risk stratification before referral 
to the urologist are needed. In addition, as far as this is not yet the case there should be 
created awareness among GPs about their potential important contribution in improving 
the harm-benefit ratio of the PCa diagnostic pathway, and they should be well trained to 
perform the tests necessary for use of the risk prediction tools. Another option could be 
a population-based PCa screening program initiated by the government, i.e. outside the 
clinical care. This raises the question: who should then after taking a PSA test perform 
the first risk stratification step for referral for further diagnostic testing? Investigators 
involved in such a government initiated program should first get familiar with urological 
physical examinations for prostate volume estimation to properly assess a man’s risk of 
PCa. This may be more time-consuming, expensive and less reliable than proper training 
of GPs that already have experience in medical physical examination.
There are numerous multivariable risk stratification tools available that could be used 
in the secondary care to select candidates for a subsequent prostate MRI, as well as 
numerous risk calculators including MRI data that could be used to select men for a sub-
sequent biopsy procedure (21). However, head-to-head comparisons of these tools are 
necessary to determine the most optimal ones in terms of clinical performance. In ad-
dition, it is mandatory for optimal implementation that the tool is free to use, available 
everywhere, extensively externally validated, and calibrated for different populations.
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The identification of genetic variants associated with PCa by PCa genome wide associa-
tion studies (GWAS) could potentially help in targeting PCa screening and detection to 
men with an increased genetic risk of PCa development, which could improve the selec-
tion of men that will benefit from further invasive testing (91). This genetic information 
could be added to existing multivariable risk stratification tools. This shift towards 
more personalized medicine provides more patient-specific intervention estimates 
which support individualized clinical decision-making, instead of using a relative risk 
of intervention (92).
Key issues for the general use of prostate MRI and TBx in PCa diagnostics are reproduc-
ible standards and stable levels of high-quality imaging and interpretation, and biopsy 
performance (93). A systematic and robust training for MRI-technologists, radiologists, 
urologists/biopsy operators and pathologists, clear quality criteria for image acquisition 
and standardized reporting, and effective quality-assurance structures are therefore 
needed (94). With the increased use of MRI and TBx in daily clinical practice and the 
increasing supply of prostate MRI and TBx training programs, it is likely that physicians 
involved in PCa care will become more experienced in structured and standardized 
interpreting and performing MRI and TBx (95). Moreover, artificial intelligence could be 
used to mitigate the subjective nature of prostate MRI interpretation. There is need for 
mature datasets with high quality annotations to continue advancements in this field 
(96, 97).
To satisfy the increasing demand for prostate MRI, there is growing interest in perform-
ing prostate MRI without DCE, a so-called biparametric MRI. Performing biparametric 
MRI allows a higher throughput at lower costs, makes prostate MRI non-invasive and 
avoids potential contrast-related side-effects. However, the use of biparametric MRI 
requires high-standard image quality and experienced radiological interpretation 
(98-100). Future prospective studies, like the ongoing PRIME study, will provide im-
portant evidence whether the contrast sequences in multiparametric MRI contribute 
significantly to the detection of csPCa (101). Next to biparametric MRI, the diagnostic 
ability of prostate-specific membrane antigen (PSMA)-PET/CT in biopsy-naïve men in 
addition to MRI is currently determined, but is yet, too far away from becoming part of 
the standard diagnostic work-up (102).
Over the years questions have arisen on what prostate biopsy approach and how many 
biopsy cores are required to meet a sufficient diagnostic accuracy. Therefore, research in 
the near future should focus on the impact of upcoming in-office transperineal prostate 
biopsy with local anesthesia and TBx with focal saturation procedures. Recent studies 
have shown interesting potential for TBx with focal saturation by additional perilesional 
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cores to improve the csPCa detection and decrease the detection of low-risk PCa com-
pared to the performance of TBx alone or TBx with SBx (70, 103). Philosophizing about 
the future, pathological verification by biopsy cores of the suspected disease on imag-
ing may even not be necessary anymore when the imaging modalities have reached 
diagnostic test characteristics of 100%. Furthermore, the personalized diagnostic path-
way needs to be further improved by the development of dynamic prediction models 
for the follow-up of men considered to be at low-risk of PCa (after the performance of a 
prostate MRI) or men with a negative biopsy procedure (104).
Important for future PCa research is to invest in research collaborations and sharing of 
relevant research data, as well as publishing study results according to standardized 
guidelines to easily reproduce and validate findings. A striking example of a joint effort 
to resolve several critical questions regarding the screening, diagnosis and treatment 
of PCa patients, is the EAU lead PIONEER (Prostate Cancer DIagnOsis and TreatmeNt 
Enhancement through the power of big data in EuRope) project (105, 106). The PIO-
NEER project will assemble, standardize, harmonize and analyze high-quality big data 
from diverse European populations of PCa patients to provide evidence-based data for 
improving decision-making. Fortunately, there are more (inter)national initiatives to 
follow this idea in the years to come.
PART II: CAN RISk STRATIFICATION AT INITIATION AND DURING ACTIVE 
SURVEILLANCE REDUCE UNNECESSARY TESTS AND OVERTREATMENT 
WITHOUT MISSING CLINICALLY SIGNFICANT PROSTATE CANCER THAT COULD 
HARM A PATIENT IF LEFT UNTREATED?
Can we identify those men at high risk of disease upgrading who need a 
follow-up biopsy using magnetic resonance imaging and clinical parameters, 
avoiding unnecessary follow-up biopsies in men at low risk of disease 
upgrading?
Data from the pre-MRI era have shown that Active Surveillance (AS) is a safe strategy for 
carefully selected men, with a disease-specific survival at long-term follow-up ranging 
from 94-100% (107-110). The fear of under grading at time of diagnostic biopsy has 
led to the development of AS protocols with strict criteria for inclusion and monitoring. 
Many newly diagnosed low- and intermediate-risk PCa patients do not meet these strict 
eligibility criteria, although only a subgroup of these men will develop metastatic dis-
ease if their cancer is left untreated. On the other hand, many men initially considered 
suitable for AS experience a form of disease reclassification during follow-up and are 
then advised to switch to an active treatment (108). This indicates that a better selec-
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tion at time of diagnosis of men who are suitable for AS and more flexible criteria for 
disease upgrading during follow-up are necessary (111-113). Therefore, PRIAS recently 
updated its protocol by recommending the performance of a prostate MRI before every 
(repeat) biopsy session with in case of a positive MRI the performance of TBx and SBx, 
using the presence of ISUP grade 2 but with invasive CR/IDC and higher grade PCa at 
biopsy as upgrading criterion (114). This means that men with ISUP grade 2 without 
invasive CR/IDC PCa are considered as candidates for AS according to the PRIAS study, 
and that the presence of ISUP grade 2 PCa is not necessarily a strict exclusion criterion 
at inclusion or during follow-up (Figure 3).
Additional testing by MRI and TBx can result in accurate patient selection for AS, but 
comes with an extra invasive procedure next to the already performed repeated tests 
(115). This could increase the burden for patients on AS, especially for men at (very) low 
risk of disease upgrading who will experience only little to no benefit from frequent 
(invasive) follow-up testing. The currently applied one size fits all approach in most 
AS protocols could as such result in a lot of unnecessary follow-up testing and related 
costs (116). Furthermore, it is known that over time compliance to AS protocols, mainly 
because of invasive follow-up biopsies, declines (117). The low biopsy compliance 
indicates that repeat biopsies are considered burdening for patients and that strategies 
are needed to safely reduce the number of unnecessary follow-up biopsies to increase 
adherence to the surveillance protocol, without missing csPCa that could harm a patient 
(118). Preferably, invasive follow-up testing should only be performed in men with a 
long life expectancy being at high risk of disease upgrading (Chapter 1). Prostate MRI 
could potentially help to identify these men at high risk of disease upgrading and 
thereby being good candidates for invasive follow-up testing, both at initiation and 
during AS. Refinements in the role of MRI in AS are not yet clearly established in the 
new PRIAS protocol (114).
In Chapter 7 and 8 refinements in conducting a surveillance policy with prostate MRI 
were investigated. It was shown that risk stratification based on PI-RADS score with or 
without PSA-density (PSA-D) could avoid follow-up biopsies in men on AS with PI-RADS 
score 1-2, in the majority of men with PI-RADS score 3 and even in some carefully se-
lected men with PI-RADS score 4 on MRI. Overall, these risk-based strategies including 
MRI at initiation or during AS could result in avoiding approximately 60% of follow-up 
biopsy procedures in the studied cohorts, at the cost of missing a small number of ISUP 
grade 2 PCa and almost no ISUP grade 3 and higher PCa that likely will be detected 
within the window of curability during further follow-up (119, 120). The findings in 
these Chapters were done in AS cohorts where ISUP grade 1 PCa was initially detected 
by SBx before deciding to perform subsequent surveillance with pre-biopsy prostate 




Figure 3. Follow-up schedule of the PRIAS study: A) traditional follow-up schedule without MRI, 
B) follow-up schedule if MRI is available and not used at inclusion, C) follow-up schedule if MRI is 
available and used at inclusion (114).
PSA: prostate-specific antigen; DRE: digital rectal examination; MRI: magnetic resonance imaging; 




MRI. Incorporating prostate MRI at primary PCa diagnosis, as now is recommended by 
the new (inter)national PCa guidelines, will probably result in a smaller group of men 
with an overdiagnosis of ISUP grade 1 PCa (44-49). However, extension of the inclusion 
and monitoring criteria of AS protocols by allowing ISUP grade 2 without invasive CR/
IDC PCa as proposed by the new PRIAS protocol means that a substantial part of the 
men with initially detected ISUP grade 2 PCa is also considered as a good candidate 
for a surveillance strategy rather than immediate active treatment (114). The group of 
cancers regarded as ‘overdiagnosed’ will become larger indicating the persistent neces-
sity for risk-based AS strategies, also in the current MRI era (121). Incorporation of the 
secondary Gleason 4 growth patterns CR and IDC and thereby shifting the upgrading 
threshold for active treatment, opens possibilities to avoid even more follow-up biopsy 
procedures in men on AS since the majority of men on AS, if upgrades, upgrades from 
ISUP grade 1 to grade 2 without invasive CR/IDC PCa (120, 122). This new upgrading 
threshold as proposed by the PRIAS study could keep more men on AS and (falsely) 
exclude less men from AS, thereby reducing the rate of overtreatment and treatment 
related side-effects.
It can be concluded that risk stratification strategies based on prostate MRI with or 
without clinical parameters at initiation and during AS can be used to select men at high 
risk of disease upgrading for follow-up biopsy and avoid unnecessary biopsies in men 
at low risk of disease upgrading, at the cost of missing only a small amount of upgrading 
that likely will be detected and treated later on during follow-up. This way of using the 
prostate MRI, next to help for the guidance of TBx of suspicious prostate lesions, is a 
step towards a more personalized and refined surveillance approach rather than the 
current one size fits all approach in AS. It is likely that surveillance management of men 
on AS will incorporate results from MRI and TBx into multivariable prediction models 
with the emerging concept of personalized medicine (Figure 4).
Can serial magnetic resonance imaging be used to monitor low-risk prostate 
cancer patients during follow-up?
Patients on AS following the current updated protocols and guidelines including the 
performance of pre-biopsy MRI at diagnosis and during further follow-up will, when 
looking at these current AS protocols, at least undergo two prostate MRIs (i.e. at 
baseline and confirmatory biopsy). In addition, a considerable part of the patients will 
undergo three or more prostate MRIs during follow-up (48, 49, 114). This gives radi-
ologists the opportunity to compare two or more MRI scans per patient and determine 
whether there are radiological changes (e.g. in lesion size/stage/conspicuity/PI-RADS 
score) visible over time. This could result in a further refinement in the role of MRI in the 
risk-based selection of AS participants for follow-up testing by also taking radiological 
CHAPTER 9 | GENERAL DISCUSSION
200
progression on serial MRI into account, although recommendations on clinical utility of 
such a refinement are still premature (111, 123-125). An MRI-based monitoring strategy 
in men on AS seems attractive to health care systems and patients, potentially avoiding 
follow-up biopsy procedures with its attendant morbidities in the absence of radiologi-
cal progression on serial prostate MRI (126, 127).
In Chapter 8, the guidance of serial prostate MRIs with or without radiological progres-
sion (defined according to the PRECISE criteria) in the utility of repeat prostate biopsies 
at time of confirmatory biopsy in AS was assessed (120, 128). In serial MRI-positive 
men with and without radiological progression, the overall upgrading as a result of TBx 
and/or SBx was similar. In both groups the additional value of SBx in upgrading was 
substantial. These findings argue for still performing repeat biopsy procedures during 
surveillance in men with and without radiological progression on a positive serial MRI, 
while repeat SBx in serial MRI-negative men could be considered to be avoided as previ-
ously discussed.
Hence, the role of serial prostate MRIs in men on AS is challenging. Clear consensus 
on how to define radiological progression on serial MRI is still lacking, i.e. volume or 
diameter thresholds that allow to reliably distinguish between expected interscan vari-
ability and true progression are lacking (129). The PRECISE recommendations aim to 
facilitate a standardized and structured reporting of serial MRIs in men on AS in order to 
create a robust dataset to further determine the role of MRI (128). Highly experienced 
radiologists have shown to achieve substantial reproducibility for the PRECISE scor-
ing system (129, 130). There are data showing a more favorable discrimination of the 
PRECISE scoring system for AS disqualification than shown in Chapter 8 (131). However, 
a not negligible amount of upgrading to high-risk PCa is still detected in men on AS 
with an apparent radiological stable low-risk disease on serial positive MRI (132-134). 
With the currently defined radiological thresholds of csPCa on serial MRI in men on AS 
the meaning of absence of radiological progression on positive MRI, which comprises a 
considerable amount of men on AS during follow-up, remains unclear. The absence of 
radiological progression possibly does not reflect the histopathological status of the 
disease. Therefore, clear consensus on how to define radiological progression (e.g. by 
further refined PRECISE criteria) is necessary, which subsequently needs to be validated 
extensively in clinical AS cohorts to define proper radiological thresholds of csPCa in 
men on AS. Refinements to the PRECISE criteria that can support risk assessment of pa-
tients on AS are for example the use of MRI-derived parameters as the ADC (135, 136).
In conclusion, risk-based patient selection in AS for follow-up biopsy triggered only 
by radiological progression on serial MRI is not (yet) possible. Currently, such an MRI-
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based monitoring strategy will most likely miss a substantial number of high-risk PCa. 
However, prostate MRI can definitely aid in the risk-based selection for follow-up 
biopsy. Combining data of clinical predictors (e.g. PSA-D), MRI outcome (i.e. positive 
or negative) and potentially visible changes on MRI is advisable as risk stratification 
strategy before deciding to perform a repeat biopsy procedure in men on AS. Doing so, 
substantial unnecessary follow-up biopsy procedures will be avoided, while maintain-
ing a high detection rate of upgrading to high-risk PCa that could potentially harm a 
patient if left untreated.
Conclusion
Most well-established AS programs have updated their follow-up protocols by recom-
mending, if available, the performance of a prostate MRI with or without TBx at initia-
tion and during surveillance before every repeat biopsy procedure. Prostate MRI with or 
without TBx in AS improves the patient selection by early identifying men who harbor 
higher grade disease, and on the other hand safely including men on AS with high vol-
ume low-risk disease. Additional testing by MRI and TBx comes, however, with an extra 
invasive procedure next to the already performed tests in men on AS. This is especially 
the case, when the current AS protocols and thereby the one size fits all approaches 
are conducted. This increases the burden for men on AS, especially for men at low risk 
of disease upgrading. The role of MRI in men on AS can be further refined. Prostate 
MRI in AS cannot only be used to help for the guidance of TBx of potential suspicious 
lesions, but also to better assess someone’s risk of disease upgrading to improve the 
patient selection for invasive follow-up testing. Risk stratification strategies based on 
prostate MRI outcome, radiological changes on MRI and clinical parameters such as 
PSA-density can help to identify those men at high risk of disease upgrading who need 
a follow-up biopsy and safely avoid a biopsy in men at low risk of disease upgrading, 
both at initiation and during AS. To date, an MRI only-based monitoring strategy is not 
possible due to substantial added value of repeat SBx in all MRI-positive men, and 
because the definition of radiological progression on MRI needs to be strengthened. 
Furthermore, the histological secondary Gleason 4 patterns invasive cribriform growth 
and intraductal carcinoma are helpful in identifying men with ISUP grade 2 PCa that are 
suitable for AS. Incorporation of these growth patterns in risk assessment can further 
help to avoid follow-up biopsy procedures and keep more men safely on AS, thereby 
reducing overtreatment and treatment related side-effects. Extension of the inclusion 
and monitoring criteria of AS protocols makes a surveillance policy an interesting and 
safe option for a larger group of men with localized PCa, despite the new PCa guide-
lines that recommend the performance of a primary pre-biopsy MRI at diagnosis. The 
suggested improvements for AS protocols in this general discussion constitute the first 

































































































































































steps towards a more personalized AS pathway as proposed in figure 4, which could be 
more (cost-)effective and count on more physician’s and patient’s adherence.
Future perspectives
Following the course of a man’s PCa with an AS protocol is most likely something that 
continues for many years. Developing individually tailored risk stratification strategies 
will be the key for (a continuous) successful implementation of AS. Similar to other 
stages of the PCa pathway from diagnosis to palliative care, prediction models are also 
being introduced in AS. The currently available  models for prediction of disease up-
grading perform reasonably well, but need further adaptation and external validation 
prior to widespread adoption in clinical practice (137-141). Figure 4 shows a proposal 
for an individualized risk-based AS pathway which utilizes methods for an improved 
prediction of a patient’s risk of disease upgrading. It is likely that in the future follow-up 
of men on AS will be more personalized making use of dynamic risk prediction models 
that incorporate both repeated measurements of clinical and radiological data, as po-
tentially newly validated risk stratification tools like novel blood and urinary (genetic) 
biomarkers (91, 142-148). These dynamic prediction models should also take into ac-
count the patient’s comorbidity and life expectancy, and thereby his ability to receive 
active treatment (1, 149). The work from Tomer et al. is a step in this direction in which 
the choice, timing and intensity of biopsy is based on a personalized schedule weigh-
ing the number of biopsies and the delay in the detection of disease upgrading (150, 
151). The next step would be the incorporation of prostate MRI data to this personalized 
model to improve the prediction of disease upgrading. The resulting predictions can 
then be used to decide the timing of the next MRI as well as to make a decision about 
the biopsy intensity (TBx ± SBx). Key component to reliably use prostate MRI and TBx 
data for proper risk assessment during AS is well trained (uro-)radiologists and urolo-
gists (152). It is likely that with the increased use of MRI and TBx in clinical practice and 
the increasing supply of prostate MRI and TBx training programs, physicians involved 
in PCa care will become more experienced in interpreting and performing MRI and TBx 
(94, 95). MRI reports will become more structured and standardized which will further 
improve the quality and value of prostate MRI in AS. In addition, the increased use of 
MRI will generate sufficient research data that could be used to strengthen the defini-
tion of radiological progression on follow-up MRI (130). As a result of the growth in 
demand for MRI, the workload for radiology departments will also increase. Introduc-
tion of a biparametric MRI protocol could be a solution for the increased workload and 
could potentially result in an optimized workflow while maintaining similar detection 
of disease upgrading compared to a multiparametric MRI scan protocol (99, 152, 153). 
On the other hand, the use of prostate MRI opens other new (research) possibilities. MRI 
does not only produce rough anatomical maps, it can also be used to get more in-depth 
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knowledge on functional aspects of cellular structure or information on a cellular level 
(154, 155). These aspects need more research in PCa and AS. MRI might also be supple-
mented by other new imaging modalities (e.g. prostate-specific membrane antigen 
[PSMA] positron-emission tomography [PET]) in AS, which could further improve risk 
stratification and especially the patient selection for AS at initiation (156-158). How-
ever, improvement of the quality of prostate MRIs and their radiological reports takes 
priority over exploring the role of PSMA-PET in AS. The risk of promising new tools like 
the PSMA-PET is extensively and unnecessary use in all men. In addition, it remains to 
be seen whether the upcoming use of in-office transperineal prostate biopsy with local 
anesthesia by better sampling of the prostate already can result in an improved risk 
stratification and selection for AS without the use of extra imaging modalities (126, 131, 
159, 160). In this process of improving prediction in AS with potentially promising new 
risk models, biomarkers, imaging modalities and biopsy methods, the patient and his 
quality of life have to be at the center of it all (161). An AS strategy for low-risk PCa could 
be regarded as a chronic disease and therefore, although treatment related side-effects 
are delayed or even completely avoided, still substantially impact a patient’s quality of 
life. The diagnosis and continuous medical checkups can cause patients experiencing 
a loss of control over their disease and themselves. Therefore, in the current digital era 
the development of innovative electronic or mobile apps that could help to guide pa-
tients through this process is meaningful. These so-called eHealth applications provide 
patients with the opportunity to monitor their disease, plan and manage appointments 
and questions for their physician (162, 163). This will encourage active participation 
and can have a positive effect on the quality of life of the patient. Furthermore, it can 
improve the quality of care as it can focus on patients’ needs more specifically (i.e. per-
sonalized care). Therefore, within the PRIAS study the ‘MyPSA’-app is being developed 
with this purpose (164). Finally, a patient’s diet will play an increasing role in future PCa 
personalized management. Although there is no clear evidence that dietary differences 
may influence PCa progression, a balanced diet and regular exercise are recommended 
for all PCa patients because they are beneficial for overall health (165). Specifically, it is 
suggested that green tea polyphenols, soy isoflavones, phytoestrogens, lycopene, red 
wine and sunshine may have a favourable effect on PCa (23). Researchers will continue 
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Chapter 1 (General Introduction) gives an overview of the pathophysiology, epidemiol-
ogy and diagnosis of prostate cancer. The concepts of screening and detection, active 
surveillance and risk stratification in prostate cancer care are introduced. Main objective 
of this thesis is to study whether the use of risk stratification strategies at time of pros-
tate cancer detection (Part I) and at initiation and during an active surveillance strategy 
for low-risk prostate cancer (Part II) could safely reduce the harms of prostate cancer 
screening without affecting the benefit of screening, and reduce the harms of unnec-
essary immediate active treatment while having full cancer control. Several research 
questions regarding this objective are formulated in Chapter 1, and are answered in 
Chapter 9 (General Discussion).
Part I – Screening and Detection
Chapter 2 reviews the most recent evidence for the currently available risk stratifica-
tion tools in the detection of clinically significant prostate cancer (csPCa), and evaluates 
diagnostic strategies that combine these tools. Merging biomarkers, risk calculators and 
prostate MRI results in higher diagnostic performances than their use as standalone 
tests. In state-of-the-art clinical decision-making the patient should benefit from fur-
ther testing and treatment, even when the diagnostic test is ‘easy-to-perform’. The way 
forward in prostate cancer (PCa) diagnosis seems to be multivariable risk assessment 
based on blood and clinical parameters, potentially extended with information from 
urine samples, as a triaging test for the selection of candidates for subsequent prostate 
MRI and biopsy. Large prospective and comparative studies are necessary to fully assess 
the potentials and risks of these combined diagnostic strategies.
Reporting on the basis of long-term follow-up without PSA contamination seems crucial 
to get insight into the full effect of PSA-based PCa screening. In Chapter 3 it was shown 
that data from the first pilot study of the European Randomized Study of Screening 
for Prostate Cancer (ERSPC) Rotterdam section (median follow-up time of 19 years, 
almost no PSA contamination and more than 60% of men deceased at time of analysis) 
suggest that there could be a more substantial reduction in metastatic disease (54%) 
and PCa-specific mortality (52%) in favor of PSA-based PCa screening than previously 
reported. Confirmation of these findings in the ongoing trials is necessary to continue 
the discussion and evaluation of the benefits and harms of screening for PCa.
One of the biggest challenges in PCa screening still remains to decrease its harms with-
out affecting its benefits. Better prediction of a patient’s risk of harboring csPCa and 
thereby better selection for referral for further testing (i.e. MRI, biopsy) could reduce 
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the percentage of unnecessary testing and cause a more favorable clinically significant 
to insignificant ratio of PCa detected. In the Dutch health care system general practi-
tioners (GPs) play an important role since they are the first link in the chain of many 
diagnostic pathways. The implementation of validated PCa diagnostic risk models in 
the primary care could be the first optimization step in the PCa diagnostic pathway and 
may help the GPs to facilitate informed decision-making and improve patient selection 
for referral. In Chapter 4 it was shown that the use of the ERSPC Rotterdam Prostate 
Cancer Risk Calculator (RPCRC) in the primary care could reduce the rate of men with 
a PSA level ≥3.0 ng/ml referred to the urologist with almost 50%, without missing any 
csPCa in men considered to be at low-risk of PCa.
The recently updated PCa guidelines recommend to perform a pre-biopsy prostate MRI 
in all men with a suspicion of csPCa. However, performing an MRI in all men with an 
elevated PSA level is a challenge due to limits in resources, capacity and availability of 
expertise. In addition, in a considerable proportion of patients the MRI will not show 
any abnormalities making it thereby potentially a redundant test. Furthermore, some 
patients will have false positive abnormalities on MRI resulting in unnecessary biopsies. 
Multivariable risk stratification could potentially help to better select upfront which 
men will benefit from a prostate MRI and subsequent biopsies. Chapter 5 shows the 
preliminary results of a large prospective multicenter clinical effectiveness study, 
investigating the performances of a new risk-based PCa diagnostic strategy. The first 
clinical outcomes provide evidence that the ERSPC RPCRC can be used as upfront risk 
stratification tool for the selection of biopsy-naïve candidates for an MRI and biopsy 
procedure. The ERSPC RPCRC-MRI pathway resulted in men considered to be at high-
risk of PCa in a csPCa and low-risk PCa detection rate of 27% and 9%, respectively. 
Restricting prostate MRIs and biopsies to only high-risk men could reduce 20% of MRIs 
and 59% of biopsies performed, at the cost of missing only 4% csPCa.
An important clinical predictor of csPCa is the PSA-density (i.e. PSA divided by prostate 
volume [PSA-D]). Especially in the PSA range of 4-20ng/ml, PSA-D could improve cancer 
risk stratification compared with PSA alone. In Chapter 6 the added value of PSA-D in 
predicting csPCa in PI-RADS 3 cases is shown. Applying solely PSA-D as risk stratifica-
tion tool in PI-RADS 3 men could result in 25% less targeted biopsy (TBx) sessions and 
11% less low-risk PCa diagnoses, missing only 5% csPCa. Risk stratification of PI-RADS 
3 cases could further be improved by a model-based approach in which MRI-derived 
parameters (i.e. largest index lesion diameter) and clinical parameters (i.e. PSA-D and 
age) are combined in a multivariable prediction model. Such a model-based approach 
in PI-RADS 3 men, would result in 34% less TBx sessions and 23% of low-risk PCa 
diagnoses avoided, missing no more than 5% of csPCa diagnoses.
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Part II – Active Surveillance
The currently applied one size fits all approach in most Active Surveillance (AS) proto-
cols could result in a lot of unnecessary follow-up testing and related costs. Strategies 
are needed to safely reduce the number of unnecessary follow-up biopsies to increase 
adherence to the surveillance protocol, without missing csPCa that could harm a pa-
tient. Prostate MRI could potentially help to identify these men at high risk of disease 
upgrading and thereby being good candidates for invasive follow-up testing, both at 
initiation and during AS. In Chapter 7 and 8 refinements in conducting a surveillance 
policy with prostate MRI were investigated. It was shown that risk stratification based 
on PI-RADS score with or without PSA-D could avoid follow-up biopsies in men on AS 
with PI-RADS score 1-2, in the majority of men with PI-RADS score 3 and even in some 
carefully selected men with PI-RADS score 4 on prostate MRI. Overall, these risk-based 
strategies including MRI at initiation or during AS could result in avoiding approximately 
60% of follow-up biopsy procedures in the studied cohorts, at the cost of missing a 
small number of International Society of Urological Pathology (ISUP) grade 2 PCa and 
almost no ISUP grade 3 and higher PCa that likely will be detected within the window of 
curability during further follow-up.
An MRI only-based monitoring strategy in men on AS seems attractive to health care sys-
tems and patients, potentially avoiding follow-up biopsy procedures with its attendant 
morbidities in the absence of radiological progression on serial prostate MRI. In Chapter 
8, the guidance of serial prostate MRIs with or without radiological progression (defined 
according to the PRECISE criteria) in the utility of repeat prostate biopsies at time of 
confirmatory biopsy in AS was assessed. In serial MRI-positive men with and without ra-
diological progression, the overall upgrading as a result of TBx and/or systematic biopsy 
(SBx) was similar. In both groups the additional value of SBx in upgrading to csPCa was 
substantial. These findings argue for still performing repeat biopsy procedures during 





In Hoofdstuk 1 (Algemene Introductie) wordt een overzicht gegeven van de pathofy-
siologie, epidemiologie en diagnose van prostaatkanker. De begrippen ‘screening en 
detectie’, ‘active surveillance’ en ‘risicostratificatie’ in de prostaatkankerzorg worden 
geïntroduceerd. Het doel van dit proefschrift is om te bestuderen of de toepassing 
van risicostratificatie-strategieën op het moment van de detectie van prostaatkanker 
(Deel I) en op het moment van start en tijdens een active surveillance strategie voor 
laag-risico prostaatkanker (Deel II) veilig de nadelen van prostaatkankerscreening 
zou kunnen reduceren zonder het voordeel van screenen te beïnvloeden, evenals de 
nadelen van onnodige actieve behandeling zou kunnen reduceren zonder de controle 
over de prostaatkanker te verliezen. Verschillende onderzoeksvragen met betrekking 
tot dit doel zijn geformuleerd in Hoofdstuk 1, en worden beantwoord in Hoofdstuk 9 
(Algemene Discussie).
Deel I – Screening en Detectie
In Hoofdstuk 2 wordt het meest recente bewijs voor de hedendaags beschikbare risico-
stratificatie hulpmiddelen in de detectie van klinisch significant prostaatkanker (csPCa) 
besproken, en worden diagnostische strategieën die deze hulpmiddelen combineren 
geëvalueerd. Het combineren van biomarkers, risicocalculatoren/predictiemodellen en 
prostaat MRI bevindingen resulteert in betere diagnostische prestaties dan het gebruik 
van deze hulpmiddelen afzonderlijk van elkaar. In de moderne klinische besliskunde 
moet een patiënt voordeel halen uit verdere onderzoeken en behandelingen, zelfs als 
de diagnostische test ‘makkelijk’ uitvoerbaar is. De te volgen koers in de diagnostiek 
naar prostaatkanker (PCa) lijkt het gebruik van multivariabele risicostratificatie geba-
seerd op bloedwaardes en klinische karakteristieken, eventueel uitgebreid met data uit 
urine-onderzoeken, om patiënten te selecteren voor een prostaat MRI en biopten. Grote 
prospectieve en vergelijkende studies zijn nodig om de mogelijkheden en risico’s van 
zulke gecombineerde diagnostische strategieën volledig in kaart te brengen.
Onderzoeken gebaseerd op lange termijn data zonder PSA contaminatie zijn cruciaal 
om inzicht te krijgen in het volledige effect van PSA-gebaseerde prostaatkankers-
creening. In Hoofdstuk 3 wordt gesuggereerd met data van de eerste pilot studie van 
de European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam 
sectie (mediane follow-up van 19 jaar, bijna geen PSA contaminatie en meer dan 60% 
van de mannen overleden op het moment van analyse) dat er een substantieel grotere 
reductie in gemetastaseerde ziekte (54%) en PCa-specifieke dood (52%) in het voor-
deel van PSA-gebaseerde prostaatkankerscreening zou kunnen zijn dan tot op heden 
is gerapporteerd. Een bevestiging van deze bevindingen in de lopende onderzoeken is 
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cruciaal om de discussie en evaluatie van de voor- en nadelen van het screenen naar 
PCa te kunnen continueren.
Een van de grootste uitdagingen binnen de prostaatkankerzorg blijft het verminderen 
van de nadelen van screening zonder de voordelen van het screenen naar PCa te beïn-
vloeden. Een betere voorspelling van het risico van een patiënt op csPCa en daarmee 
een betere selectie voor een verwijzing voor verder onderzoek (m.a.w. MRI, biopten) 
zou het percentage onnodige onderzoeken kunnen reduceren en een gunstigere ver-
houding tussen de detectie van klinisch significant en insignificant PCa kunnen bewerk-
stelligen. In de Nederlandse gezondheidszorg spelen huisartsen een belangrijke rol, 
aangezien zij de eerste schakel zijn in veel diagnostische zorgpaden. De implementatie 
van gevalideerde PCa diagnostische risicomodellen in de eerstelijnszorg zou de eerste 
optimalisatiestap in het PCa diagnostische zorgpad kunnen zijn en zou huisartsen 
kunnen ondersteunen in de gedeelde geïnformeerde besluitvorming en in verbetering 
van de patiëntenselectie voor een verwijzing naar de tweede lijn. In Hoofdstuk 4 wordt 
aangetoond dat het gebruik van de ERSPC Rotterdam Prostate Cancer Risk Calculator 
(RPCRC) / Prostaatwijzer in de eerste lijn het percentage mannen met een PSA ≥3.0 ng/
ml verwezen naar de uroloog zou kunnen reduceren met bijna 50%, zonder het missen 
van csPCa in de mannen die zijn beoordeeld als laag-risico op PCa.
De recent bijgewerkte PCa richtlijnen bevelen de verrichting van een pre-biopsie 
prostaat MRI in alle mannen met een verdenking op csPCa aan. Echter is het verrichten 
van een MRI in alle mannen met een verhoogde PSA waarde een uitdaging gezien de 
beperkingen in capaciteit en expertise. Daarnaast zal de MRI in een aanzienlijk deel van 
deze mannen geen afwijkingen laten zien, waardoor de MRI in deze mannen beschouwd 
zou kunnen worden als een overtollig onderzoek. Verder zal in een deel van de patiën-
ten de MRI vals-positief zijn, resulterend in onnodige prostaatbiopten. Multivariabele 
risicostratificatie zou kunnen helpen om initieel beter te selecteren welke mannen 
zullen profiteren van een prostaat MRI en zo nodig biopten. In Hoofdstuk 5 worden 
de eerste resultaten van een groot prospectief multicenter onderzoek, dat een nieuw 
risico-gebaseerd PCa diagnostisch zorgpad bestudeert, besproken. De eerste resulta-
ten laten zien dat de ERSPC RPCRC / Prostaatwijzer gebruikt kan worden als initieel 
risicostratificatie hulpmiddel voor de selectie van biopsie-naïve mannen voor een MRI 
en bioptprocedure. Het Prostaatwijzer-MRI zorgpad resulteert in hoog-risico mannen in 
detectiepercentages van csPCa en laag-risico PCa van respectievelijk 27% en 9%. Het 
verrichten van prostaat MRI’s en biopten in alleen hoog-risico mannen zou het aantal 
verrichtte MRI’s en biopten met respectievelijk 20% en 59% kunnen reduceren, ten 
koste van het missen van 4% csPCa.
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Een belangrijke klinische voorspeller van csPCa is de PSA-densiteit (m.a.w. het PSA 
gedeeld door het prostaatvolume [PSA-D]). Met name in het PSA gebied 4-20ng/ml, zou 
de PSA-D de risicostratificatie kunnen verbeteren in vergelijking met gebruik van alleen 
de PSA waarde. In Hoofdstuk 6 wordt de toegevoegde waarde van PSA-D in de voorspel-
ling van csPCa in PI-RADS 3 mannen bestudeerd. Het toepassen van alleen de PSA-D 
als risicostratificatie hulpmiddel in PI-RADS 3 mannen zou kunnen resulteren in 25% 
minder gerichte biopten (TBx) sessies en 11% minder laag-risico PCa diagnoses ten 
koste van het missen van 5% csPCa. Risicostratificatie in PI-RADS 3 mannen zou verder 
verbeterd kunnen worden met een op een model-gebaseerde benadering, waarin MRI-
karakteristieken (m.a.w. grootste index laesiediameter) en klinische karakteristieken 
(m.a.w. PSA-D en leeftijd) worden gecombineerd tot een multivariabel predictiemodel. 
Zo een risicostratificatie strategie in PI-RADS 3 mannen zou kunnen resulteren in 34% 
minder TBx sessies en 23% minder laag-risico PCa diagnoses, ten koste van het missen 
van niet meer dan 5% csPCa diagnoses.
Deel II – Active Surveillance
De hedendaagse universele benadering in de meeste Active Surveillance (AS) protocol-
len zou kunnen resulteren in veel onnodige vervolgonderzoeken met daarbij komende 
kosten. Er zijn strategieën nodig om veilig het aantal onnodige vervolgbiopten te 
verminderen om op die manier de naleving van AS protocollen door patiënt en dokter 
te vergroten, zonder dat csPCa wordt gemist die een patiënt schade in de vorm van 
uitzaaiingen en/of de dood zou kunnen toebrengen. Prostaat MRI zou zowel op het 
moment van start als tijdens AS kunnen helpen in het beter identificeren van mannen 
met een verhoogd risico op meer agressieve vormen van PCa en daarmee dus zijnde 
goede kandidaten voor invasieve vervolgonderzoeken. In de Hoofstukken 7 en 8 wor-
den verfijningen in het uitvoeren van een AS beleid met prostaat MRI onderzocht. Er 
wordt aangetoond dat een risicostratificatie gebaseerd op de PI-RADS score met of 
zonder PSA-D vervolgbiopten in mannen op AS met een PI-RADS score 1-2, in de meeste 
mannen met een PI-RADS score 3 en zelfs in nauwkeurig geselecteerde mannen met 
een PI-RADS 4 score op MRI zou kunnen voorkomen. Samenvattend zouden deze risico-
gebaseerde strategieën op het moment van start en tijdens AS kunnen resulteren in het 
voorkomen van ongeveer 60% van de vervolgbiopten in de onderzochte cohorten, ten 
koste van het missen van een klein aantal International Society of Urological Pathology 
(ISUP) graad 2 PCa and bijna geen ISUP graad 3 en hoger PCa. Deze in eerste instantie 
gemiste hooggradige tumoren zullen vermoedelijk gedurende het verdere vervolgtra-
ject gedetecteerd worden en dan nog steeds te genezen zijn.
Een vervolgstrategie gebaseerd op alleen MRI bevindingen in mannen op AS lijkt 
attractief voor gezondheidszorgsystemen en patiënten vanwege de potentie om 
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vervolgbiopten en de bijkomende morbiditeit achterwege te laten in mannen zonder 
radiologische progressie op herhaalMRI’s. In Hoofdstuk 8 wordt het nut van vervolgbi-
opten op het moment van verificatiebiopten in AS in mannen met herhaalMRI’s met én 
zonder radiologische progressie (gedefinieerd volgens de PRECISE criteria) bestudeerd. 
In zowel mannen met een positieve MRI mét radiologische progressie als in mannen 
met een positieve MRI zónder radiologische progressie, was het percentage reclas-
sificatie naar een meer agressieve vorm van PCa vergelijkbaar. In beide groepen van 
mannen was de toegevoegde waarde van systematische prostaatbiopten substantieel. 
Deze bevindingen pleiten voor het blijven verrichten van vervolgbiopten tijdens AS in 




Daniël Fernando Osses was born in Leiderdorp on the 28th of 
February 1990. He completed his secondary school in 2008 at 
the Bonaventuracollege in Leiden. From 2008 until 2015 he 
studied medicine at the University of Leiden. The final year of 
his medical studies consisted of a dedicated year at the Urology 
department of the Haga Teaching Hospital in The Hague under 
the supervision of drs. J.D. Tijsterman, drs. F.M.J.A. Froeling and 
dr. H. Roshani. After obtaining his medical degree he worked 
as a resident (not in training) at the Urology department of the 
Haga Teaching Hospital. From April 2017 until December 2020 he worked on his PhD 
project at the departments of Urology and Radiology & Nuclear Medicine of the Erasmus 
University Medical Center in Rotterdam under the supervision of prof. dr. M.J. Roobol, 
prof. dr. G.P. Krestin and dr. I.G. Schoots. From July 2020 until March 2021 he worked 
as a resident (not in training) at the Urology department of the Canisius-Wilhelmina 
Hospital in Nijmegen under the supervision of dr. D.M. Somford. As part of his Urology 
traineeship, he is currently working as a resident at the General Surgery department of 
the Rijnstate Hospital in Arnhem under the supervision of dr. J.H.P. Lardenoije. In the 
future, he will continue this traineeship at the Urology departments of the Canisius-
Wilhelmina Hospital (supervisor: dr. D.M. Somford) and Radboud University Medical 





1. Osses DF, Dijkmans AC, van Meurs AH, Froeling FM. Neisseria Mucosa: A New Urinary 
Tract Pathogen? Current Urology, 2017;10(2):108-10.
2. Osses DF, van Asten JJ, Kieft GJ, Tijsterman JD. Prostate cancer detection rates of 
magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging 
Reporting and Data System score. World Journal of Urology, 2017;35(2):207-12.
3. Osses DF, Alberts AR, Bausch GCF, Roobol MJ. Multivariable risk-based patient selec-
tion for prostate biopsy in a primary health care setting: referral rate and biopsy results 
from a urology outpatient clinic. Translational Andrology and Urology, 2018;7(1):27-
33.
4. Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders G, Bangma CH, 
Roobol MJ. Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on 
active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds 
for significant disease. Translational Andrology and Urology, 2018;7(1):132-44.
5. Osses DF, van Asten JJ, Tijsterman JD. Cognitive-Targeted versus Magnetic Resonance 
Imaging-Guided Prostate Biopsy in Prostate Cancer Detection. Current Urology, 
2018;11(4):182-8.
6. Osses DF, Roobol MJ, Schoots IG. Prediction Medicine: Biomarkers, Risk Calculators 
and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diag-
nosis. International Journal of Molecular Sciences, 2019;20(7):1637.
7. Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. 
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting 
prostate cancer. Cochrane Database of Systematic Reviews, 2019;4:CD012663.
8. Osses DF, Remmers S, Schroder FH, van der Kwast T, Roobol MJ. Results of Pros-
tate Cancer Screening in a Unique Cohort at 19yr of Follow-up. European Urology, 
2019;75(3):374-7.
9. Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, 
Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C. Prediction of High-grade 
Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving 
the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk 
Calculators. European Urology, 2019;75(2):310-8.
10. Brown P, RELISH Consortium, Zhou Y. Large expert-curated database for benchmark-
ing document similarity detection in biomedical literature search. Database (Oxford), 
2019;2019.
11. Drost FH, Osses DF, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, Schoots IG. 
Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-
targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane 
Systematic Review and Meta-analysis. European Urology, 2020;77(1):78-94.
APPENDICES | LIST OF PUBLICATIONS
230
12. Osses DF, Drost FH, Verbeek JFM, Luiting HB, van Leenders G, Bangma CH, Krestin 
GP, Roobol MJ, Schoots IG. Prostate cancer upgrading with serial prostate magnetic 
resonance imaging and repeat biopsy in men on active surveillance: are confirmatory 
biopsies still necessary? British Journal of Urology International, 2020;126(1):124-
132.
13. Osses DF, Arsov C, Schimmöller L, Schoots IG, van Leenders G, Esposito I, Remmers S, 
Albers P, Roobol MJ. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance 
Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. Journal of Per-
sonalized Medicine, 2020;10(4):270.
14. Osses DF, Roobol MJ, Schoots IG, The MR PROPER Registry Investigators. Risk assess-
ment and MR imaging in initial prostate cancer diagnosis: an impact analysis – MR 





ADC  apparent diffusion coefficient
ADT  androgen deprivation therapy
Apps  mobile applications
AS  active surveillance
AUA  American Urological Association
AUC   area under the receiver operation curve
BPH  benign prostatic hyperplasia
bPSA   benign PSA
C-arm  control arm
CR  cribriform growth pattern
csPCa   clinically significant prostate cancer
CT  computed tomography
DCE  dynamic contrast enhanced
DRE  digital rectal examination
DWI  diffusion weighted imaging
EAU   European Association of Urology
EBRT  external beam radiation therapy
ERSPC   European Randomized study of Screening for Prostate Cancer
fPSA   free PSA
FU  follow-up
G  ISUP grade
GG   grade group
GP  general practitioner
GS   gleason score
GWAS  genome wide association studies
hK2   human kallikrein 2
IDC  intraductal carcinoma
iPSA   intact PSA
IQR  interquartile range
ISUP   International Society of Urological Pathology
LUTS  lower urinary tract symptoms
M+  metastatic disease
MiPS   MiProstate Score
mpMRI  multiparametric MRI
MRI   magnetic resonance imaging
MRI-TBx  MRI-targeted prostate biopsies
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MRI ± TBx  MRI with or without TBx
MR PROPER  MRI PROstate with Prior Risk Assessment
mRNA   messenger RNA
ND  not determined
Non-csPCa  clinically insignificant prostate cancer
NND  number needed to diagnose
NNI  number needed to invite
NNS  number needed to screen
NPV   negative predictive value
PCa   prostate cancer
PCA3   prostate cancer antigen 3
PCPT   Prostate Cancer Prevention Trial
PET  positron-emission tomography
PHI  Prostate Health Index
PIONEER  Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the 
power of big data in EuRope
PI-RADS  Prostate Imaging – Reporting and Data System
PIVOT  Prostate Cancer Intervention Versus Observation Trial
PLCO  Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
PPV  positive predictive value
PRECISE  Prostate Cancer Radiological Estimation of Change in Sequential Evalua-
tion
PRIAS  Prostate cancer Research International Active Surveillance
PROBASE  Prostate Cancer Early Detection Study Based on a “Baseline” PSA Value in 
Young Men
ProtecT  Prostate Testing for Cancer and Treatment trial
PSA  prostate-specific antigen 
PSA-D  PSA-density
PSA-DT  PSA-density
PSMA  prostate-specific membrane antigen
PV  prostate volume
QALYs  quality-adjusted life years
QoL  quality of life
RARP  robot assisted radical prostatectomy
RC  risk calculator
RCT  randomized controlled trial
ROC  receiver-operating characteristic curve
RPCRC  Rotterdam Prostate Cancer Risk Calculator
RR  relative risk
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S-arm  screening arm
S3M  Stockholm-3 model
SBx  systematic prostate biopsy
START  Standards of reporting for MRI-targeted biopsy studies
T2W  T2-weighted
TBx  targeted prostate biopsy
tPSA  total PSA
TRUS  transrectal ultrasound
TRUS-Bx  transrectal ultrasound systematic biopsy
US  ultrasound
USA  United States of America
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